Stem Life

Contents
ABOUT US
02 Statement by Chairman & Managing Director
06 Vision / Mission
08 Milestones
10 StemLife Baby
13 StemLife Baby - Transplants
14 StemLife Baby - Thalassaemia
16 StemLife Baby - Leukaemia
18 StemLife Baby - Cerebral Palsy
20 StemLife Therapeutics Services
22 StemLife Therapeutics Awareness
23 StemLife Therapeutics Healthy Storage
24 StemLife Therapeutics - Osteoarthritis
25 StemLife Therapeutics - Diabetic Foot Ulcer
26 Our Quality
27 Our Successful Transplants
28 Our Advisory Panels
32 Our Logistics
34 Our Laboratory
38 Our Innovations
39 Our CSR and Stem Cell Awareness Activities
40 Asia Pacic Cord Blood Bank Consortium
CORPORATE
42 Directors Proles
46 Management Team
48 Group Structure
49 Corporate Overview
50 Corporate Information
ANNUAL REPORT 2010 STEMLI FE BERHAD ( 566770- D)
2
On behalf of the Board of Directors, we are pleased
to present the Annual Report and Financial
Statements of the StemLife Croup for the year
ended 31 December 21.
Statement by Chairman &
Managing Director
3
The StemLife Group continues to position itself as the industry leader in cord blood stem cell banking. Our
community of banked customers in the region has grown by more than six thousand units, maintaining our regional
lead in terms of new and cumulative units stored.
One of our key missions is to make cord blood stem cells available and accessible to families who have chosen to
store their babys cord blood stem cells. We are therefore pleased to share that StemLife has assisted three more
families this year. Of the three cord blood units released, one was for a child who inherited thalassaemia major and
two were released for clinical trials on children who suffered birth trauma resulting in cerebral palsy.
We believe that in this decade we will be seeing the
results of research from leading trial centres that will
further endorse and conrm the social and economic
merits of private stem cell banking.
This year we have heard and seen the term stem cell used to sell everything from face cream to fruit juice. This
has fuelled further market confusion as certain members of the public perceive incorrectly that stem cells can
be extracted from various plants or animal organs, bottled or pressed into pills and sold off-the-shelf. As these
products are neither classied as a medical product or a service, they are openly marketed to the public. We often
nd ourselves having to clarify to our clients that plants do not have placentas and that sheep stem cells should
be recommended for use in sheep. StemLife operates in a restrictive medical advertising regulatory environment,
which makes the creation of awareness challenging and costly. Malaysias regulations governing the promotion
and advertising of our service remain among the strictest in the world.
At StemLife, we believe that there is still signicant growth potential in the market and remain focused on offering
therapies and technologies that have demonstrated safety in clinical settings.
New achievements in Cord Blood & Regenerative Medicine
Stem cells are a prominent topic of conversation, confusion and sometimes consternation as many hoped for
outcomes take a long time to be thoroughly validated by the international medical community. However, a number
of studies are now progressing through various phases of clinical trials with many now suggesting encouraging
results. These results in turn feed more exciting research. A simple search on the US National Institutes of Health
website (www.nih.gov) shows the plethora of medical research projects currently underway using stem cells.
Most signicantly, three research papers for neurology - which were a culmination of several years of work - were
published in medical journals by renowned research physicians.
(1) Dr. Joanne Kurtzberg and co-workers from Duke University (who have been working on this area since 2005),
have nally published their paper
1
establishing the safety of using autologous cord blood for neurological
injury.
(2) Dr. Cox and co-workers from the University of Texas
2
established the safe use of autologous bone marrow
mononuclear cells (similar to cord blood stem cells) for children with severe traumatic brain injury. All
patients demonstrated improvement within 6 months and 70% were classied with good outcomes and mild
disabilities on the Glasgow Outcome Scale for functional disability.
4
StemLifes Commitment to Quality
Although StemLife received our accreditation as a licensed Ministry of Health cord blood stem cell and peripheral
blood stem cell bank, we initiated pursuit of other external quality indicators to benchmark ourselves against
the best international banks. The StemLife Group already operates under ISO9001:2008 standards for company
procedures.
Additionally, our laboratory team and directors are pleased to announce that we are the rst comprehensive stem
cell laboratory in Malaysia to be awarded the ISO15189:2007 which sets high specications for the operation of
laboratories.
We warmly congratulate THAI StemLife on the
expansion and launch of their new facility in Bangkok.
Their new premises include a cutting edge facility which
has won praise from visiting physicians and international
scientists. THAI StemLifes laboratory is the only stem
cell laboratory in Thailand that is ISO15189:2007
accredited.
Concluding Comments
The current operating environment remains challenging
and our margins and prots are still under pressure
from competitors and the difculty of growing the
(3) StemLife is also proud to present our contribution to medical progress. Our landmark paper, led by Dr.
Kostas Papadopoulos of THAI StemLife, on the use of cord blood stem cells and GCSF
3
was published in the
Journal of Restorative Neurology and Neuroscience in February 2011 and is the worlds rst paper to discuss
medical outcomes of the procedure.
Our medical directors and entire team are very excited about what these papers represent for the future use of
autologous (ones own) stem cells for brain injury, especially considering that there are currently no satisfactory
treatments. We believe that in this decade we will be seeing the results of research from leading trial centres that
will further endorse and conrm the social and economic merits of private stem cell banking.
StemLife Malaysia is the founder of the Asia Pacic Cord Blood Bank
Consortium and in 2010 we were pleased to attend our 8
th
anniversary
annual meeting, held this time in Hong Kong. Representatives from
14 stem cell banks around the world (our membership has grown
far beyond Asia Pacic) attended our symposium. We had the
privilege of having Professor Wise Young from the WM Keck Spinal
Cord Research Center of Rutgers University visit personally to share
his work with us. His large-scale clinical trials that are presently
underway in selected hospitals use tissue-matched cord blood
stem cells to attempt to promote healing and repair in spinal injury
cases. We eagerly await his results which should become available
in the next 5 years. Later this year we very much look forward to
our symposium which will be held in Pune, India, and will feature
industry and academic representation from 5 continents.
Statement by Chairman &
Managing Director (Contd)
... we initiated pursuit
of other external
quality indicators to
benchmark ourselves
against the best
international banks.
5
market when the law severely restricts educational
activities. Our accounts reect prudent management.
Our balance sheet remains robust with zero debt and
we remain cash ow positive. Operationally we have
conducted more transplants than any other private
stem cell bank in the region and our very high transplant
success rate is testament to our stringent laboratory
processes and strong relationships with top transplant
doctors in South East Asia.
We are optimistic that with more scientic and clinical
knowledge in the public domain and StemLifes quality
and operating stability, customers will continue to
choose us as their stem cell bank.
Appreciation
On behalf of the Board of Directors, we would like to
thank our clients, shareholders and business partners
for their consistent support. We record our thanks and
sincere appreciation to Mr. K.L. Loh who has resigned
as our Independent Director due to health reasons and wish him a speedy recovery. His contributions and insights
were invaluable to us. We would like to extend a warm welcome to Ms. Yap Yu Ming who joined the board in
February 2011 and takes on the role of an Independent Director. We are sure that the Company will benet from
her extensive corporate and business experience. We would also like to express our condolences to the family of
the late Dr. Selvaratnam A/L Govindaraju whose sudden passing was a shock to all of us. He served on StemLifes
Medical Advisory Panel for 8 years and was very much a respected doctor and a trusted friend.
My appreciation also goes to our fellow Directors for their dedication and valuable guidance to our team, and to
our management and staff whose persistence, passion and determination help to overcome challenges and deliver
a year of stable performance.
Thank You.
... rst comprehensive stem cell
laboratory in Malaysia to be awarded
the ISO15189:2007...
References:
1. Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children
with acquired neurologic disorders.
Transfusion 2010 Sep;50(9):1980-7; Sun J, Allison J, McLaughlin C, Sledge L, Waters-Pick B, Wease S, Kurtzberg J.
2. Autologous Bone Marrow Mononuclear cell therapy for severe traumatic brain injury in children.
Neurosurgery 2011 68;588-600; Charles S. Cox Jr MD, et al.
3. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony
stimulating factor injections.
Journal of Restorative Neurology and Neuroscience 29 (2011) 17-22; Kostantinos I. Papadopolous, Sharon Su Shing Low, Tar Choon Aw, Teerachai
Chantarojamasiri
Tan Sri Dato Seri Dr. Aseh Bin Che Mat
Independent Non-Executive Chairman
Dato Low Su-Shing, Sharon
Managing Director
6
To establish stem cell therapy as one of the three
pillars of Healthcare Management in Malaysia and
the region and to achieve global recognition as
the leading stem cell company in Regenerative
Medicine.
Vision
6*'4#2;
56'/%'..5
2
*
#
4
/
#
%
'
7
6
+
%
#
.
5
7
4
)
+
%
#
.
7
To promote Regenerative Medicine using Stem Cell
Technology and offer end-to-end stem cell services
of the highest standard and quality through cutting-
edge technology.
Mission
88
Milestones
2001
Incorporation of StemLife Sdn Bhd
2002
1
st
UCBSC unit collected and stored
Ofcial launch of StemLife Laboratory at
CHIME (Centre for Health, Innovation Medical
Enterprise), Cyberjaya
2003
Expanded nationwide
Expanded to East Malaysia
1
st
overseas UCBSC unit
Co-founded APCBBC
2004
Prot achieved
(after only 3 years of operation)
2009
Launch of new benet services for clients
StemCourier and StemShieldPLUS
32,000 total cumulative UCBSC units stored
2010
Incorporation of PT Prodia StemLife, Indonesia
StemLife Managing Director Dato Sharon Low
awarded the position of Distinguished Fellow by
MABIC (Malaysian Biotechnology Information
Centre)
2011
Publication of the worlds rst scientic report on
cord blood stem cells for children with Cerebral
Palsy in international journal by StemLife & THAI
StemLife
2005
Ofcial launch of PBSC (Peripheral Blood Stem
Cell) service
1
st
PBSC unit harvested and stored
Incorporation of Thai StemLife
2006
Change of status to public company status:
StemLife Berhad
Listed on the MESDAQ board, Bursa Malaysia
(now known as ACE)
Launch of new StemLife Laboratory Kuala Lumpur
Research collaboration with:
- UPM and KLSMC (KL Sports Medicine
Centre) for cartilage damage stem cell
application
- NUSNNI and Cryo Stemcell (Karnataka)
Pte Ltd to study cord blood stem cell expansion
2007
StemLife Therapeutics begins operation to fully
undertake all PBSC services
Launch of StemLife Logistics Sdn Bhd to provide
end-to-end comprehensive Logistics service with a
eet of acquired logistics vehicles
Publication of 3 research papers on bone cell
growth with nanobre technology in international
journals in conjunction (with NUSNNI)
Launch of new benet services for clients
StemGuard, StemAssured, Stem21
2008
Brieng and update to the Minister of Health
Malaysia, Y. B. Dato Liow Tiong Lai, on stem cells
and its increasing numbers of applications
Inaugural public stem cell seminar featuring world-
renown cord blood stem cell expert Prof. Dr. Colin
McGuckin, Professor of Regenerative Medicine,
Newcastle University, UK
Relaunch of Maternal Blood Testing service for
clients
Commence use of AXP automated processing
system enabling time efciency in cord blood stem
cell processing
Launch of new benet service for clients
StemShield
&RUSRUDWH0LOHVWRQHV
9
2004
1
st
UCBSC unit released for transplant AML
(Acute Myeloid Leukaemia) and the 1
st
in the
country to use stem cells stored with a private
bank
2002
Granted MSC (Multimedia Super Corridor) status
Granted Pioneer Status under the Promotion of
Investments Act 1986 by MITI (Ministry of International
Trade and Industry)
2005
1
st
stem cell therapy for DFU (diabetic foot
ulcer)
1
st
stem cell therapy for heart failure
2008
PHFS Act 1998 License (under Ministry of Health)
awarded to StemLife for both UCBSC and PBSC banking
Certied ISO9001:2000 (UKAS & COFRAC) for testing,
processing and storage of stem cells
2006
2
nd
UCBSC unit released -Thalassaemia
Major and the 1
st
Thalassaemia case in the
country to use stem cells stored with a private
bank
2009
Certied with ISO9001:2008 (UKAS & COFRAC)
2011
StemLife Laboratory accredited ISO15189:2007
the international recognition for quality and
competence in patient care
2007
3
rd
UCBSC unit released ALL (Acute
Lymphoblastic Leukaemia)
4
th
UCBSC unit released CP (Cerebral Palsy)
1
st
stem cell therapy for knee cartilage injury in
collaboration with KLSMC
2006
TBR (Technology Business Review) Award -
Excellence in Biotechnology [Stem Cell Application]
Deloitte Technology Fast 500 Asia Pacic Award
2007
TBR Award - Excellence in Biotechnology [Stem
Cell Technology Application]
Deloitte Technology Fast 500 Asia Pacic Award
StemLife Managing Director Dato Sharon Low
awarded Top Nomination in Ernst & Young
Entrepreneur of the Year 2007 Award, Malaysia
2008
BioInno Award - New Innovations at BioMalaysia
Exhibition
OGSM Congress Scientic Research Presentation
category
MTERMS (Malaysian Tissue Engineering &
Regenerative Medicine Society) Scientic
Research Presentation Category
2009
OGSM Congress Scientic Research Presentation
category
2010
BrandLaureate Master Award (Stem Cell Banking)
Frost & Sullivan Malaysia Excellence Award in
Growth Leadership - Stem Cell Banking and
Therapeutics
2008
5
th
UCBSC unit released -Thalassaemia Major
Over 220 PBSC units released for therapy
2009
6
th
UCBSC unit released CP
7
th
8
th
9
th
UCBSC unit released Brain Injury
2010
10
th
UCBSC released -Thalassaemia major
11
th
UCBSC released -Thalassaemia major
2011
12
th
UCBSC released CP
13
th
UCBSC released CP
7UDQVSODQWV
/LFHQVHV&HUWLFDWLRQ
$FFUHGLWDWLRQV
$ZDUGV
10
StemLife Baby
6WHP/LIH %DE\ KDV VWUHQJWKHQHG LWV SRVLWLRQ E\ SURYLGLQJ D ZLGH UDQJH RI LQWHJUDWHG VHUYLFHV
ZKLOVWFRQWLQXRXVO\LPSURYLQJRQDOOIURQWVWRZDUGVDEULJKWHUIXWXUH
StemLife, in its drive to provide a brighter future for all stakeholders, has successfully renewed its license under the
Private Healthcare Facilities & Services (PHFS) Act, 1998. In addition, it has continuously improved its facilities and
services and participated in relevant quality programs, accreditations and certications such as CAP, AABB membership,
ISO15189:2007, World Courier and ISO9001:2008.
The Group continued to lead in the umbilical cord blood stem cell UCBSC banking industry in Malaysia by enhancing
strategic channels to increase market share and market depth. The Groups activities in this business segment are
designed to provide safe services, timely collection, viable cells and ensuring successful utilization of the UCBSC.
The UCBSC business is envisaged to grow signicantly in light of the Groups publication of its R&D in international
journals and the announcement of exciting results obtained in various clinical trials throughout the world. Having banked
over 37,000 UCBSC units, the Group has cemented its position as the premier service provider and is acknowledged as
the preferred brand in the market.
11
StemLife Baby Clients
CnIy Ihc BcsI Ior IhcIr Baby
Mark Chen, Actor & Businessman
I want the best for our baby. Before my wife and I
decided on whether to store our rst babys cord blood,
we checked the company background, its technology and
prociencies, storage system and lab facilities. Thats why
I decided to bank with StemLife.
An Assurancc Ior IcaIIh
Nana AF, DJ
We wish for Althea the best in health but at the same
time we realise we need to be prepared for any possibility.
Cord blood banking is a form of insurance to secure her
health in the future. We did a lot of research on our own
before making our decision it is so important to choose
a company that we can trust in the long-term.
IcaIIh Concs IIrsI
Dato Sheila Majid, Celebrated jazz artist
My familys welfare is always foremost on my mind it was the
driving reason why I chose to store for my 4
th
baby. When I had my
previous children, StemLife had not made this service available in
Malaysia yet, otherwise I would have denitely banked their cord
blood stem cells with them as well.
12
StemLife Baby Clients
Datin Olive was 5 months pregnant when Dato
and her met up with a good friend of theirs who
proceeded to tell them about a new service that
was saving lives in Malaysia. We immediately
went home to research cord blood banking, said
Datin Olive excitedly, We found so many news
and magazine articles on the topic, with stories
on how it could help with child cancers and other
conditions. It was with that knowledge that they
decided to take up the service.
That was 6 years ago, and today, with 4 children in tow, she is proud to say that she has banked cord blood stem cells for
every single one of them. After I decided to store, my next important decision was to nd out which company I should
choose. I always want the best for my children, and so I wanted to go with the company with the highest quality, with
a management and background I can rely on. Because youre storing for so many years, there is so much to consider!
Datin Olive laughed. On a more serious note she continued, With the pace at which science research is going, and with
so many cord blood units stored worldwide, there is a lot of potential. I hope they never have to use it, but I have peace
of mind knowing that my children have their own stem cells for their health in the future.
Datin Olive Choo
StemLife Baby Client
Datin Olive Choo and her children,
Yu, Louisse and Johannes
13
StemLife Baby Transplants
CORD BLOOD
TRANSPLANT OVERVIEW
STEMLIFES EXPERIENCE
A S C 1 A S C 1
New Regenerative Applications
ln precllnlcal research and cllnlcal frlal phases
Sfem cells are proposed fo regenerafe or
repalr ofher fypes ol damaged cells and
flssues
Cnly aufologous cells are used ln cllnlcal frlals
Traditional Transplantation
Esfabllshed cllnlcal use
40 year hlsfory
Sfem cells regenerafe fhe blood & lmmune
sysfem
Typlcally requlres lmmune suppresslon or
ablaflon (desfrucflon)
Allogenelc or aufologous cells have been
used (lor leukaemla)
Generally used lor freafmenf ol lmmedlafe
llle-fhreafenlng condlflons
C
C
C
C
C
C
C
C
C
C
C
8 l
C
C
C
? 1
C
M
A
1 M
1 M
1 M
L
1 M
L
*For condentiality, we withhold publication of the patients identity.
A procedure ln whlch fhe paflenf ls lnlused wlfh sfem
cells lrom a mafchlng donor. The donor may or may
nof be relafed. HLA-Typlng (a serles ol fesfs) ls
carrled ouf belore a fransplanf fo defermlne how
closely fhe flssues ol a donor and paflenf mafch.
l SL

C S D
1
L
A procedure ln whlch fhe sfem cells are drawn lrom
fhe paflenf hlmsell/hersell, sfored and lafer lnlused
back lnfo fhe paflenf. ln fhls case, fhe paflenf ls bofh
fhe donor and fhe reclplenf. Hence aufologous
fransplanfs are nof appllcable lor lnherlfed
dlsorders.
14 14
StemLife Baby
Thalassaemia
WHAT IS THALASSAEMIA?
It is the most common genetic (inherited) blood disorder in the world which causes part or complete suppressed
production of haemoglobin, the body protein that enables red blood cells (RBC) to carry oxygen (O
2
) to the cells in all
parts of the body.
Insufcient production in either 1 of the 2 main haemoglobin protein chains (alpha- or beta-) leads to the defective
formation of RBCs which in turn causes insufcient O
2
to be carried to different parts of the body. Organs starved for
oxygen are unable to function properly.
` in cvcry 2O Malaysians carrics a Thalassacmia gcnc`
MAIN TYPES OF THALASSAEMIA
ALPHA () OR BETA () THALASSAEMIA MINOR:
o Patients are only carriers of one copy of the disorder
gene;
o Produce no or weak symptoms of the Thalassaemia
characteristics (mild anaemia etc.) hence patients
lead a normal life;
o Usually do not require any specic treatment;
o Carriers can pass down the Thalassaemia trait to
subsequent generations.
-THALASSAEMIA MAJOR:
o Involves defects in genes required to make each ()
protein chain;
o Life-threatening - Produces strong symptoms of
Thalassaemia characteristics.
SYMPTOMS OF -THALASSAEMIA MAJOR:
o Newborn appears normal at birth but as they grow
the infants exhibit progressive anaemia (variable
severity); jaundice; paleness; fussiness (irritability);
shortness of breath;
o Increased susceptibility to infection;
o Facial bone deformities;
o Weaker and slower growth appear in the 1
st
and 2
nd
years of life;
o The abdomen may swell (enlarged liver and spleen,
intestinal problems)
TREATMENT
-THALASSAEMIA MAJOR PATIENTS
o Regular treatment to sustain life: chronic blood
transfusion therapy, iron chelation treatment (painful
and costly), splenectomy, and allogeneic
hematopoietic transplantation.
o Stem cell transplantation is the only cure for
Thalassaemia. It can eliminate a patients dependence
on transfusions.
o Untreated patients eventually leads to death, usually
by heart failure.
A Parent with
Thalassaemia Minor
Thalassaemia
Major
Thalassaemia
Minor
Thalassaemia
Minor
Normal
Blood
(25%)
(25%) (50%)
A Parent with
Thalassaemia Minor
Chance of a child getting the disorder if both parents are carriers
YONG TAI
Diagnosis : 1 year old
Disease : -Thalassaemia Major
Treatment Center : University Malaya Medical Centre, Malaysia
Treatment Date : April 2008
Prognosis:
o His sister Sin Yees cord blood stem cells were stored with StemLife
o He underwent a successful stem cell transplant using Sin Yees stem
cells
THALASSAEMIA
CASE SUMMARY
References
o Ministry of Health, Malaysia
o http://www.medicinenet.com/beta_thalassemia/page2.htm
o http://childrenscbf.org/index.php/medical/single/what_you_need_to_know_about_thalassemia/?gclid=CPCb-f7c9qACFcFR6wodGy0_uQ
o http://www.wrongdiagnosis.com
o StemLife Berhad
15
At the age of 1, Shana Grace was diagnosed with
Thalassaemia major, with blood tests conrming that both
her parents are Thalassaemia carriers.
Shana and her parents lives were deeply affected by her
condition. Beginning with her lack of appetite and energy,
the situation worsened when she was required to undergo
frequent blood transfusions. On top of that, they were
required to wait when the hospital did not have enough
units of blood.
With hope of improving Shanas condition, her mother
researched and came across stories on how cord blood
stem cells help in Thalassaemia. Immediately she contacted
StemLifes representative in Kota Kinabalu and as it turned
out, Shanas sister (Aila) who has her stem cells stored with
StemLife, was a perfect HLA match for her.
In January 2010, Shana underwent a successful stem cell transplant using Ailas cord blood stem cells. Post-transplant,
Shana no longer needed blood transfusions and her overall health improved. It was a brighter beginning for her and her
family.
Shanas parents were ecstatic with the results, and they made sure to share it with others. I encourage relatives, friends
and colleagues to store cord blood. Shana now has the chance of a better health and life, thanks to cord blood stem
cells and StemLife. She is much more energetic and happy now, and cant wait to go back to school, beamed her father.
+/-... .-- ./ ,- // .-,,/.-..- .,
- /- -.,../ .., ( .-.,.-/,
. ,./, .-. /.- ( . .
Prof. Dr. Chan Lee Lee MBBS,DCH,MRCP,FRCP
Med J Malaysia Vol.56 (4)
Shana Grace
Talassaemia Survivor
StemLife Baby
Thalassaemia
16 16
StemLife Baby
Leukaemia
`Out ol 256,OOO childrcn and adults around thc world who dcvclopcd
a lorm ol lcukacmia, 2O9,OOO dicd lrom it`
MAIN TYPES OF LEUKAEMIA
ACUTE LEUKAEMIA
o Characterized by the rapid increase of immature
blood cells which crowds the bone marrow and
restricts production of healthy blood cells.
o Immediate treatment is required before the cancer
cells spread throughout the body.
o Is the most common form of Leukaemia in children.
CHRONIC LEUKAEMIA
o Excessive build up of mature abnormal white blood
cells over months or years.
o Chronic forms are sometimes monitored for
some time before treatment to ensure maximum
effectiveness of therapy.
o Mostly occurs in older people.
SOME SYMPTOMS OF LEUKAEMIA
o Easily bruised, excessive bleeding;
o Frequent infections;
o Anaemia, which may cause pallor;
o Feeling sick (fevers, chills, night sweats etc.);
o Feeling fatigued;
o A feeling of fullness due to an enlarged liver and
spleen (this can result in unintentional weight loss).
CAUSES
No single known cause for all of the different types of
Leukaemia exists. The known causes (as a result of exposure
to radiation or carcinogenic substances etc.), which are not
generally factors within the control of the average person,
account for relatively few cases. The different Leukaemias
likely have different causes.
TREATMENT
Most forms of Leukaemia are treated with pharmaceutical
medications, typically combined into a multi-drug
chemotherapy regimen. Some are also treated with
radiation therapy. In most cases, stem cell transplantation
is useful.
WHAT IS LEUKAEMIA?
A cancer of the blood or bone marrow characterized by an abnormal increase of blood cells, usually leukocytes (white
blood cells). Leukaemia is a broad term covering a spectrum of diseases.
CHRISTIAN WILLIAMS
Diagnosis age : 4 years old
Disease : Acute lymphocytic leukemia (ALL)
Treatment Center : Cooks Childrens Hospital in Ft. Worth, Texas
Prognosis & Outcome:
o Was considered to be high risk and underwent intense
chemotherapy.
o Infused with his younger brothers cord blood stem cells which was a
perfect match for him.
o Successful engraftment and production of healthy blood cells post-
transplant. He is now able to lead a normal and healthy life.
References
o Cord Blood Registry, U.S.A. (http://www.cordblood.com)
o The Daily Herald (http://www.heraldextra.com)
o World Health Organisation (http://www.who.int/entity/healthinfo/paper13.pdf)
LEUKAEMIA
CASE SUMMARY
17
StemLife Baby
Leukaemia
Angel
Leukaemia Survivor
At the age of 6 months, Angel was diagnosed with acute
myeloid leukaemia, ravaging her little body in less than a month.
Doctors had given her less than 10% chance of survival.
Desperately looking for a cure for Angel, a distraction in the
form of a second pregnancy to Angels mother during these
dark days brought further anguish to the family and the thought of terminating the pregnancy was at the top of her
mind. She consulted various doctors about the possibility of an abortion.
Fortunately, a gynaecologist advised her not to, and instead introduced her to a new procedure that could give Angel
a ghting chance a cord blood stem cell transplant. If her newborns umbilical cord blood stem cells were a match for
Angel, and Angel lived long enough for the birth of her baby brother, she stood a chance to undergo a cord blood stem
cell transplant using her younger baby brothers stem cells.
In April 2004, Samuel, Angels baby brother, was born. More good news followed: the cord blood stem cells collected
at Samuels birth and stored by StemLife, were an exact match. Angel and Samuels parents were elated. The stem cell
transplant took place in June and went without a hitch. Angel regained her health in months to become the bouncy baby
that her parents had prayed for. A wonderful life was saved.
t ,., - ./ ., . /. ,.,,(.//, .
/./.- ./ /.|.-.. .-. / /. ..,.,
Dr. Mary J. Laughlin MD
The Ireland Cancer Centre, University Hospitals of Cleveland
18
StemLife Baby
Cerebral Palsy
` in cvcry 3O3 childrcn worldwidc havc Ccrcbral Palsy`
WHAT PART OF THE BODY IS AFFECTED BY CP?
This is different from one person to another. In CP, certain
words are used to describe the parts of the body affected:
Diplegia; Hemiplegia; Quadriplegia.
more affected areas
less affected areas
Diplegia Hemiplegia Quadriplegia
WHAT CAUSES CP?
Damage to one or more specic areas of the brain, caused
by:
o injury that occurred during pregnancy;
o infant develops severe infection (meningitis etc.);
o head injury due to accidents etc. For most people
with cerebral palsy, the cause is unknown.
TREATMENT FOR CP
There is no cure for CP, but various forms of therapy
can help a person with the disorder to function and live
more effectively. Treatment may include physical therapy,
drugs to control seizures, surgery to correct anatomical
abnormalities or release tight muscles.
WHAT IS THE FUTURE FOR PEOPLE WITH
CEREBRAL PALSY?
Cerebral Palsy is a lifelong condition. It is important for
children to receive treatment and support from an early
age to ensure they have every opportunity to reach their
full potential.
WHAT IS CEREBRAL PALSY (CP)?
CP is an umbrella term encompassing a group of non-progressive, non-contagious motor conditions that cause physical
disability in human development, chiey in the various areas of body movement and muscle coordination. Its effect
ranges from mild (just a weakness in one hand) to an almost complete lack of movement
DALLAS HEXTELL
Diagnosis age : 8 months old
Symptom : Limited motor movement
Treatment Center : Duke University Medical Centre, U.S.
Treatment Date : July 2007
Prognosis:
o Infused with his own cord blood
o Condition improved after transplant: is now able to crawl, sit up,
wave and clap.
CEREBRAL PALSY
CASE SUMMARY
References
o CDC, USA (www.cdc.gov/features/cerebralpalsy)
o http://www.disabilitymalaysia.com
o http://www.thespasticcentre.org.au
o http://www.medtronic.com
o http://www.fortunecity.com/millenium/rugrats/311/ page4.html
o Cord Blood Registry, U.S.A (http://www.cordblood.com)
19
StemLife Baby
Cerebral Palsy
Pole, 2 years and 8 months old, suffers from cerebral
palsy. He is a spastic diplegic, meaning he has weakness
in his legs. His parents, Mr. and Mrs. Kitikorn, realised
there was something wrong when he could not walk by
the age of 1.
There werent any complications during my delivery
and nothing was wrong with Pole when he was born,
explained Mrs. Kitikorn. Poles parents were advised by
doctors to put him on a twice-a-week schedule of physiotherapy treatment. He improved only marginally, and could only
take a mere 10 steps even with assistance of orthotics.
Mr. and Mrs. Kitikorn had heard about the possibility of stem cells being used for CP, and since they stored Poles
umbilical cord blood stem cells (UCBSCs) with a Thai private stem cell bank (THAI StemLife) they took advantage of the
opportunity.
In June 2009, Poles own UCBSCs were transported to a private hospital in Bangkok, Thailand, where the unit was
thawed, and infused intravenously. The procedure was simple, non-invasive and took only 10 minutes. Post-infusion,
Pole, still lying in bed, continued to laugh and smile
at the cartoon he was watching. A wave of relief
washed over his parents.
The results we saw after a week are very
encouraging! He looked more alert and interested
in his surroundings, speaks clearly now, and see how
normal the angle of his feet are now? He doesnt
even need corrective shoes anymore. Well be
happy if he can improve enough to walk by himself
and go to school like other kids. We didnt want his
inability to hold him back, said Mrs. Kitikorn as Pole
gets up from his mat and walks un-coaxed towards a
white board on the wall.

c. /. ,.., /.., /.
,. ( . ., -.../.,
Dr.Joanne Kurtzberg MD
Division Chief, Pediatric Blood
and Marrow Transplantation
Pole
Cerebral Palsy Patient
Pole and Fam
ily
erapy treatment. He improved only marginally, and could only
Mrs. Kitikorn and Pole at their home in
Thailand post-stem cell therapy.
20 20
StemLife Therapeutics
Services
STEM CELL BANKING FOR ADULTS
StemLife Therapeutics offers adults the opportunity to preserve their healthy stem cells for future use in case of an
unexpected turn of events. First introduced in 2005, the company is a licensed peripheral blood stem cell banking and
storage services provider under the Private Healthcare Facilities & Services (PHFS) Act 1998.
Traditionally, stem cells used to be harvested from the bone marrow, a painful and invasive method. With the
advancements made in medical science technology, stem cells today can be harvested from the peripheral blood (blood
circulating in our veins) in a painless, risk-free, non-invasive manner at our modern, fully equipped, custom-built stem cell
harvest centre. The harvested cells are then processed at our internationally accredited, state-of-the-art cell processing
laboratory before being stored in deep freeze for future usage.
Stem Cell Therapy
Peripheral blood stem cells (PBSCs) have been proven to be successful in tens of thousands of stem cell therapies for
blood malignancies and disorders over the past forty years and have demonstrated immense potential benets for
ischaemic limbs, joint and cartilage injuries, heart disease, neurodegenerative conditions, and possibly even anti-aging
treatments.

StemLife works in collaboration with experienced doctors and clinicians from both private and public hospitals both in
Malaysia as well as internationally, to facilitate the collection of stem cells in the treatment of various medical conditions.
With the wealth of experience StemLife has gained through its involvement in stem cell therapy over the past ten years,
StemLife is able to offer specialized consultation to patients who require access for both pioneering and established stem
cell therapies. StemLife continues to educate the public, bringing awareness on the benets of storing adult stem cells,
as storing electively when healthy ensures that the stem cells are in optimal condition for future use.
StemLife continues to champion and pioneer the usage of stem cells for an ever-increasing range of diseases, and
believes that medical science is on the verge of an explosion in offering many new cell-based treatment modalities to
improve the quality of life of people across the globe.
21
Stem Cells for Aging diseases
Stem cells like all other tissues and organs, undergo
changes with the passage of time. As we age, our bodies
deteriorate with the wear and tear of daily life. Healthy
people and patients all around the world are looking for
ways to delay the aging process and improve or regain the
use of their organs, revitalizing their quality of life.
Your own stem cells hold the key to anti-aging. Stem cells have the ability to rejuvenate old and tired cells, replacing
them with new cells that can actively carry out cellular regeneration promoting healthy body functions.
Today people from all walks of life have the opportunity to use their stem cells in the ght against aging. What we hope
for all our clients is to be able to maintain, and enjoy a good quality of life for years to come. Your stem cells for a better
today, for a healthier future.
21 21 21 21 21 21 21 22221 21 211 21 21
22
Awareness
If a person suffers from any form of blood cancer, there is little hope of getting a bone marrow transplant in Malaysia.
With only 17,120 registered donors, the Malaysian Marrow Donor Registry is facing an acute shortage.
-Institute of Medical Research
Many Malaysians are unaware of the chilling realistic gures of a major shortage of stem cell donors in Malaysia, and the
probability of nding a matching stem cell donor is only 1:30,000.
In view of this, StemLife Therapeutics marketing arm embarked on a year-long intensive awareness program to educate
the public on the increasing importance of more healthy adults have their stem cells collected and stored for future use.
We participated in many relevant health and wellness exhibitions, conducted health talks in clubs and wellness centers
and distributed yers in housing estates educating the public on the necessity of having their stem cells stored early
before being aficted with a debilitating disease.
A strategic collaboration was initiated with PMCare, a leading company specialising in the management medical benets
for employees of various corporate entities. This collaboration launched our stem cell banking awareness program with
many large corporations including GLCs such as Tenaga Nasional Berhad, CIMB, UMW, Sapura Crest, Toyota Bokoshu
and Symphony Group. The company also participated in the Health, Wellness and Beauty exhibition at Mid Valley
Exhibition Centre where we showcased the potential benets of using stem cells in the ght against aging.
Malaysia Beauty, Spa & Wellness Carnival 2010
UMNO General Assembly
Tenaga National Berhad
PMCare GP Of The Year Award 2008/2009
StemLife Therapeutics Awareness Programs
o I Love Me Health Conference
Organized by the Obstetrical and Gynecological
Society of Malaysia
o PMCare GP Of The Year Award 2008/2009
An event held to honour and reward General
Practitioners who provide quality and ethical care for
their patients
o Vistage Members Talk
Exclusive talk on stem cells for CEOs and MDs of
Major Corporations
o Tenaga National Berhad
Preventive Health Screening Program for staff
o UMNO General Assembly
o Toyota Boshoku UMW
o Sapura Crest
o Wellness Club Members
Organized by a certied wellness planner for club
members
o Lions Club, Wellness Talk
Stem cell talk exclusive for Lions Club members in KL
North
o Malaysia Beauty, Spa & Wellness Carnival 2010
Showcasing the best spa therapies and wellness
products and services
23
Healthy Storage
When I was expecting my rst child, I was approached by several
sales counselors from different stem cell companies. All of them
said more or less the same things, but what really intrigued me
most was, Cord blood contains stem cells that could save my
babys life. Could it be true? Could my babys stem cells come
to his rescue if he gets leukaemia or thalassaemia?
I decided to do my own research on stem cells and googled
for days, and to my amazement, I found so many websites with
scientic evidence and testimonials from recipients of stem cell
transplants. That convinced me of the vast potential that stem
cells hold in the treatment of many debilitating diseases.
Now I had to make a decision on the right stem cell bank to save my babys stem cells. I had my sister, who works in a bank,
do a background search on all the stem cell banks in Malaysia, and she highly recommended StemLife. She said, They are the
pioneers in this industry, they are public-listed, nancially they are very stable,
and they have done the most number of stem cell transplants in Malaysia. I
have never looked back since, and today I have saved both my rst and second
childrens stem cells with StemLife.
Yap See Chien
StemLife Baby & StemLife Adult client
My son and I
. -..-, ( ,- //,
Then in mid-2010, I received a mailer from StemLife, offering adults the
opportunity to save their own stem cells. I was intrigued. I immediately called
for an appointment and after learning about the potential uses of my own
stem cells, I jumped at the opportunity to not only save my husbands and my
stem cells, but my parents and sisters as well.
I feel good about the decision I made to convince my entire family to save
their stem cells. With the increasing risk of disease today, saving our entire
familys stem cells has been the best health investment we have ever made!
0(
a
h
c
T
o
fo
s
s
I
t
fa M
y Family
My Children
./ ,-/.(
24
En. Ahmad believed in the regenerative power of stem cells. Having come across many stem cell articles on
research around the world, he chose to bank his own stem cells in 2007 just in case he needed it for his heart
condition in the future.
3 years later, he began having stiff knees in the morning, which caused him severe pain even when doing
simple things like climbing stairs and getting out of bed. To alleviate his condition, his orthopaedic specialist
placed him on the usual treatment of regular hyaluronic acid injections. Though this treatment provided him
with relief, it lasted only a couple of months, and his pain came back worse than ever.
Worried that he would need to undergo surgery to replace his troubled knees, he turned to StemLife in the
hope that he would be able to use his stem cells for his painful condition. Stem cell therapy was arranged for
him with an orthopaedic specialist from a leading private hospital and after 5 weekly consecutive stem cell
injections, his knee pain was greatly reduced.
Three months post-stem cell therapy, En. Ahmad happily said, I feel great and very much relieved. My knee
pain has vanished and I can climb stairs without any problems, and I have no more stiffness or pain in the
mornings. I believe that others with similar knee problems should consider stem cells as a relatively painless
option for treatment of osteoarthritis. Im glad I did!
En Ahmad Habib
age 63, Company Director
Osteoarthritis
25
Diabetic Foot Ulcer
SAVING DIABETIC PATIENTS FROM AMPUTATIONS
The results of the 3
rd
National Health and Morbidity Survey (NHMS III) 2006 state that one in six adult Malaysians
above 30 years of age suffers from diabetes an estimated 1.4 million in number. The incidence and prevalence of
diabetes are escalating rapidly especially in developing and newly industrialized nations.
The complications of diabetes include vascular disease, diabetic retinopathy leading to blindness as well as diabetic
neuropathy, with the risk of leg amputations due to non-healing foot ulcers 27.7 times greater than non-diabetics.
Researchers and physicians have achieved remarkable success in treating non-healing ulcers of diabetic patients
with their own stem cells. In a recent study presented at the 2
nd
International Congress on Responsible Stem
Cell Research November 2009 in Monaco by Dr. Kostas I. Papadopoulos of THAI StemLife, in collaboration with
Bangkok Hospital Medical Centre (BMC) and Samitivej Srinakarin Childrens Hospital, autologous peripheral blood
stem cells were used to treat eighteen patients with non-healing lower limb ulcers.
PBSCs were harvested and subsequently injected into the patients lower limbs. Eighteen of a total of twenty
one ulcers healed completely (85.7%) with a mean healing time of 100.2 days while avoidance of amputation was
seen in 94.7% of the cases, thus concluding that PBSC therapy is a viable and effective therapeutic option in the
treatment of a diabetic non-healing lower limb ulcer.
Non-healing Wound PBSC transplant started
Wound healing at
20 weeks
Wound healed at
24 weeks
Healing of an ulcer treated with Stem Cells
26
Our Quality
COMPANY QUALITY ASSURANCE
Fully Licensed Cord Blood and PBSC Banking
Facility
StemLife is fully licensed by the Ministry of Health Malaysia,
under the Private Healthcare Facilities and Services Act,
1998 to process and cryopreserve cord blood stem cell
units. In addition, StemLife is licensed to conduct Peripheral
Blood Stem Cell banking (for adults).
ISO9001:2008
StemLife Berhad and its branches nationwide have a quality
management system certied under ISO (International
Organisation for Standardisation) 9001: 2008 from UKAS
(nationwide) and COFRAC (headquarters).
This certication is maintained annually in line with our
effort to continuously improve our services to enhance and
meet clients satisfaction.
Round-the-Clock 24 hours 365 days Service
With our 24 hour in-house secure logistics chain and a
24 hour on-call laboratory testing and processing facility,
your stem cells can be transported and processed as soon
as it reaches our laboratory. This efcient transport and
processing protocol ensure a maximum number of cells
are preserved.
Secure Facility
StemLifes own Genset Generator (Volvo Penta) assures a continuous supply for the entire facility and functions in
tandem with our uninterrupted power supply for critical areas. CCTV monitoring, biometrics identication and secure
data storage enhances our security system.
27
Our Successful Transplants
STEMLIFE: STEM CELL RELEASE DATA
StemLifes experience in processing, storing and releasing stem cells in treatment for our clients is unparalleled among
private cord blood banks in South East Asia. Since 2004, we have released 275 units for use at leading hospitals in
Malaysia. All of StemLife clients stem cell units have proven viable when released for use and were chosen as the best
course of treatment by the transplant specialists.
StemLifes proprietary processing and storage methods have produced some of the highest cell recovery rates in the
industry. StemLifes expertise and proven experience is well-respected among clients and the stem cell transplant
community.
For all transplants listed below (unless stated otherwise):-
Source of Stem Cells (SSC) : Peripheral Blood Stem Cells (PBSC)
Transplantation Mode (TM) : Autologous
TRANSPLANTS (2004-2011 to date)
MEDICAL CONDITIONS NO. OF CASES
Acute Myeloid Leukaemia (SSC: PBSC) (TM: Autologous) 8
Ankle Injury 1
Brain Injury (SSC: UCB*) (TM: Autologous) 1
Cartilage Joint Injury 168
Cerebral Palsy (SSC: UCB*) (TM: Autologous) 6
Diabetic Foot Ulcer 20
Gouty Arthritis 1
Heart Disease 30
Heel Injury 1
Leukaemia (SSC : UCB*) (TM: Allogeneic) 2
Leukaemia (SSC: PBSC) (TM: Allogeneic) 6
Lymphoma 9
Multiple Myeloma 1
Neuropathy 3
Shin Injury 2
Spine / Spinal Cord Injury 8
Stroke 3
Thalassaemia Major (SSC: UCB*) (TM: Allogeneic) 3
Wrist Injury 2
TOTAL 275
* UCB - Umbilical Cord Blood
Our Advisory Panels

Members of StemLifes advisory panels provide medical input, on a voluntary basis, to assist in policy-making
and analysis for the company to assume our role as Malaysians leading-edge life science company in the
stem cell industry.
The members will also assist in fostering interactions among Malaysian and international scientists, offer
suggestions to improve StemLifes services and where possible, promote StemLifes mission and services to
members of the profession.
OUR EXPERTS IN THE FIELD : MEDICAL ADVISORY PANEL
StemLife has a panel of experienced leaders in the eld of stem cell transplantation and cord blood cryopreservation
as our Medical Advisors. Their wide-ranging expertise and guidance has kept StemLife at the forefront of these elds.
PROF. DR. CHAN LEE LEE
MBBS (Mal), DCH (London), MRCP
(UK), FRCP (Edin)
Prof. Dr. Chan is a senior
paediatric consultant in the
Department of Paediatrics,
University of Malaya. She
is a practising paediatric
haematologist and oncologist
with specialised training in the eld of paediatric stem cell
transplantation. She performed the rst cord blood and
peripheral blood stem cell transplantation in Malaysia and
has initiated the unrelated cord blood transplantation
programme for paediatric patients. Prof. Chan is also
president of the Thalassaemia Society of University
Hospital (THASUH) and past president of the Malaysian
Society of Paediatric Oncology (MASPO).
DATO DR. HARNAM SINGH
A/L MANTHA SINGH
MBBS (NUS)
Dato Dr. Harnam graduated
with MBBS degree from the
University of Singapore and went
on to do his post-graduate in
the United Kingdom at Warwick
Hospital and the Royal National
Ear, Nose and Throat/Head and Neck Hospital, Grays Inn
Road, London. He worked as Consultant Otolaryngologist
until 1969 and in 1970, set up his own Ear, Nose and Throat
Centre in Kuala Lumpur.
Dato Dr. Harnam is a member of various medical bodies,
which includes a role as Founder Member of the Malaysian
Society of Otorhinolaryngology and World Society
of Otolaryngic Allergy. He has also written numerous
articles for Anti-Aging Medical Therapeutics and other
publications.
PROF. DR. ELIZABETH
GEORGE
MBBS (Malaya), DCP, FRCPA,
FRCPE, MD
Prof. George is currently a
Professor of Haematology at
the Universiti Putra Malaysia
and a visiting consultant at the
Institute of Medical Research,
Assunta Hospital and Prince Court Medical Centre. She
was previously a Professor of Pathology at the Universiti
Kebangsaan Malaysia. She obtained her medical degree
at the Universiti Malaya and subsequent specialist
training at the University of London. She has a fellowship
in haematology from the Royal College of Pathologists
(Australasia).
Her specialisation in the eld of thalassaemia has made
her a widely published author. She was instrumental in
setting up the haematological services at the Department
of Pathology, Universiti Kebangsaan Malaysia in 1977 and
has expertise in the clinical management of patients with
thalassaemia and haemoglobinopathies. She has conducted
extensive research studies to characterise thalassaemia
in Malaysia and completed a doctoral dissertation on
thalassaemia at the National University of Singapore. Prof.
Georges current projects include the development and
assessment of thalassaemia screening protocols and the
screening of thalassaemia in umbilical cord blood samples
in Malaysia. She is also the invited Scientic Collaborator
to the Thalassaemia International Federation (TIF).
ith
cted
ia
PROF. MAUDE ELVIRA

PHIPPS
PHD (UK)
Prof. Maude Elvira Phipps
graduated with a BSc. Honours
in Genetics from University
of Malaya. She obtained the
Cambridge Commonwealth
Trust Scholarship award to
pursue doctoral studies at University of Cambridge UK
in 1990 where she researched molecular genetics of Von
Hippel Lindau disease & Chromosome 3p- syndrome.
In 1994, she joined and contributed to the Faculty of
Medicine, University of Malaya through development
of biomedical sciences, specialist training and research
into molecular genetics of autoimmune diseases and
transplantation mechanisms, in collaboration with the
Oxford Transplant Centre and University of Western
Australia, supported by CICHE and UNESCO Human
Genome Fellowship awards. This resulted in a new
service for molecular immunogenetics and transplantation
matching at University of Malaya Medical Centre (UMMC).
Her current research focuses on human genomics and she
is a keen advocate of bioethics education and research. She
has published extensively in international journals, been
an invited speaker at numerous international meetings,
and supervised many graduate students over the years.
Prof. Maude is currently Associate Professor at School
of Medicine and Health Sciences, Monash University and
consultant specialist UMMC. She is an active member of
the Human Genome Organization (HUGO), Australian
South East Asian Tissue Typing Association (ASEATTA)
and the UNESCO Bioethics programme. She is co-chair of
the Policy Review Board of the Pan-Asia SNP Initiative and
is Vice President of the Genetics Society of Malaysia.
DR. RAJA ABDUL MALEK
BIN RAJA JALLALUD
MBBS (Universiti Malaya)
Dr. Raja Malek graduated from
the Universiti Malaya in 1972 and
was a practising senior partner in
Drs. Caterall, Khoo, Raja Malek
& Partners, one of the oldest
group practice overseeing local
and expatriate health in the Klang Valley, Malaysia. He
retired from the rm in 2003 after 31 years of practice.
From 1990 - 1995, Dr. Malek had been an honorary
clinical tutor at the Department of Primary Care Medicine,
University of Malaya. He held a part-time appointment
as the Director of Medical Affairs at Parke-Davis/Warner-
Lambert for Singapore-Malaysia Company for sixteen
years. Having a keen interest in corporate executive health
and sports, he has taken on active roles in various elds
including Vice-President of the Malaysian Association of
Sports Medicine, Chairman of the Asian Hockey Federation
Medical Committee, Pakistan and a member of the Medical
Commission of the International Hockey Federation
in Brussels, Belgium. He also served as the FIH Medical
Ofcer at the 12th Asian Games, Japan and the 16th KL
Commonwealth Games in Kuala Lumpur for Dope Control
and was the Chairman of the Steering Committee for the
formation of Masters Programme in Sports Medicine and
Rehabilitation (1994-95) of his alma mater.
Dr. Maleks driving interest in local healthcare and its
ethical issues have seen him serving as Chairman of
Council, Academy of Physicians, Malaysia (1997-98) and
as member of the National Health Plan Committee (1996-
97), National Committee on Managed Care (1996-97), and
the Ethical Committee of the Malaysian Medical Council,
Malaysia (2000-04). His is currently the Director of Medical
& Scientic Affairs for HOE Pharmaceutical Sdn. Bhd., a
Malaysian multi-national pharmaceutical rm.

Our Advisory Panels Medical
DR. TECK LING

MD, PhD
Dr. Teck Ling has over 14 years of safety and clinical
research experience in the development of healthcare
products. She graduated in Chemistry from the University
of Malaya in 1974 and proceeded to obtain her PhD in
Pharmaceutical Chemistry in the University of California,
San Francisco in 1979. She was awarded the University
of California Regents Fellowship and thereafter, she
worked in the pharmaceutical industry investigating drug
metabolism at Syntex for 8 years. She then completed her
Doctor of Medicine at the University of Miami in 1989 and
spent four years of residency in Internal Medicine at Kaiser
Permanente, Sante Clara. She served as the Associate
Medical Director at Alza Corporation and was appointed
the Senior Director for Pharmacovigilance and Medical
Information at Intermune Pharmaceuticals. She has since
become an independent consultant in her own capacity.
OUR EXPERTS IN THE FIELD: INTERNATIONAL ADVISORY PANEL
StemLifes diverse International Advisory Panel consists of professionals in the eld of oncology, blood and tissue
banking, clinical research and tissue engineering to provide medical expertise, updates and global insights into the stem
cell industry at large.
DR. FREDERICK L KIECHLE
MD, PhD
Dr. Kiechle graduated in
Chemistry from the Evansville
College, US in 1968 and went on
to obtain his PhD in Biochemistry
in Indiana University, US in 1973.
He has vast experience in the
medical sector, having served
amongst others as the Medical Director of the Beaumont
Reference Laboratory, US and Chairman of the Department
of Clinical Pathology, William Beaumont Hospital, US. Dr.
Kiechle is currently the Adjunct Professor of the Medical
Laboratory Services Program, Oakland University and
Clinical Associate Professor, Department of Pathology,
Wayne State University School of Medicine.
Dr. Kiechle is also a member of the American Society of
Clinical Pathologist and sits on several of its committees.
DR. PATRICK TAN
MBBS (NUS), MMed (NUS)
Dr. Tan graduated with a MBBS degree from the National
University of Singapore (NUS) in 1980 and obtained his
Masters of Medicine in Internal Medicine from NUS in
1986. He has vast experience in the medical sector and
has held various positions within Tan Tock Seng Hospital,
Singapore General Hospital and Toa Payoh Hospital in
Singapore from 1980 to 1988. He also served as Fellow
to the Fred Hutchinson Cancer Research Centre in 1988,
Special Fellow to Haematology Department, Cleveland
Clinic Foundation in 1989 and Faculty Member of
Transplant Immunology, Fred Hutchinson Cancer Research
Centre, Seattle, USA in 1992.
Dr. Tan has written numerous publications in medical
journals and books in Singapore and overseas. He is
a member of various medical societies, including the
American Society of Haematology and Blood & Marrow
Stem Cell Society. Dr. Tan has also been involved in various
stem cell research programmes.
Our Advisory Panels International
31
PROF. SEERAM
RAMAKRISHNA
PhD
Prof. Seeram Ramakrishna
is Professor of Mechanical
Engineering and Vice-
President (Research Strategy)
at the National University
of Singapore (NUS). He
also assists the university
in fostering research collaborations with the members
of Campus for Research Excellence and Technological
Enterprise, CREATE and is the founding Co-Director of
NUS Nanoscience & Nanotechnology Initiative (NUSNNI)
since 2003.
Prof. Seeram chairs the governing board of Solar Energy
Research Institute of Singapore (SERIS), Clean Energy
Program Ofce, National Research Foundation. He serves
on the boards of Institution of Engineers Singapore (IES),
Energy Studies Institute (ESI), Ministry of Foreign Affairs
and Ministry of Trade & Industry, Temasek Polytechnic,
Ministry of Education, and DSO National Laboratories,
Ministry of Defence. He is a member of NUS Presidents
taskforce on Global Asia Institute.
He received his PhD in Materials Science & Engineering from
the University of Cambridge and General Management
training from the Harvard University. He is known globally
for his pioneering work on electrospinning of nanobers.
He is advancing solar energy, water treatment and
regenerative medicine using engineered nanobers. He
developed aesthetic orthodontic brackets & arch wires
and electrospinning machine, which are now commercially
manufactured. He is a Fellow of major professional societies
in Asia, Europe and USA and a recipient of Changjiang
Professorship of China, ASEAN Outstanding Engineering
Award, NUS Outstanding Researcher Award, Lee Kuan
Yew Fellowship, and Cambridge Nehru Scholarship. He is
a Fellow of Royal Academy of Engineering, UK.
s
Prof. S
Research
Program
on the
Ene
krishna a
echanniical
and Vi Vice-
earch Strate teggy)
at a ioona nall Un Univ iversity
gapore (NUS). He
assists the university
rations with the members
Excellence and Technological
is the founding Co-Director of
Nanotechnology Initiative (NUSNNI)
chair irs the governing board of Solar Energy
Institu tute te of Singapore (SERIS), Clean Energy
Ofcee, National Research Foundation. He serves
s of Institution of Engineers Singapore (IES),
Institute (ESI), Ministry of Foreign Affairs
ade & Industry, Temasek Polytechnic,
n, and DSO National Laboratories,
e. He is a member of NUS Presidents
bal Asia Institute.
d his PhD in Materials Science & Engineering from
versity of Cambridge and General Management
ing from the Harvard University. He is known globally
or his pioneering work on electrospinning of nanobers.
He is advancing solar energy, water treatment and
regenerative medicine using engineered nanobers. He
developed aesthetic orthod odon onti tic brackets & arch wires
and electrospinning machinne, which ch are now commercially
manufactured. He is a Fellow w of major pr p ofessional societies
in Asia, Europe and USA and a re reci cipi pi p en e t of Changjian angg
Professorship of China, AS ASEA EAN N Ou Ouuu Outts ttstta ttanddin ing g Engi g ne neerin inggg ggg
Award, NUS Outstanding Res e ea earc cche hherr Aw w Awar ard, d, Lee KKuaaa uan n n
Yew Fellowship, and Cambri ri i g dg d ee Ne e Ne ehr hrr h u Sc Scho hooooola la lars rshi hipp. pp H HHHee e is is is
Fellow of Royal Academy of f EEng nginee eeri rrr ng ng, UUUK K UK UK...
m Of
he boards o
Energy Studies Ins
and Ministry of Trade
Ministry of Education,
Ministry of Defence.
taskforce on Globa
He received h
the Unive
trainiinn
foor r
H
PROF. RAJALINGAM SINNIAH
DSC, PhD (QUB) MA, MBBChBAO MD, FRCPI, FRCPA, PRCPath
(Lond), FAMS
Prof. Rajalingam Sinniah received his medical education
at the Trinity College, Dublin. After his specialist training
in internal medicine, he underwent further training in
pathology and obtained his doctoral qualications in iron
metabolism and liver diseases. He was awarded a DSC
from Queens University, Belfast for his published works
on Diseases of the Kidney and Liver. He then went on
to join the teaching faculty of the Faculty of Medicine in
Singapore where he rose to the rank of Professor.

In Singapore, Prof. Sinniah was the regional adviser to the
Royal College of Physicians, Ireland and National Advisor
to the Royal College of Pathologists, London. Prof. Sinniah
is also the Founder and former President of the Singapore
Society of Pathology and past President of the Asia Pacic
Associations of Societies of Pathology. Currently, he
is a Professor of Pathology at the University of Western
Australia and Consultant Pathologist at PathWest, Royal
Perth Hospital, Australia.
32 332 32 332 32 333332 32 33332 332 32 32 332 32 32 332 332 32 32 322 32 32 322222222222
Our Logistics
LOGISTICS QUALITY ASSURANCE
5VGO.KHGKUFGFKECVGFVQRTQXKFKPI
VTWUVGFUCHGCPFUGEWTG.1)+56+%5
UGTXKEGUQHVJGJKIJGUVOGFKECN
SWCNKV[
FLEET OF DEDICATED VEHICLES including

shipment via MAS Kargo for reliable and efcient
transport, ensuring safe and swift transfer.
STEMCOOL SHIPPING SYSTEM is a proprietory system
to maintain cells within the ideal temperature, utilising
IATA compliant shipping and packaging for best
outcome during transport.
33
24 HOUR GPS AND NAVISION
TRACKING SYSTEMS
for monitoring and tracking of cord blood
units in transit at all times.
24 HOUR TRANSFER TARGET for all cord
blood units transported to our laboratory
nationwide, and 48 hours worldwide, ensuring
quality of stem cells stored.
INTERNATIONAL SHIPMENT
StemLifes staff are certied by the IATA
and World Courier certicate program.
StemLifes cryoshipper, capable of holding
liquid nitrogen and keeping stem cells cool
for up to 8 days in transit, can be used for
both nationwide and international transport
of frozen stem cells.
34 34
Our Laboratory
LABORATORY COMPANY ASSURANCE
INTERNATIONAL PROTOCOLS AND STANDARDS
Best Practices in compliance with AABB, FACT-NETCORD & MOH standards
StemLife has developed and rened good practices in compliance with international recommendations such as those by
American Association of Blood Banks (AABB) and New York Cord Blood Bank.
International Cord Blood Processing Protocol
Processing of all units at StemLife utilize international protocols including the FDA approved Thermogenesis AXP
AutoXpress
TM
Platform, enabling consistent time-saving processing practices every time. StemLife also uses the FDA-
approved bag for stem cell cryopreservation and long-term storage.
Review by Chief Medical Ofcer & Laboratory Director (Person-in-Charge)
Laboratory results on the quality and viability of stem cells are reviewed by our Chief Medical Ofcer Prof. Dr. Aw Tar
Choon (Professor of Chemical Pathology) and Laboratory Director Prof. Dr. Elizabeth George (Professor of Haematology)
to ensure all necessary processing and testing has been undertaken according to StemLife standards.
Regular Checks and Maintenance
Daily equipment checks are performed and cryopreservation tanks are continuously monitored. All equipment are
regularly serviced and calibrated for optimum performance. Procedures are validated by participating in external
quality assurance programs (College of American Pathologists, ISO15189:2007), ensuring all equipment and laboratory
technologists technical skills are on par with international standards.
35
EQUIPMENT AND MATERIALS
Internationally Accepted Equipment and Materials
All laboratory processing equipment and materials utilised
by StemLife are approved either by US FDA or carried
the CE mark (manufacturers declaration that the product
complies with essential requirements of the relevant
European Health, Safety and Environmental Protection
legislations).
StemLife chooses to use the only FDA-approved storage
system for stem cell cryopreservation the closed system
multicompartment cryobag. This technology assures safe
and secure long-term storage, maintaining optimal cell
viability and ease of use in treatment.
Clinical Waste Disposal
Pantai Medivest Sdn. Bhd. is a well established licensed
clinical waste disposal company that handles and dispose
our waste, providing us with a certied and environmentally
friendly waste management solution.
Our Laboratory
p5VGO.KHG+U%QPVKPWCNN[
5VTKXKPI6QYCTF2TQXKFKPI
%QPUKUVGPV3WCNKV[
5GTXKEG6Q#NNq
36 36
CERTIFICATION AND ACCREDITATIONS
ISO15189:2007 ACCREDITATION
ISO15189:2007 is an important accreditation of international standard. It is used by
medical laboratories worldwide to develop their quality management system and
assess their technical competence. It is also used by accreditation bodies to conrm
or recognize the competence of medical laboratories.

StemLife Berhad is ofcially accredited with ISO15189:2007 which species
requirements for quality and competence particular to medical laboratories.
The scope of accreditation covers the area of all in-house testing:
o Haematology
o Total Nucleated Cell (TNC) count
o Viability
o CD34
+
cell count
o ABO grouping
o Medical Virology
o Infectious diseases
o Microbiology
o Bacterial culture
The accreditation exercise falls under the purview of Standards Malaysia which
is the national standardization and accreditation body governed by Ministry of
Science, Technology and Innovation.
This additional international recognition puts StemLife in better standing among
other service providers assuring our clients that their familys stem cells are in the
best of hands.
THE COLLEGE OF AMERICAN PATHOLOGISTS (CAP), USA PROGRAM
Since 2003, StemLife has voluntarily participated in CAPs external quality assurance
program to monitor and maintain the quality of our laboratory services. This is achieved through well-established
professional peer review process. The CAP program encompasses testing for stem cell processing (haematology,
virology, microbiology) providing quality assurance of in-house testing methodologies.
NEBB COMPLIANCE (INTERNATIONALLY CERTIFIED CLEANROOMS)
StemLife Laboratory has HEPA ltered cleanrooms for all cord blood and peripheral blood stem cell processing. These
cleanrooms are certied in compliance with the National Environmental Balancing Bureau (NEBB).
StemLife showcased the scientic presentation titled Bacterial Contamination in Cord Blood Banking A Malaysian
Our Laboratory
MINIMAL CONTAMINATION RATES
StemLife has maintained a low average of 2.8%
contamination from year 2007 to 2010. This rate is lower
than that reported from other facilities (Reed et al.; A.
Honohan et al.). Our effective methods of surveillance has
resulted in allowing more families to be able to store with
StemLife.
2010 2008 2009 2007
2.6%
12.7%
3.5%
3.1% 2.8% 2.6%
A. Honohan et. al Reed et. al
p#%QPVKPWQWU2WTUWKVQH3WCNKV[q
37
Our Laboratory
Research And Development
Experience at the 20
th
Congress of Obstetrics and Gynaecological Society of Malaysia, 2010.
COLLABORATION WITH UNIVERSITY PUTRA MALAYSIA (UPM)
StemLife collaborated with UPM to conduct a study on A Novel Diagnostic Tool For Thalassaemia
Screening In Red Blood Cells of Cord Blood Samples: A Malaysian Cord Blood Banking Experience.
ABSTRACT
BACKGROUND - Since its inception in 2002, StemLife
Berhad Laboratory has successfully processed, screened
and stored over 30,000 units of umbilical cord blood (UCB),
ten (10) of which have been released for use in various
debilitating diseases and disorders including leukaemia,
thalassaemia and cerebral palsy.
CONCLUSION - The annual contamination rate ranged
from 0.9% - 3.2% from year 2002 to 2009. Common types
of bacteria identied are those of vaginal ora including
Bacteroides sp., Enterococcus faecalis and Escherichia coli.
Contamination rate from vaginal delivery was higher than that
seen with caesarean section. The bacterial contamination rate
is comparable to those seen in other established cord blood
centres. It was noted that risk of bacterial contamination is
present in both vaginal delivery and caesarean section.
ABSTRACT
BACKGROUND - Detection and quantication of Hb*
(haemoglobin) subtypes of human blood is integral to
presumptive identication of thalassaemias. It has been
used in neonatal screening of thalassaemia and Hb* variants.
There have been no reports of screening of thalassaemia
in cord blood banking in Malaysia. The use of red cells
remaining following processing of the cord blood for stem
cells provides a diagnostic target for thalassaemia screening.
CONCLUSION - This study indicates a way to screen for
thalassaemia in red cells from cord blood. To our knowledge
this study provides the rst protocol to use discarded red
cells in cord blood banking for the quantication of Hb
subtypes for the presumptive identication of thalassaemia.
* Haemoglobin = A type of protein (iron-containing substance) that gives red
blood cells their characteristic color; functions primarily to transport oxygen
from the lungs to the rest of the body.
CCNCLUSICN
1 SL

P

l
A uC8

Z
n M8 A u A C 8C v C
8 M 1
P A M v S
8 8 A S C
MA1LkIALS ML1nCDS
A uC8 A

l uC8
1 SL L
1
8 8u S uC8
8

v

u uC8

S SL 8
uC8

8ACkGkCUND
1

C8ILC1IVL
C uC8

8 C

S 8
A

kLSUL1S
kLSUL1S
BACTERIAL CONTAMINATION
IN CORD BLOOD BANKING-
A MALAYSIAN EXPERIENCE
L C C LP k A M v 1 P? A 1C L S SL 8
C UC8 U C D M

S
C
V
C
2009 2007 2008 2006
Reed et. al.
2.9%
12.7%
3.5%
2.6% 3.1% 2.8%
. Honohan et. al.
C k
- The diagram above shows the average contamination rate of samples processed by StemLife from year 2006-2009.
C UC8 U C S
8 1
C

A
8
c
c

C
l
l
5
5
5 C 8
5
A \
\
S
8
uC8 S
C 8 L L
C C C S M !
RESEARCH & DEVELOPMENT
38
Q $TKPIKPIC0GY&KOGPUKQPVQ/GFKECN6JGTCRKGU
Q +PVTQFWEKPI0QXGN5GTXKEGU
CLINICAL TRIALS FOR CEREBRAL PALSY CHILDREN
Infusion of autologous (ones own) cord blood stem cells for children aficted with
Cerebral Palsy (CP) has been performed as early as 2005 and in 2007 StemLife
began a small scale clinical trial (still ongoing) to clients with CP children.
In March 2011, StemLife announced the publication of the worlds rst scientic
journal publication on Cerebral Palsy using a combination therapy of stem cells
and G-CSF. This journal evaluated a 2 year study on 2 toddlers who used their own
cord blood stem cells, previously banked with Thai StemLife. It was reported that
there were no side effects of infusing ones own cord blood stem cells, consistent
with results from other reports of autologous infusion.
StemLife has released 6 cord blood units for children with Cerebral Palsy to-date.
The medical report Safety and feasibility of autologous umbilical cord blood
transfusion in 2 toddlers with cerebral palsy and the role of low-dose granulocyte-
colony stimulating factor injections can be found in the Journal of Restorative
Neurology and Neuroscience 29 (2011) 17-22.
RESEARCH AND DEVELOPMENT
National University of Singapore Neuroscience and Nanotechnology Initiative (NUSNNI)
StemLife contributes towards downstream R&D programs to investigate into the area of stem cells. This is in collaboration
with the NUSNNI, Singapore and Cryo Stemcells (Karnataka) Pte. Ltd.
Recent published papers include:
o Biomimetic Hydroxyapatite-containing Composite Nanobrous Substrates for Bone Tissue Engineering Venugopal
J, Prabhakaran MP, Zhang Y, Low S, Choon AT, Ramakrishna S. ; Philos Transact A Math Phys Eng Sci 2010 Apr 28; 368 (1917):2065-81
o Aligned and Random Nanobrous Substrate for the In Vitro Culture of Schwann Cells for Neural Tissue Engineering
Venugopal J, Prabhakaran MP, Low S, Choon AT, Deepika G, Dev VR, Ramakrishna S. ; Acta Biomater 2009 Sep; 5 (7):2560-9
Kuala Lumpur Sports Medicine Centre (KLSMC) and University Putra Malaysia (UPM)
StemLife and KLSMC explored stem cell application for cartilage joint injuries in knees in collaboration with UPM. Animal
trials were conducted over 12 months demonstrating revolutionary results when stem cells and hyaluronic acid were
administered to damaged joints. Now in human clinical trials, stem cell units from over 150 StemLife clients have been
used autologously to successfully treat and improve their cartilage joint injuries.
NOVEL SERVICES
All StemLife Baby clients (newly enrolled) receive novel enhanced benets with their StemLife Baby package.
StemShieldPLUS, StemAssured, Stem21 and StemCourier are our exclusive services. StemShieldPLUS offers
comprehensive coverage for cord blood stem cell transplants using either the childs own cord blood unit or another
matched unit. It has a maximum coverage of up to RM100,000 and covers use by baby, babys siblings and babys
parents until the child is 21 years old.
Our Innovations
39
Corporate Social Responsibility
& Stem Cell Awareness Activities
o Support of the Thalassaemia Foundation in UMMC.
o Sponsorship of cord blood and peripheral blood
stem cell banking to raise funds for the Dreamz
Foundation.
o Sponsorship of cord blood banking and therapeutics
for blood cancer patients.
o Sponsorship and participation in Obstetrical &
Gynaecological Society of Malaysias (OGSM)
Walking Tall Charity Walk to raise awareness and
funds for health in young women.
o Participation in Malay Mail Big Walk for charity to
raise funds for children with bone cancer.
o Participation in Terry Fox Run for the Terry Fox
Foundation towards Cancer Research Funding.
o Spreading Christmas cheer with Santa and gifts
amongst hospitalized patients in local hospitals.
o StemLife Blood Donation Drive 2009.
o StemLife Donation Drive for the Malaysian
Thalassaemia Foundation, 2009.
o Stem21 a special program for all StemLife Baby
clients to offer waiver of storage fees until the child
is 21 years old should one of his/her parents pass
away.
Parenting and Baby Fairs
o Motherhood Expo
o Smart Kids, PWTC
o Mom & Baby Expo
o 6
th
Parenthood Expo
o 1
st
Malaysia Baby, Children & Parents Expo
Workshops, Forums, Talks
In view of our support for healthy lifestyle in parenting,
StemLife works in collaboration with other corporations.
o Parenthood Workshop, (Seremban)
o Healthy Mama, Happy Baby Forum (Alor Setar)
o Healthy Mama, Happy Baby Forum (Selangor)
o Healthy Mama, Happy Baby Forum (Kota Kinabalu)
o Healthy Mama, Happy Baby Forum (Johor Bahru)
o Stem Cells Resource Session by Vistage (Kuala
Lumpur)
o ANCs nationwide
Continuous Medical Education Programs
StemLife also works closely with healthcare providers to
encourage exchange of information and experience on
stem cell applications and benets.
o Workshop on Proling and Intervention of Children
with Developmental Disabilities (Swan Convention
Centre)
o CNE Talk at KPJ Kuantan Specialist Hospital
o CNE Talk at COOP Medical Centre
As a private cord blood banking facility, StemLife not only focuses on our clients but also on giving back to the
community whether they are the general public or healthcare providers. Here are some examples of community
involvement StemLife has engaged in a socially benecial way:
40 40
Asia Pacific Cord Blood
Bank Consortium
A MISSION FOR CORD BLOOD STEM CELLS
Promoting the concept and elevating the signicance of cord blood stem cell banking and therapy to health professionals,
parents in the community and the general public throughout the region.
Objectives as a consortium member:
1. To be primary providers of quality cord blood stem cell banking services;
2. To provide culturally appropriate, relevant and accessible services to diverse groups of parents throughout the
region;
3. Empower positive change and continuous improvement for cord blood banks;
4. Promote the benets of cord blood stem cells to health professionals and parents in the community;
5. Highlight cord blood stem cell transplantation and the benets of cord blood stem cells to family associations;
6. Elevate the signicance of cord blood stem cell banking to government, business, non-government and families.
Ethical Standards of Practice (ESP)
APCBBC members agree to uphold recognition standards of Ethical Standards of Practice (ESP), in areas of practice,
integrity and condentiality in each organization towards the public and industry players.

The objective of ESP is to create an environment for leading cord blood banks in Asia Pacic
to support each other in line with APCBBCs mission to serve the community better.
SECRETARIAT & FOUNDING MEMBER
Malaysia StemLife Berhad
OTHER FOUNDING MEMBERS
Taiwan Bionet Corp.
Korea LifeCord Inc.
Hong Kong CRYOLIFE
Singapore CordLife
MEMBERS
Japan StemCell Institute
Australia Cryosite Ltd.
Thailand THAI StemLife
India StemOne Biologicals
Indonesia PT CordLife
South Africa Lazaron Biotechnologies
Vietnam MekoStem
ESP encompasses areas in:
o Practice
o Integrity
o Condentiality
41 41
APCBBC Forum
Established in 2002, annual meetings bring together the regions foremost and leading cord blood stem cell banking
companies in the Asia Pacic region to meet, discuss and collaborate in addressing current issues surrounding the
industrys development. The forums address industry perspectives, medical breakthroughs and the applications of cord
blood stem cells in the region today and in the future. Industry perspectives include how cord blood stem cell banking
has provided for successful patient transplantations and enabled doctors to offer their patients stem cell therapy as an
option, and how the industry is perceived by the general public.
APCBBC Forum 2010
APCBBC 2010 was hosted by CRYOLIFE and held in the Marco Polo Hong Kong Hotel, Hong Kong. With the theme
Stem Cell Banking Hot Square, the forum included topics on HLA typing, use of stem cells in stroke and use of cord
blood stem cells in spinal cord injuries. Guests from Greece (Biohellenika S.A.) and several renowned scientists were also
in attendance to share their research and expertise.
Main Topic of The Forum:
Cord Blood Stem Cells for Spinal Cord Injury
Research and extensive clinical trials on using cord blood
stem cells to treat spinal cord injuries in China.
Prof. Wise Young M.D. Ph.D.
Professor II Richard H. Shindell Chair in Neuroscience,
Founding Director, W.M. Keck Center for Collaborative
Neuroscience, Rutgers, The State University of New
Jersey, Distinguished Visiting Professor, The University of
Hong Kong
HLA Typing
Dr. Janette Kwok
Transplantation and Immunogenetics Division, Department
of Pathology, Queen Mary Hospital
Preclinical Studies of Stem Cells in Animal Stroke
Model
Dr. Kent Tsang
Bone Marrow Transplant Laboratory, Division of
Haematology, Department of Anatomical and Cellular
Pathology, The Chinese University of Hong Kong
Introduction of MekoStem: establishment and
function of the rst MOH licensed stem cell bank
in Vietnam
Dr. LE Van Dong MD., Ph.D.
MekoStem Chief Scientist, Vietnam
42
Directors Profile
Tan Sri Dato Seri Dr. Aseh obtained his Bachelor of Economics degree with
Honours from the University of Malaya in 1974. He also holds a Masters
Degree in Public Administration from the University of Southern California,
United States of America. Upon his graduation, Tan Sri Dato Seri Dr. Aseh
joined the Ministry of Finance as Assistant Secretary. Up until his retirement
in October 2007 as Secretary General of the Ministry of Home Affairs, he
held various positions in the civil service, ranging from Principal Assistant
Secretary in the Education Services Commission, various positions in Ministry
of Home Affairs to Director General of Immigration Malaysia. Tan Sri Dato
Seri Dr. Aseh is active in community services and is currently the Chairman
of Volunteers Corp Cooperatives, Malaysia (RELA) and President of UMNO
Club, Retired Senior Civil Servants.
Tan Sri Dato Seri Dr. Asehs current directorships includes Non-Independent
Non-Executive Chairman of Pos Malaysia Berhad, Independent Non-
Executive Chairman of MWE Holdings Berhad and Independent Non-
Executive Director of Lion Diversied Holdings Berhad.
Tan Sri Dato Seri Dr. Aseh does not have any family relationship with any other directors or major shareholders of the
Company. He has no conict of interest with the Company and has not been convicted of any offences within the past
ten (10) years, other than trafc offences, if any. Tan Sri Dato Seri Dr. Aseh was appointed on 16 April, 2008.
Tan Sri Dato Seri Dr. Aseh attended all four (4) Board Meetings of the Company held during the nancial year.
Dato Low started StemLife in 2001 and is currently its Managing Director
and is responsible for the management, strategies and business direction
of StemLife. She holds a Bachelor of Science (Hons) in Biochemistry from
the University of Bristol, UK. She was previously a research scientist at the
Institute of Molecular Agrobiology afliated to the National University of
Singapore.
She co-founded the Asia Pacic Cord Blood Bank Consortium (APCBBC) and
is its industry Chairperson. She is also an invited scientic advisory panel
member for the US-based Parents Guide to Cord Blood Foundation and also
for a Malaysian-based biotechnology education group MABIC.
Dato Low does not sit on the board of any other public listed company.
Dato Low does not have any family relationship with any other directors or
major shareholders of the Company. She is also a substantial shareholder
of the Company. She has no conict of interest with the Company and has
not been convicted of any offences within the past ten (10) years, other than
trafc offences, if any.
Dato Low attended all four (4) Board Meetings of the Company held during
the nancial year.
TAN SRI DATO SERI DR. ASEH BIN CHE MAT
Malaysian, age 59, was appointed as Independent Non-Executive Chairman of StemLife (the Company)
on 16 April 2008.
DATO LOW SU-SHING, SHARON
Singaporean, age 35, was appointed as Executive Director of the Company on 13 December 2001.
She is also the Chairperson of the remuneration Committee of the Company.
43
She is a co-founder of StemLife and is currently its Deputy Managing Director.
She is responsible for the management of the operations of StemLife. She
has extensive experience in business development, nancial planning and
advisory management.
Dato Lim does not sit on the board of any other public listed company.
Dato Lim does not have any family relationship with any other directors or
major shareholders of the Company except for Mr. Lim Jit Soon who is her
brother and an Executive Director of the Company. She is also a substantial
shareholder of the Company. She has no conict of interest with the Company
and has not been convicted of any offences within the past ten (10) years,
other than trafc offences, if any.
Dato Lim attended all four (4) Board Meetings of the Company held during
the nancial year.
Prof. Aw is a co-founder of StemLife and is currently the Chief Medical
Ofcer, overseeing the Companys medical and scientic matters. Prof. Aw
graduated as a medical doctor (MBBS) from the University of Malaya and
trained in internal medicine at the Singapore General Hospital and Kings
College Hospital, UK. He underwent further training at the Hospital of
University of Pennsylvania, Philadelphia, US. He has Specialist Certication
in Internal Medicine from the National University of Singapore (NUS) and
the Royal College of Physicians, UK and in chemical pathology from the
Royal College of Pathologists of Australasia. Prof. Aw was the Chief of the
Department of Laboratory Medicine at the National University Hospital,
Singapore from 1988 to 2002. He was the Vice Dean of the NUS Medical
School from 1994 to 2002 and served as the Chief Executive of Alexandra
Hospital in Singapore from 1995 to 2002. Prof. Aw has published widely in
the medical literature, lectured in numerous congresses in 23 countries and
received several distinguished awards.
Prior to joining StemLife, he was Group Medical Advisor to the Health
Management International Group, a Singapore public listed company.
He also co-founded two medical science companies in Thailand and Singapore.
Prof. Aw does not sit on the board of any other public listed company.
Prof. Aw does not have any family relationship with any other directors or major shareholders of the Company. He is also
a substantial shareholder of the Company. He has no conict of interest with the Company and has not been convicted
of any offences within the past ten (10) years, other than trafc offences, if any.
Prof. Aw attended all four (4) Board Meetings of the Company held during the nancial year.
PROF. DR. AW TAR CHOON
Singaporean, age 59, was appointed as Executive Director of the Company on 18 March 2003.
DATO LIM OI WAH
Malaysian, age 57, was appointed as Executive Director of the Company on 13 December 2001.
44
Directors Profile
Mr. Lim is the Chief Financial Ofcer responsible for overseeing StemLifes
nances, corporate matters, and administration. He qualied as an accountant
in 1983 and is a Fellow of the Institute of Chartered Accountants in England
and Wales. Prior to joining StemLife, he was the Senior Vice President of
Finance of the Star Cruises Group.
During the last 15 years of his working experience he has held senior
management positions in several companies, including 3 public listed
companies in Malaysia, Singapore, and Hong Kong, namely Star Cruises
Group, Ipco International Ltd. and Kuala Lumpur Industries Holdings Berhad.
Mr. Lim does not sit on the board of any other public listed company.
Mr. Lim does not have any family relationship with any other directors or major
shareholders of the Company except for Dato Lim Oi Wah who is his sister
and an Executive Director of the Company. He has no conict of interest with
the Company and has not been convicted of any offences within the past ten
(10) years, other than trafc offences, if any.
Mr. Lim attended all four (4) Board Meetings of the Company held during the
nancial year.
LIM JIT SOON
Malaysian, age 54, was appointed as Executive Director of the Company on 02 November 2006.
Mr. Loh graduated with a degree of Bachelor of Laws (Hons) from University
of Singapore in 1965. He was active in private legal practice after being called
to the Malaysian and Singaporean Bars in the mid and late sixties respectively
and helped to build a small legal rm into a moderately large one until he
retired in 2001.
Upon retirement from active legal practice, Mr. Loh was engaged in part-
time consultancy and devoted more time to charity organizations which he
served for approximately 15 years in various capacities. Apart from looking
after the legal affairs of the entities under the organizations, he expanded
efforts in ensuring proper management and reporting of accounts, corporate
governance and transparency in all the entities, particularly in respect of the
charitable funds under their care. Mr. Loh also had interests in other non-
governmental organizations and has served as legal advisor and sat on the
management boards/councils in such organizations. He joined the Board in
March 2005 and is consulted on the legal aspects of the companys business.
Mr. Loh does not sit on the board of any other public listed company.
Mr. Loh does not have any family relationship with any other directors or major
shareholders of the Company. He has no conict of interest with the Company
and has not been convicted of any offences within the past ten (10) years,
other than trafc offences, if any.
Mr. Loh attended all four (4) Board Meetings of the Company held during the
nancial year.
LOH YOON KWAI
Malaysian, age 69, was appointed as Independent Non-Executive Director of the Company on 16 February 2005.
He is also Chairman of the Nomination Committee and a member of the Audit Committee and Remuneration
Committee of the Company.
45
Tengku Putra is the Chairman of Illuminex Sdn Bhd, Executive Director of KB
Enviro Sdn Bhd and was the Chief Executive Ofcer of KB Enviro Sdn Bhd
from 2002 to 2008. He was also a director of Kangzen-Kenko International
Group from 1998-2004 and Senior Advisor of Spektrum Ribu (M) Sdn Bhd
from 2001-2004. Prior to this he was Senior Dealer in Pengkalen Securities
Sdn Bhd.
Tengku Putra graduated in 1990 from the Arkansas State University, US with
a Bachelor of Science majoring in Business Administration. He is a member
of UMNO and has been the Vice Chief of the Pulai Division since 2004. He is
also the Chairman of the Education Bureau and Constitutional Amendments
Committee for the Division.
Tengku Putra does not sit on the board of any other public listed company.
Tengku Putra does not have any family relationship with any other directors
or major shareholders of the Company. He has no conict of interest with the
Company and has not been convicted of any offences within the past ten (10)
years, other than trafc offences, if any.
Tengku Putra attended all four (4) Board Meetings of the Company held
during the nancial year.
TENGKU PUTRA HARON AMINURRASHID BIN TAN SRI TENGKU HAMID JUMAT
Malaysian, age 47, was appointed an Independent Non-Executive Director of the Company
on 13 December 2001. He is also Chairman of the Audit Committee and member of
the Nomination Committee of the Company.
Ms. Yap is a Certied Practising Accountant of the Australian Society
of Certied Practising Accountants (ASCPA), and is registered with the
Chartered Accountant of Malaysian Institute of Accountants (MIA). In 1990,
she graduated from University of Newcastle, Australia, with a Bachelor
of Commerce majoring in Accounting, and later on obtained a Master of
Business Administration (MBA) from Universiti of Malaya in 2000. She has 19
years of experience in nance and administration in various industries, mostly
in property development and management.
Ms. Yap does not sit on the board of any other public listed company.
Ms. Yap does not have any family relationship with any other directors or
major shareholders of the Company. She has no conict of interest with the
Company and has not been convicted of any offences within the past ten (10)
years, other than trafc offences, if any.
Ms. Yap has attended one (1) out of four (4) Board Meetings of the Company
held during the nancial year.

f

YAP YU MING
Malaysian, age 42, was appointed as Independent Non-Executive Director of the Company
on 16 February 2011. She is also a member of the Audit Committee, Remuneration Committee
and Nomination Committee of the Company.
46
Group Management Team
ZAHREIN REDZA
Chief Operating Ofcer, StemLife Berhad
Mr. Redza is StemLifes Chief Operating Ofcer (COO). He obtained his Masters in Biochemistry from Queens
University at Kingston, Ontario, Canada in 1993. He has had a diverse range of healthcare and clinical exposure in
industry, hospitals and academia in Canada, Singapore and Malaysia. His tenure includes positions as Research Scientist
in Clinical Research Institute of Montreal, Canada, Research Scientist at Scitech Genetics, Singapore, Diagnostics
Division Executive in Subang Jaya Medical Centre, Director of Malaysian Technology Development Corporation and
management positions at other private hospitals. More recently, he was the Group Manager of Business Development
at Columbia Asia Group of Hospitals as well as the Administrator of Columbia Asia Medical Center, Miri. In 2004 he
was appointed the Chief Operating Ofcer of the Tun Hussein Onn National Eye Hospital. He joined StemLife as
Director of Operations in June 2005.
LIEW SIEW NGOR
Company Secretary
Ms. Liew is a Chartered Secretary as well as a qualied lawyer. She qualied as a Chartered Secretary in 1981 and is
an Associate with the Institute of Chartered Secretaries and Administrators, UK, as well as a registered member with
the Malaysian Institute of Chartered Secretaries and Administrators (MAICSA). In 2007, she graduated with a Bachelor
of Laws (Hons) from University of London and had successfully passed the post graduate Certicate of Legal Practice.
She has 20 years of working experience in the securities industry holding various positions as Company Secretary,
Investment Analyst and Manager in a stockbroking rm, specializing in nominees and fund management services and
last held the position as Head of Operations of Private Banking of a local investment bank.
VOON KE QIN
Operations Manager
Mr. Voon holds a Bachelors degree in Biotechnology from Monash University. He joined StemLife in 2003 and is
now the Operations Manager overseeing branch operations and business opportunities. He is also responsible for
development of sales packages and overall strategy.
DATO LOW SU-SHING, SHARON
Managing Director
Refer to Board of Directors/ Directors Prole Page 42
DATO LIM OI WAH
Deputy Managing Director
PROF. DR. AW TAR CHOON
Chief Medical Ofcer
MBBS, MMed (Internal Medicine), MRCP, FRCP Edin, FRCPA, FAMS, MPP
LIM JIT SOON
Chief Financial Ofcer
RAVINDRAN BPM
Chief Operating Ofcer, StemLife Therapeutics
Mr. Ravindran was appointed as the Chief Operating Ofcer (COO) of StemLife Therapeutics Sdn Bhd in October 2009.
He has been trained in Medical Science and has been involved in the healthcare industry for over 20 years, of which he
dedicated 7 years to the stem cell industry. Mr. Ravindran has over the course of his career worked with both local and
multinational organizations in various industries ranging from Medical Healthcare to Talent Recruitment Management
to Biotechnology, where he held several senior management positions including Vice President (Operations) and
COO. Prior to his current role in StemLife, he served as COO of Cryocord Sdn Bhd (one of the players in the stem
cell industry) and subsequently after served as COO of Pantai Hospital Ipoh. In both organizations his role was to set
the direction, planning, management and growth of various operating divisions within the organization. He has been
invited to give numerous talks at various seminars and symposia on the advances in the stem cell eld.
47
Group Management Team
HOE LU LU
Director of StemLife Therapeutics - Marketing
Ms. Hoe has held the position of Senior Account Director in multinational advertising agencies and subsequently as
VP in the corporate sector and consultant with a public listed company in the property business. She joined StemLife
in 2005 holds the position as Director of PR & Communications, responsible for the growing developments and
marketing of Adult Stem Cell Banking at StemLife.
LIM MUI LAN
Director of StemLife Therapeutics - Operations
Ms. Lim was a remisier in a stockbroking rm before she joined StemLife 5 years ago. She now holds the position as
Manager for the Adult Stem Cell Banking Department and is responsible for all aspects of the departments operation.
CHOW LAI MUN
Finance & Administration Manager
Ms. Chow completed the Chartered Institute of Management Accountants in 1999 and qualied as an accountant in
2000. She held the position of Finance & Administration Manager of Parisign Exhibition Manufactures (Beijing) Co.,
Ltd. and joined StemLife Berhad as Finance & Administration Manager in July 2008.
GOH SIEW POH
Human Resource & Training Manager
Ms. Goh joined StemLife Berhad as HR & Training Manager in June 2009. She holds an Executive Diploma in Human
Resource Management from University of Malaya Centre for Continuing Education. She has over 20 years human
resource, admin and training related experiences in different industries ranging from management consultancy,
property services, hospitality and healthcare related organizations. Ms. Goh was previously HR & Admin Manager at
Mahkota Medical Centre, Melaka.
LOW SHUHUA
Special Projects Manager
Ms. Low graduated from Kings College University, London in 2004 with a Bachelors degree in Biomedical Science
Hons. Subsequently, she attained a research assistant position conducting research into stem cells in the Agency of
Science, Technology and Research (A*STAR), Singapore. She joined StemLife in 2006 and now holds the position of
Special Projects Manager, assisting in internal projects and Operations and heading the marketing department.
KAMALAN ASOKAN
Business Development Manager (Technical)
Mr. Asokan graduated from Universiti Kebangsaan Malaysia with a Bachelor degree in Biomedical Science (Hons) in
2003. Upon graduation he took up the role of a Biochemist at a private laboratory in Penang. He joined StemLife
in 2003 previously as Laboratory Supervisor, and is now the Business Development Manager of laboratory technical
matters, certication and accreditation.
GOH ERN HUEI
Laboratory Manager
Ms. Goh graduated from University Malaya with a Bachelor degree in Biotechnology (Hons) in 2005. She joined
StemLife 2005 and currently holds the position as Laboratory Manager, overlooking all laboratory operations,
certication and accreditation.
48
Group Structure
100% StemLife Therapeutics Sdn. Bhd.
100% StemLife Diagnostics Sdn. Bhd.
100% StemLife Properties Sdn. Bhd.
100% StemLife Logistics Sdn. Bhd.
73% StemVet Sdn. Bhd.
60% Advent Capital Sdn. Bhd.
40% THAI StemLife Co. Ltd.
40% Prodia StemLife Indonesia, PT.
49 49
REGIONAL STRATEGIC ALLIANCES AND COLLABORATIONS
BANGKOK, THAILAND THAI StemLife
THAI StemLife, established in 2005, is the rst private stem cell bank in Thailand with storage facilities in the country, with
an aim to provide cord blood and peripheral blood stem cell banking services to the nation. The company was founded
as a joint venture between StemLife Berhad, Superior Biotech Co. Ltd. (Thailands leading healthcare provider) and
Jetanin Hospital, Bangkok. Its practices are AABB compliant and it is also a member of the APCBBC which recognises
THAI StemLife to be the pioneer and leading bank in Thailand. Its customised world-class laboratory has been accredited
with ISO15189:2007 since 2009 and is located in their own building in central Bangkok.
JAKARTA, INDONESIA PT Prodia Widyahusada
PT Prodia Widyahusada and StemLife entered into a joint venture to form Prodia StemLife. The company will provide
private stem cell banking services for Indonesia. Prodia Clinical Laboratory is the business unit of PT Prodia Widyahusada,
specialising in laboratory services. It is one of Indonesias leading clinical laboratory groups with over
35 years experience in the industry. It currently manages the biggest clinical
laboratory operation in Indonesia, with over 106 branches (located
in 73 cities in 25 provinces) and 2,000 staff. It serves approximately
1.5 million customers yearly ranging from doctors and hospitals to
laboratories and the general public. Prodia also provides special
laboratory diagnoses for clinical trials. Prodia StemLife is expected
to commence stem cell services in the 2
nd
half of 2011.
T
wit
JAKART
PT Prodia
private st s em
sp pecialising iin n l
355 years experien
labo boratory operation
in 73 3 ci citi t es in 25 provin
1.5 million cu c stomers ye
laboratories aand n the laboratories annd th
laboratory diagn no
to com omme m nce
Corporate Overview
p# UJCTGF XKUKQP HQT GUVCDNKUJKPI UVGO EGNN VJGTCR[ CU QPG QH VJG
VJTGGRKNNCTUQHJGCNVJECTGOCPCIGOGPVq
Peninsular
Malaysia
East
Malaysia
HEADQUARTERS
Kuala Lumpur
BRANCH OFFICES
Penang
Ipoh
Malacca
Batu Pahat
Johor Bahru
Kota Kinabalu
Sibu
Kuching
REPRESENTATIVE
AREAS
Kedah
Pahang
Negeri Sembilan
Miri
Muar
MALAYSIA REGIONAL COVERAGE
50
Corporate Information
BOARD OF DIRECTORS
TAN SRI DATO SERI DR. ASEH BIN CHE MAT Independent Non-Executive Chairman
DATO LOW SU-SHING, SHARON Managing Director
DATO LIM OI WAH, CHRISTINA Deputy Managing Director
PROF. DR. AW TAR CHOON Chief Medical Ofcer
LIM JIT SOON, MICHAEL Chief Financial Ofcer
LOH YOON KWAI Independent Non-Executive Director
TENGKU PUTRA HARON AMINURRASHID
BIN TAN SRI TENGKU HAMID JUMAT Independent Non-Executive Director
YAP YU MING Independent Non-Executive Director
AUDIT COMMITTEE MEMBERS
Tengku Putra Haron Aminurrashid
bin Tan Sri Tengku Hamid Jumat
Chairman
Loh Yoon Kwai
Yap Yu Ming
REMUNERATION COMMITTEE MEMBERS
Chairperson
Loh Yoon Kwai
Yap Yu Ming
NOMINATION COMMITTEE MEMBERS
Loh Yoon Kwai
Chairman
bin Tan Sri Tengku Hamid Jumat
Yap Yu Ming
COMPANY SECRETARIES
Laang Jhe How (MIA 25193)
No. 37, Jalan Sri Petaling 16, Sri Petaling,
57000 Kuala Lumpur.
Liew Siew Ngor (MAICSA 0757010)
81, Jalan Burung Tekukur,
Taman Bukit Maluri Kepong,
52100 Kuala Lumpur.
REGISTERED OFFICE
149A, Jalan Aminuddin Baki, Taman Tun Dr. Ismail,
60000 Kuala Lumpur.
Tel : +603 7729 1519
Fax : +603 7728 5948
SHARE REGISTRAR
Insurban Corporate Services Sdn Bhd
149, Jalan Aminuddin Baki, Taman Tun Dr Ismail,
60000 Kuala Lumpur.
Tel : +603 7729 5529 Fax : +603 7728 5948
AUDITORS
STYL Associates
107-B, Jalan Aminuddin Baki, Taman Tun Dr. Ismail,
60000 Kuala Lumpur.
Tel : +603 7727 5573 Fax : +603 7727 0771
PRINCIPAL BANKERS
Alliance Bank Malaysia Berhad
Hong Leong Bank Berhad
Public Bank Berhad
CIMB Bank Berhad
EON Bank Berhad
United Overseas Bank (Malaysia) Berhad
STOCK EXCHANGE
ACE Market of Bursa Malaysia Securities Berhad
Stock Name: STEMLFE
Stock Code: 0137
WEBSITE
www.StemLife.com
51
Statement of Directors
Responsibility
For Preparation of Financial Statements Pursuant To Paragraph 15.26(a) of the ACE Market Listing
Requirement of Bursa Malaysia
The fnancial statements of the Group and of the Company are drawn up in accordance with the applicable approved
accounting standards in Malaysia and the provisions of the Companies Act, 1965. The Directors are responsible for
ensuring that the fnancial statements give a true and fair view of the state of affairs of the Group and of the Company
at the end of the fnancial year and of the results and cash fows of the Group and of the Company for the fnancial year.
In preparing the fnancial statements, the Directors have:
a) Selected suitable accounting policies and applied them consistently;
b) Made judgements and estimates that are reasonable and prudent;
c) Ensured that all applicable accounting standards have been followed; and
d) Prepared fnancial statements on a going concern basis as the Directors have a reasonable expectation having
made appropriate enquiries that the Group and the Company have adequate resources to continue in operational
existence in the foreseeable future.
The Directors have the responsibility for ensuring that the Company keeps accounting records which disclose with
reasonable accuracy of the fnancial position of the Group and of the Company and which enable them to ensure that
the fnancial statements comply with the Companies Act, 1965.
The Board has the overall responsibility to take all steps as are reasonably opened to them to safeguard the assets of the
Group to prevent and detect frauds and other irregularities.
52
Statement of Corporate
Governance
The Board acknowledges the importance of promoting good corporate governance and is committed to ensure
that it is practised with high integrity and transparency throughout the Group in all aspects of its business dealings
without compromising the objective of safeguarding shareholders interest and ultimately enhancing shareholders
value.

The Board of Directors (the Board) of StemLife Berhad (StemLife) are pleased to report to the shareholders on
the manner in which the StemLife group of companies (the Group) applies the principles and extent of compliance
with the Best Practices of Corporate Governance as set out in Part 1 and Part 2 of the Malaysian Code on Corporate
Governance (the Code) and pursuant to Paragraph 15.25 of the Listing Requirements of Bursa Malaysia Securities
Berhad for the ACE Market (Bursa Malaysia).
THE BOARD OF DIRECTORS

Composition, Duties and Responsibilities
The Group is led by an experienced Board under the Managing Director, Dato Low Su-Shing, supported by three (3)
Executive Directors and four (4) Independent Non-Executive Directors. This is in compliance of Paragraph 15.02 of the
Listing Requirements of Bursa Malaysia, which requires at least two (2) directors or one-third (1/3) of the Board of a listed
company, whichever is higher, are Independent Directors.
The Board is satisfed that its current composition fairly refects the investment on the Company, and that its current
size and composition are effective for the proper functioning of the Board. The Independent Non-Executive Directors,
as defned under Paragraph 1.01 of the Listing Requirements of Bursa Malaysia, are independent of management and
are free from any business or other relationships that could interfere with the exercise of independent judgement or the
ability to act in the best interests of the Group. The Independent Directors provide a broader view and an independent
and balanced assessment.
The Board has the overall responsibility for the performance of the Group by maintaining full and effective control over
strategic, fnancial, operational, compliance and governance issues. These include:

o Reviewing and adopting strategic business plans for the Group;
o Identifying principal risks and ensuring the implementation of appropriate systems to manage these risks;
o Managing and overseeing the operations of the Groups businesses; and

o Reviewing the adequacy and integrity of the Groups systems of internal controls and management systems
including systems for compliance with applicable laws, regulations, rules, directives and guidelines.

The Board which has strong independent elements provides the strategic direction and corporate objectives of
the Company and delegates the authority to the Managing Director to implement the policies and decisions of the
Board.
53
Governance (contd)
Board Meetings
The Board will meet at least four (4) times a year with the additional meetings being held as and when required. All
Directors have access to enable them to discharge their duties effectively and diligently. During these meetings, the
Board will review the Groups fnancial statements where results are deliberated. The performance of the Group and
other strategic matters are also deliberated.

For the fnancial year ended 31 December 2010, the board met four (4) times. The Board of Directors attendance record
is as follows:-

Directors Attendance Percentage
Tan Sri Dato Seri Dr. Aseh bin Che Mat 4/4 100
Dato Low Su-Shing, Sharon 4/4 100
Dato Lim Oi Wah 4/4 100
Prof. Aw Tar Choon 4/4 100
Lim Jit Soon 4/4 100
Tengku Putra Haron Aminurrashid bin Tan Sri Tengku Hamid Jumat 4/4 100
Loh Yoon Kwai 4/4 100
Loh Kiat Loon 3/4 75
(resigned on 30 Nov 2010)
Appointment and Retirement of Directors
The Nomination Committees task is to assist the Board to evaluate and recommend candidates for the appointments
to the Board.
In accordance with the Companys Articles of Association (the Article), all Directors who are appointed by the Board
during a fnancial year, will retire at the following Annual General Meeting. The Articles also provide that at least one-
third (1/3) of the Directors for the time being, or if their numbers is not in multiple of three (3), then the numbers nearest
to one-third (1/3) shall retire from offce provided always that all Directors including the Managing Director/Executive
Director shall retire from offce at least once every three years but shall be eligible for re-election.

The Articles of Association further provide that a Managing Director can be appointed for a fxed term which shall not
exceed fve (5) years.
54
Governance (contd)
Directors Training
The Company will continuously arrange for trainings for the Directors as part of the obligations to update and enhance
their skills and knowledge to enable them in carrying out their roles as Directors effectively, in accordance with best
practices particularly of corporate governance set out in the Code.
All the Directors have attended and completed the Mandatory Accreditation Programme (MAP) as prescribed by
Bursa Malaysia Securities Berhad.
Details of training courses attended by members of the Board during the fnancial year under review are as follows:
Directors
Tan Sri Dato Seri Dr. Aseh bin Che Mat
Dato Lim Oi Wah
Prof. Aw Tar Choon
Lim Jit Soon
Tengku Putra Haron Aminurrashid bin Tan Sri Tengku
Hamid Jumat
Loh Yoon Kwai
Nature of Course
In-house training on the listing requirements and guidelines of
the ACE Market and on the latest updates of the Companies
Act by the Company Secretary
in-house training on the listing requirements and guidelines of
Directors Remuneration
The Directors remuneration is linked to experience, scope of responsibility, seniority, performance and industry
information. Details of the Directors remuneration for the year ended 31 December 2010 are as follows:
Description Fees Salaries Defned Total
and Bonus Contribution
Retirement Plan
Executive Directors - 549,600 15,552 565,152
Non-Executive Director 15,000 - - 15,000
The numbers of Directors whose remuneration falls within the following band are:
Description Executive Directors Non-Executive Directors
RM150,000 - RM200,000 1 -
RM100,000 - RM150,000 3 -
RM50,000 - Below - 1
55
Governance (contd)
ACCOUNTABILITY AND AUDIT
Financial Reporting
The Board takes responsibility for ensuring that the fnancial statements of the Group and of the Company give a true
and fair view of the state of affairs of the Group and of the Company as required under Section 169(15) of the Companies
Act, 1965. Efforts are made to ensure that the fnancial statements comply with the provisions of the Companies Act,
1965 and the applicable approved accounting standards in Malaysia. The Board also ensures the accurate and timely
release of the Groups quarterly and annual fnancial results to Bursa Malaysia.
External Audit Function
The Companys independent external auditors fll an essential role by enhancing the reliability of the fnancial statements
of the Group and of the Company and giving assurance of that reliability to users of these fnancial statements. The
external auditors, STYL Associates had reported to the members of the Company on their fndings which has been
included as part of the Groups and of the Companys fnancial reports with respect to the audit on the statutory
fnancial statements for the year ended 31 December 2010. In doing so, the Group and the Company have established
a transparent arrangement with the auditors to meet their professional requirements. From time to time, the auditors
highlight to the Audit Committee and the Board on matters that require the Boards attention.
RELATIONS WITH SHAREHOLDERS AND INVESTORS
Annual General Meeting
Annual General Meeting (AGM) is the principal forum for dialogue with shareholders. At the Companys AGM,
shareholders have direct access to the Board and are given opportunities to ask questions. The shareholders are
encouraged to participate in the question and answer session. The Chairman of the Board in the AGM often presents to
the shareholders, the Companys operations in the fnancial year and outlines future prospects of the Group. Further, the
Groups Company Secretary could provide shareholders and investors with a channel of communication on which they
can provide feedback to the Group. Queries regarding the Group may be conveyed to the Company Secretary at the
Companys registered address.
Dialogue between the Company and Investors
The Group values dialogue with shareholders and investors as a means of effective communication that enables the
Board to convey information with regards to the Groups performance, corporate strategy and other matters that effect
shareholders interest. The Company holds regular discussion with analysts and institutional shareholders regularly.
Presentations based on permissible disclosure are made to explain the Groups performance and major development
plans. However, price sensitive information about the Group is not discussed in these exchanges until after the prescribed
announcement to Bursa Malaysia has been made.
In addition to the various announcements made during the year in respect of corporate developments of the Group, the
timely release of fnancial results on a quarterly basis provides shareholders with an overview of the Groups performance
and operations. Copies are supplied to the shareholders and members of the public upon request. The full fnancial
results and the Companys announcements can also be obtained from the Bursa Malaysia website.
OTHER COMPLIANCE INFORMATION
Share Buybacks
The Company does not have a scheme to buy back its own shares at this time.
Options, Warrants or Convertible Securities
There were no options, warrants or convertible securities in issue as at 31 December 2010.
American Depository Receipts (ADR) / Global Depository Receipts (GDR)
During the year, the Company did not sponsor any ADR or GDR programme.
Sanctions and / or Penalties
There were no sanctions and/or penalties imposed on the Company and its subsidiaries, the Directors or the management
by the relevant regulatory bodies.
56
Governance (contd)
Non-audit Fees
The amount of non-audit fees that were paid to the external auditors by the Company for the fnancial year 2010 was nil
(2009 nil).

Proft Estimates, Forecast or Projections
The Group did not issue any proft forecast for the fnancial year ended 31 December 2010.
Status Of Utilisation Of Listing Proceeds From Public Issue
StemLife was listed on 17 October 2006. The Company raised RM13.2 million from its Initial Public Offering (IPO) and
the details of utilisation of such proceeds as at 31 December 2010 is as follows:
Purpose Proposed Intended Actual Balance % Extended Explanations
Amount Timeframe for Utilisation as RM000 Timeframe for
RM000 Utilisation at 31.12.10 Utilisation
RM000
Third 2,600 Within three (3) - 2,600 100.0 by 31 March ^ ##
Laboratory years from Date of 2012
Listing i.e.
17 October 2006
(Date of Listing)
Laboratory 3,000 Within three (3) 998 2,002 66.7 by 31 March ^ ##
Equipments years from Date of 2012
Listing
Logistics 600 Within three (3) 600 0 - -
Expansion years from Date of
Listing
Branch 2,500 Within three (3) 637 1,863 74.5 by 17 october ^
Expansion years from Date of 2011 ##
Listing
Working 2,500 - 2,998 (498)* - - *
Capital
Listing 2,000 - 1,502 498* - - *
Expenses
Total 13,200 6,735 6,465 49.0

Notes:
* The under utilisation of the listing expenses was adjusted to working capital and utilised fully in the 1st quarter
2007.
^ The approved timeframe for utilisation is 3 years from the date of listing.
## The Board of Directors had on 20 October 2009 approved and announced the extension of time for the utilisation
of the balance of the IPO proceeds in the extended timeframe mentioned.
Proft Guarantee
During the year, there was no proft guarantee given by the Company.
Material Contracts of the Company and its Subsidiaries, involving Directors and Substantial Shareholders
There were no material contracts involving the company and its subsidiaries, involving Directors and substantial
shareholders.
Revaluation Policy on Landed Properties
The properties are stated at cost less accumulated depreciation and impairment losses. The Group does not adopt a
policy on regular valuation during the fnancial year.
57
Governance (contd)
AUDIT COMMITTEE REPORT
The Board of Directors (the Board) of StemLife is pleased to present the report of the Audit Committee for the fnancial
year ended 2010.
Composition of Audit Committee
The Audit Committee was established on 26 April 2006 and comprised a majority of Independent Non-Executive
Directors. The Chairman of the Audit Committee shall be an Independent Non-Executive Director and the members are
as follows:
Tengku Putra Haron Aminurrashid bin Tan Sri Tengku Hamid Jumat
Chairman/Independent Non-Executive Director
Loh Yoon Kwai
Member/Independent Non-Executive Director
Yap Yu Ming (appointed on 16 Feb 2011)
Loh Kiat Loon (resigned on 30 Nov 2010)
Meetings of Audit Committee
The Audit Committee met fve (5) times during the year and were attended by all members. The representative(s) of
external auditors of the Company were also invited to attend the Audit Committee meetings.
TERMS OF REFERENCE OF THE AUDIT COMMITTEE
Objective
The primary objective of the Audit Committee is to assist the Board in fulflling its fduciary duties relating to corporate
accounting and reporting practices of the Company and its subsidiary companies (the Group). Additionally, the Audit
Committee shall:
provide assistance to the Board in fulflling its fduciary responsibilities particularly relating to business ethics,
policies and practices and fnancial management and control;
provide greater emphasis on the audit functions by increasing the objectivity and independence of external and
internal auditors and providing a forum for discussion that is independent of the management; and
maintain, through regularly scheduled meetings a direct line of communication between the Board and the external
auditors, internal auditors and fnancial management.
1. Composition of Members
The Board of Directors shall elect an Audit Committee from amongst themselves (pursuant to a resolution of Board
of Directors) comprising of no fewer than three (3) directors, all of whom shall be non-executive.
In this respect, the Board adopts the defnition of independent directors as defned under the Paragraph 1.01 of
the Listing Requirements of Bursa Malaysia Securities Berhad for the ACE Market (Bursa Malaysia).
All members of the Audit Committee shall be fnancially literate and at least one (1) member of the Audit Committee:-
must be a member of the Malaysian Institute of Accountants (MIA); or
if he is not a member of the MIA, he must have at least 3 years of working experience and;
- he must have passed the examinations specifed in Part 1 of the First Schedule of Accountants Act 1967;
or
- he must be a member of one (1) of the associations of accountants specifed in Part II of the First
Schedule of the Accountants Act 1967.
fulfls such requirements as prescribed or approved by Bursa Malaysia Securities Berhad.
No alternate Director of the Board shall be appointed as members of the Audit Committee.
58
Governance (contd)
Retirement and Resignation
If a member of the Audit Committee resigns, dies or for any reason ceases to be a member resulting in non-compliance
to the composition criteria as stated in paragraph 1 above, the Board shall within three (3) months of the event appoint
such member of the new members as may be required to fll the vacancy.
2. Chairman
The Chairman of the Audit Committee, elected from amongst the Audit Committee members, shall be an
Independent Director. The Board of Directors shall approve the Chairman of the Committee.
In the absence of the Chairman of the Audit Committee, the other members of the Audit Committee shall amongst
themselves elect a Chairman who must be an Independent Director to chair the meeting.
3. Secretary
The Secretary of the Audit Committee shall be the Company Secretary. The Secretary shall be responsible for
keeping the minutes of meetings of the Audit Committee, circulating them to members of the Audit Committee
and to the other members of the Board of Directors and for following up outstanding matters.
4. Terms of Offce
The Board of Directors of the Company shall review the terms of offce and performance of the Audit Committee
and each of its members at least once in every three (3) years to determine whether such Audit Committee and
members have carried out their duties in accordance with their terms of reference.
5. Meetings
The Audit Committee meetings shall meet regularly, with due notice of issues to be discussed, and shall record its
conclusions in discharging its duties and responsibilities. In addition, the Chairman may call for additional meetings
at any time at the Chairmans discretion.
Upon the request of the external auditors, the Chairman of the Audit Committee members shall convene a meeting
of the Audit Committee to consider any matter the external auditors believe should be brought to the attention of
the Directors or shareholders.
Notice of Audit Committee meetings shall be given to all the Audit Committee members unless the Audit
Committee waives such requirement.
The Chairman of the Audit Committee shall engage on a continuous basis with senior management, such as the
Chairman, the Chief Executive Offcer, the Finance Director, the head of internal audit and the external auditors in
order to be kept informed of matters affecting the Company.
The Finance Director, the head of internal audit and a representative of the external auditors should normally attend
meetings. Other Board members and employees may attend meetings upon the invitation of the Audit Committee.
The Audit Committee shall be able to convene meetings with the external auditors, the internal auditors or both,
without executive Board members or employees present whenever deemed necessary and at least twice a year
with the external auditors.
Questions arising at any meeting of the Audit Committee shall be decided by a majority of votes of the members
present, and in the case of equality of votes, the Chairman of the Audit Committee shall have a second or casting
vote.
6. Minutes
Minutes of each meeting shall be kept at the registered offce and distributed to each member of the Audit
Committee and also to the other members of the Board. The Audit Committee Chairman shall report on each
meeting to the Board. The minutes of the Audit Committee meeting shall be signed by the Chairman of the
meeting at which the proceedings were held or by the Chairman of the next succeeding meeting.
59
Governance (contd)
7. Quorum
The quorum for the Audit Committee meeting shall be the majority of members present whom must be Independent
Directors.
8. Reporting
The Audit Committee shall report to the Board of Directors, either formally in writing, or verbally, as it considers
appropriate on the matters within its terms of reference at least once a year, but more frequently if it so wishes.
The Audit Committee shall report to the Board of Directors on any specifc matters referred to it by the Board for
investigation and report.
9. Authority
The Audit Committee shall, in accordance with a procedure to be determined by the Board of Directors and at the
expense of the Company:
(a) have explicit authority to investigate any activity within its terms of reference, the resources to do so, and full
access to information. All employees shall be directed to co-operate as requested by members of the Audit
Committee.
(b) have full and unlimited/unrestricted access to all information and documents/resources which are required
to perform its duties as well as to the internal and external auditors and senior management of the Company
and the Group.
(c) obtain, at the expense of the Company, other independent professional advice or other advice and to secure
the attendance of outsiders with relevant experience and expertise if it considers necessary.
(d) have direct communication channels with the external auditors and person(s) carrying out the internal audit
function or activity (if any).
(e) where the Audit Committee is of the view that the matter reported by it to the Board has not been satisfactorily
resolved resulting in a breach of the Listing Requirements, the Audit Committee shall promptly report such
matter to Bursa Securities.
10. Duties and Responsibilities
The duties and responsibilities of the Audit Committee are as follows:-
(a) To consider the appointment of the external auditors, the audit fee and any question of resignation or
dismissal;
(b) To discuss with the external auditors before the audit commences, the nature and scope of the audit, and
ensure co-ordination where more than one audit frm is involved;
(c) To review with the external auditors their evaluation of the system of internal controls and their audit report;
(d) To review the quarterly and year end fnancial statements of the Board, focusing particularly on:-
any change in accounting policies and practices;
signifcant adjustments arising from the audit;
the going concern assumption; and
compliance with accounting standards and other legal requirements.
(e) To discuss problems and reservations arising from the interim and fnal audits, and any matter the auditor may
wish to discuss (in the absence of management, where necessary);
(f ) To review the external auditors management letter and managements response;
60
(g) To do the following, in relation to the internal audit function:-
review the adequacy of the scope, functions, competency and resources of the internal audit function,
and that it has the necessary authority to carry out its work;
review the internal audit programme and results of the internal audit process and, where necessary,
ensure that appropriate actions are taken on the recommendations of the internal audit function;
review any appraisal or assessment of the performance of members of the internal audit function;
approve any appointment or termination of senior staff members of the internal audit function; and
take recognizance of resignations of internal audit staff members and provide the resigning staff
member an opportunity to submit his reasons for resigning.
(h) To consider any related party transactions and confict of interest situation that may arise within the Company
or Group including any transaction, procedure or course of conduct that raises questions of management
integrity;
(i) To report its fndings on the fnancial and management performance, and other material matters to the
Board;
(j) To consider the major fndings of internal investigations and managements response;
(k) To verify the allocation of employees share option scheme (ESOS) in compliance with the criteria as
stipulated in the by-laws of ESOS of the Company, if any;
(l) To determine the remit of the internal audit function;
(m) To consider other topics as defned by the Board; and
(n) To consider and examine such other matters as the Audit Committee considers appropriate.
Summary of the Activities of the Audit Committee
During the year 2010, the Audit Committee carried out its duties as set out in the terms of reference. Other main
activities carried out by the Audit Committee during the fnancial year included the following:-
1. Financial Results
(a) Reviewed the quarterly and year-to-date unaudited fnancial results of the Group before tabling to the Board
for consideration and approval; and
(b) Reviewed the reports and the audited fnancial statements of the Company and of the Group together with
the external auditors prior to tabling to the Board for approval.
2. External Audit
(a) Reviewed the external auditors scopes of work and audit plan for the year and make recommendations to
the Board on their appointment and remuneration;
(b) Reviewed and discussed external auditors audit report and areas of concern highlighted including
managements response to the concerns raised by the external auditors; and
(c) Discussed on signifcant accounting and auditing issues, impact of new or proposed changes in accounting
standards and regulatory requirements.
Governance (contd)
61
Governance (contd)
REMUNERATION COMMITTEE REPORT
Objective
The Group operates in a competitive environment and it is essential that part of its strategy is to attract, motivate
and retain the highest achievers who are able to deliver towards achievement of the business objectives. The level of
remuneration and benefts the Company offers is the key to support the objectives and maintaining the Groups market
position as an employer of choice. The Company provides competitive salaries and benefts for all employees, consistent
with its business strategy and performance.
Composition of Remuneration Committee
The Remuneration Committee was established on 1 August 2006 and comprises of mainly the Non-Executive Directors
as follows:
Chairperson/Managing Director
Loh Yoon Kwai
Member/ Independent Non-Executive Director
The Remuneration Committee recommends to the Board the reward framework to allow the Company to attract and
retain its Executive Director giving due regards to the fnancial and commercial health of the Company. The Remuneration
Committees approach refects the Groups overall philosophy that all employees should be appropriately rewarded.
Remuneration Policy
The Company aims to align the interests of its Executive Directors as closely as possible with the interests of shareholders
in promoting the Groups strategies. Total remuneration comprises fxed salary, Directors fees, performance related
bonus, and beneft-in-kind. Salary and benefts are competitive and are reviewed annually. In making recommendations
on the framework for retaining and rewarding senior management, the Remuneration Committee reviews the total
reward package, making use of internally and externally published information. The salaries of the Executive Directors
is set by the Remuneration Committee annually after consideration of the Groups performance, market conditions, the
level of increase awarded to employees throughout the business and the need to reward the individual performance.
Quorum
The quorum for meetings shall be a minimum of two (2) members.
Responsibilities
a) To recommend to the Board, the remuneration and compensation of the Executive Directors in all its form, drawing
from external advice where necessary; and
b) To establish a formal procedure for developing policy on Executive Directors remuneration and compensation
package.
Attendance
Remuneration Committee met one (1) time during the year.
62
NOMINATION COMMITTEE REPORT
Objective
The Nomination Committee was set out to ensure business continuity of the Company and the Group by having in place
a succession plan for the Board of Directors (the Board) and senior management.
Composition of Nomination Committee
The Nomination Committee was established on 1 August 2006 and comprises of Non-Executive Directors as follows:
Loh Yoon Kwai
Chairman/Independent Non-Executive Director
Tengku Putra Haron Aminurrashid bin Tan Sri Tengku Hamid Jumat
NOMINATION COMMITTEE POLICY
Fundamentally, new appointments to the Board are made by the whole Board and potential Non-Executive Directors
are suggested by any Director and reviewed by the Nomination Committee before the candidate is being approached.
Any new appointment is made by the Board only after a recommendation from the Nomination Committee. In view
of the essential requirement of potential Directors to understand the nature of responsibilities of the Board and the
extensive operations of the Group, it is vital for the Chairman to take part in the briefng of any nominees to the Board.
Accordingly, the Nomination Committee is structured as sub-committee of the whole Board so that all Directors can
participate in the nomination process.
QUORUM
The quorum for meetings shall be a minimum of two (2) members.
RESPONSIBILITIES
a) To review the structure, size and composition of the Board;
b) To review formal succession plan in identifying and mentoring potential Executive Directors, Non-Executive
Directors and senior management personnel;
c) To propose and recommend new appointments of potential candidates to the Board; and
d) To propose and recommend to the Board, the retirement and re-appointment of existing Executive and Non-
Executive Directors in accordance with the Articles of Association of the Company.
ATTENDANCE
The Nomination Committee met one (1) time during the year 2010.
Governance (contd)
63
Statement on Internal
Control
INTRODUCTION
Paragraph 15.26(b) of the Listing Requirements of Bursa Malaysia Securities Berhad for the ACE Market (MMLR)
requires the Board of Directors of public listed companies to include in its annual report a statement about the state of
internal control of the listed issuer as a group. The Board, committed to maintaining a sound system of internal control
in the Group, is pleased to provide the following statement outlining the nature and scope of internal control of the
Group during the fnancial year ended 31 December 2010.
Board Responsibility
The Board recognizes its responsibility over the Groups system of internal control, which includes the establishment of
an appropriate control environment and reviewing the adequacy and integrity of these systems on a regular basis.
Nevertheless, inherent limitations in any system of internal control preclude absolute assurance against material
misstatement or loss, as the system is designed to manage, rather than eliminate, risk of failure.
The Board has established a process for identifying, evaluating and managing principle risks faced by the Group. This
process was in place throughout the fnancial year under review. The Board regularly reviews this process in conformity
with the Statement on Internal Control: Guidance for Directors of Public Listed Companies (the Internal Control
Guidance).
Although the Board are the ultimate owners of risk assessment process and internal control systems, Management
has been tasked with the implementation of the risk management and internal control systems, within the framework
adopted by the Board.
Enterprise Risk Management Framework
The Board affrms the contents of the Internal Control Guidance and through the Audit Committee, identifes principal
risks faced by signifcant operating entities of the Group, and evaluates the systems in place to manage these risks.
The outworking of the Groups risk management framework can be demolished by the following practices:
Establishment of a risk management structure, which depicts the lines of reporting and responsibility at the
Board, Audit Committee and Management levels. A specifc grouping of management personnel, i.e. the Group
Risk Management Committee is responsible to enhance risk oversight and management, one way of which is to
integrate risk management issues into quarterly performance reporting;
Identifcation of principal risks (present and potential) faced by operating units in the Group and management plans
to mitigate or manage these risks. The identifcation process is driven by the Audit Committee. For each principal
risk, the assessment process considers the potential impact and likelihood of occurrence, effectiveness of controls
in place (if any), and action plans being taken to manage those risks to the desired level. A database of these risks
and controls has been created to produce a risk register and individual risk profles for the major business unit;
Determination of risk appetite (qualitative and quantitative) for major business units in the Group;
Issuance of a Risk Management Policy and Guidelines Document for the Group. The document offers practical
guidance to all employees on risk management issues; and
Preparation of action plans to address risk and control issues on an ongoing basis.
The Board considers that the enterprise risk management framework is robust, but will still subject the framework to
continuous improvement, taking into consideration better practices and the changing business environment, where
appropriate.
64
Statement on Internal
Control (contd)
Internal Audit Function
The Group have outsourced the internal audit function to an independent professional audit frm.
The Audit Committee receives reports from the proposed Group Internal Audit function and considers Management
response to issues raised in the reports, before making recommendations to the Board to fortify the Groups internal
control and governance systems. Remedial actions taken by Management in response to internal control defciencies are
monitored by the Group Internal Audit function.
Apart from conducting risk-based internal audits for the Company and its subsidiaries, the proposed Group Internal
Audit function also performs routine and fnancial-based audits as part of its programme to cover strategic, operational
and fnancial aspects of Group operations.
Other Risk and Control Processes
The Board considers the following as complements to the goals embraced by the risk management process and internal
audit activities:
An organizational structure with formally defned lines of responsibility and delegation of authority;
A hierarchical reporting process which provides a documented and auditable trail of accountability;
An update Management Staff Handbook and Collective Agreement emphasizing policies on health and safety,
training and development, equality of opportunity, staff performance and repercussions of serious misconduct; and
A chart of authority prescribing limits of authority.
Weakness in Internal Controls That Result in Material Losses
There were no material losses during the fnancial year ended 31 December 2010 as a result of weaknesses in internal
control. Nevertheless, Management remains vigilant and continues to take measures to strengthen the control
environment.
Date: 11 April 2011
Financial Statements
66 Directors Report
70 Statement By Directors
70 Statutory Declaration
71 Auditors Report
73 Statements Of Financial Position
74 Statements Of Comprehensive Income
75 Statements Of Changes In Equity
76 Consolidated Statements Of Cash Flows
77 Statements Of Cash Flows
78 Notes To The Financial Statements
66
Directors Report
The Directors are pleased to submit their report and the audited fnancial statements of the Group and of the Company
for the fnancial year ended 31 December 2010.
PRINCIPAL ACTIVITIES
The Company is principally engaged in the following activities:
stem cell therapy and stem cell consultancy services;
collection, testing, processing and preservation of umbilical cord blood stem cells;
testing, processing and preservation of peripheral blood stem cells; and
investment holding.
The principal activities of its subsidiary companies are disclosed in Note 5 to the fnancial statements.
There have been no signifcant changes in the nature of these activities during the fnancial year.
FINANCIAL RESULTS
GROUP COMPANY
RM RM
(Loss)/Proft for the year (176,650) 1,584,839
Attributable to:
Equity holders of the Company (377,253) 1,584,839
Minority interest 200,603 -

(176,650) 1,584,839
DIVIDENDS
A frst and fnal tax exempt dividend of 10% amounting to RM1,650,000, for the fnancial year ended 31 December 2009
was paid during the current fnancial year.
At the forthcoming Annual General Meeting, a single tier fnal dividend of 10% on 165,000,000 ordinary shares amounting
to RM1,650,000 in respect of the fnancial year ended 31 December 2010 will be proposed for shareholders approval.
The fnancial statements for the current fnancial year do not refect this proposed dividend. Such dividend, if approved
by the shareholders, will be accounted for in equity as an appropriation of retained earnings in the fnancial year ending
31 December 2011.
ISSUE OF SHARES AND DEBENTURES
No shares or debentures were issued during the fnancial year.
RESERVES AND PROVISIONS
There were no material transfers to or from reserves or provisions during the fnancial year other than those disclosed in
the fnancial statements.

67
Directors Report (contd)
SHARE OPTIONS
No options have been granted by the Company to any parties during the fnancial year to take up unissued shares of
the Company.
No shares have been issued during the fnancial year by virtue of the exercise of any option to take up unissued shares in
the Company. As at the end of the fnancial year, there were no unissued shares of the Company under options.
INFORMATION ON THE FINANCIAL STATEMENTS
Before the statements of comprehensive income and statements of fnancial position of the Group and of the Company
were made out, the Directors took reasonable steps:
(a) to ascertain that proper action had been taken in relation to the writing off of bad debts and the making of
allowance for doubtful debts and have satisfed themselves that all known bad debts have been written off and that
adequate allowance had been made for doubtful debts; and
(b) to ensure that any current assets which were unlikely to be realised in the ordinary course of business including their
values as shown in the accounting records of the Group and of the Company have been written down to an amount
which they might be expected so to realise.
At the date of this report, the Directors are not aware of any circumstances:
(a) which would render the amount written off for bad debts or the amount of the allowance for doubtful debts in the
fnancial statements of the Group and of the Company inadequate to any substantial extent; or
(b) which would render the values attributed to current assets in the fnancial statements of the Group and of the
Company misleading; or
(c) which have arisen which render adherence to the existing method of valuation of assets or liabilities of the Group
and of the Company misleading or inappropriate.
No contingent or other liability has become enforceable or is likely to become enforceable within the period of twelve
months after the end of the fnancial year which, in the opinion of the Directors, will or may substantially affect the ability
of the Group or of the Company to meet their obligations as and when they fall due.
At the date of this report, there does not exist:
(a) any charge on the assets of the Group or of the Company which has arisen since the end of the fnancial year which
secures the liability of any other person; or
(b) any contingent liability of the Group or of the Company which has arisen since the end of the fnancial year.
68
DIRECTORS OF THE COMPANY
Directors who served on the Board of the Company since the date of the last report are as follows:
TAN SRI DATO SERI DR. ASEH BIN CHE MAT
DATO LOW SU-SHING
DATO LIM OI WAH
PROF. AW TAR CHOON
LIM JIT SOON
TENGKU PUTRA HARON AMINURRASHID BIN
TAN SRI TENGKU HAMID JUMAT
LOH YOON KWAI
YAP YU MING (APPOINTED ON 16.02.2011)
LOH KIAT LOON (RESIGNED ON 30.11.2010)
In accordance with Article 116 of the Companys Articles of Association, Tan Sri Dato Seri Dr. Aseh Bin Che Mat and
Tengku Putra Haron Aminurrashid Bin Tan Sri Tengku Hamid Jumat retire at the forthcoming Annual General Meeting
and, being eligible, offer themselves for re-election.
In accordance with Article 92(2) of the Companys Articles of Association, Yap Yu Ming retires at the forthcoming Annual
General Meeting and, being eligible , offers herself for re-election.
DIRECTORS INTERESTS
The shareholdings in the Company of those who were Directors at the end of the fnancial year, as recorded in the
Register of Directors Shareholdings kept by the Company under Section 134 of the Companies Act, 1965 were as
follows:
Number of ordinary shares of RM0.10 each
Balance at Balance at
01.01.2010 Bought Sold 31.12.2010
Direct Interest
DATO LOW SU-SHING 18,481,600 - - 18,481,600
DATO LIM OI WAH 18,465,200 - - 18,465,200
PROF. AW TAR CHOON 7,600,400 - - 7,600,400
LIM JIT SOON 2,855,120 - - 2,855,120
LOH YOON KWAI 1,379,500 - - 1,379,500
Indirect Interest
LOH YOON KWAI * 365,000 - - 365,000
* Deemed interest by virtue of his spouse, Hong Fook Ling @ Hoong Fook Ling.
DIRECTORS BENEFITS
Since the end of the previous fnancial year, no Director has received or become entitled to receive any beneft (other
than benefts included in the aggregate amount of emoluments received or due and receivable by the Directors as shown
in the fnancial statements or the fxed salary of a full time employee of the Company or of related corporations) by
reason of a contract made by the Company or a related company with the Director or with a frm of which the Director is
a member, or with a company in which the Director has a substantial fnancial interest except as recorded and disclosed
in the notes to the fnancial statements.
During and at the end of the fnancial year, no arrangement subsisted to which the Company was a party whereby
the Directors of the Company might acquire benefts by means of the acquisition of shares in, or debentures of, the
Company or any other body corporate.

69
OTHER STATUTORY INFORMATION
At the date of this report, the Directors are not aware of any circumstances not otherwise dealt with in this report or the
fnancial statements, which would render any amount stated in the fnancial statements of the Group and of the Company
misleading.
In the opinion of the Directors:
(a) the results of the operations of the Group and of the Company for the fnancial year were not substantially affected
by any item, transaction or event of a material and unusual nature; and
(b) there has not arisen in the interval between the end of the fnancial year and the date of this report, any such item,
transaction or event of a material and unusual nature likely to affect substantially the results of the operations of
the Group and of the Company for the fnancial year in which this report is made.
AUDITORS
The auditors, Messrs. STYL Associates have indicated their willingness to continue in offce.
Signed on behalf of the Board in accordance with a resolution of the Directors,
__________________________ __________________________
DATO LOW SU-SHING DATO LIM OI WAH
KUALA LUMPUR
DATE:
70
Statement By Directors
Pursuant to Section 169 (15) of the Companies Act, 1965
Statutory Declaration
Pursuant to Section 169 (16) of the Companies Act, 1965
We, DATO LOW SU-SHING and DATO LIM OI WAH, two of the Directors of STEMLIFE BERHAD, state that, in the
opinion of the Directors, the accompanying Statements of Financial Position, Comprehensive Income, Changes in Equity
and Cash Flows of the Group and of the Company, together with the notes thereto, are drawn up in accordance with the
provisions of the Companies Act, 1965 and Financial Reporting Standards in Malaysia so as to give a true and fair view of
the fnancial position of the Group and of the Company as at 31 December 2010 and of their fnancial performance and
cash fows of the Group and of the Company for the year then ended.
The supplementary information set out in Note 28, which is not part of the fnancial statements, is prepared in all material
respects, in accordance with Guidance on Special Matter No. 1 Determination of Realised and Unrealised Profts or
Losses in the Context of Disclosure Pursuant to Bursa Malaysia Securities Berhad Listing Requirements as issued by the
Malaysian Institute of Accountants and the directive of Bursa Malaysia Securities Berhad.
Signed in accordance with a resolution of the Directors,
__________________________ __________________________
DATO LOW SU-SHING DATO LIM OI WAH
KUALA LUMPUR
DATE:
I, LIM JIT SOON, the Director primarily responsible for the fnancial management of STEMLIFE BERHAD, do solemnly
and sincerely declare that, to the best of my knowledge and belief, the accompanying Statements of Financial Position,
Comprehensive Income, Changes in Equity and Cash Flows of the Group and of the Company, together with the notes
thereto, are, in my opinion, correct and I make this solemn declaration conscientiously believing the same to be true, and
by virtue of the provisions of the Statutory Declarations Act, 1960.
Subscribed and solemnly declared by the }
abovenamed LIM JIT SOON at Kuala Lumpur }
in the Federal Territory this day of }
}
}
Before me: LIM JIT SOON
Commissioner for Oaths
71
Independent Auditors Report
To The Members Of STEMLIFE BERHAD (Incorporated in Malaysia)
Report on the Financial Statements
We have audited the accompanying fnancial statements of STEMLIFE BERHAD which comprise the statements of
fnancial position of the Group and the Company as at 31 December 2010, the statements of comprehensive income,
changes in equity and cash fows of the Group and the Company for the fnancial year then ended, and a summary of
signifcant accounting policies and other explanatory notes.
Directors Responsibility for the Financial Statements
The Directors of the Company are responsible for the preparation and fair presentation of these fnancial statements in
accordance with Financial Reporting Standards and the Companies Act, 1965 in Malaysia. This responsibility includes:
designing, implementing and maintaining internal control relevant to the preparation and fair presentation of fnancial
statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate
accounting policies; and making accounting estimates that are reasonable in the circumstances.
Auditors Responsibility
Our responsibility is to express an opinion on these fnancial statements based on our audit. We conducted our audit
in accordance with approved standards on auditing in Malaysia. Those standards require that we comply with ethical
requirements and plan and perform the audit to obtain reasonable assurance whether the fnancial statements are free
from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the fnancial
statements. The procedures selected depend on our judgement, including the assessment of risks of material
misstatement of the fnancial statements, whether due to fraud or error. In making those risk assessments, we consider
internal control relevant to the Companys preparation and fair presentation of the fnancial statements in order to
design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on
the effectiveness of the Companys internal control. An audit also includes evaluating the appropriateness of accounting
policies used and the reasonableness of accounting estimates made by the Directors, as well as evaluating the overall
presentation of the fnancial statements.
We believe that the audit evidence we have obtained is suffcient and appropriate to provide a basis for our audit
opinion.

Opinion
In our opinion, the fnancial statements have been properly drawn up in accordance with Financial Reporting Standards
and the Companies Act, 1965 in Malaysia so as to give a true and fair view of the fnancial position of the Group and
of the Company as of 31 December 2010 and of their fnancial performance and cash fows for the fnancial year then
ended.
Report on Other Legal and Regulatory Requirements
In accordance with the requirements of the Companies Act, 1965 in Malaysia, we also report the following:
a) in our opinion, the accounting and other records and the registers required by the Act to be kept by the Company
and its subsidiary companies have been properly kept in accordance with the provisions of the Act.
b) we have considered the fnancial statements and the auditors reports of all the subsidiary companies of which we
have not acted as auditors, which are indicated in Note 5 to the fnancial statements.
72
Independent Auditors Report (contd)
c) we are satisfed that the accounts of the subsidiary companies that have been consolidated with the Companys
fnancial statements are in form and content appropriate and proper for the purposes of the preparation of the
fnancial statements of the Group and we have received satisfactory information and explanations required by us
for those purposes.
d) the audit reports on the accounts of the subsidiary companies did not contain any qualifcation or any adverse
comment made under Section 174(3) of the Act.
Other Reporting Responsibilities
The supplementary information set out in Note 28 is disclosed to meet the requirement of Bursa Malaysia Securities
Berhad and is not part of the fnancial statements. The directors are responsible for the preparation of the supplementary
information in accordance with Guidance on Special Matter No. 1 Determination of Realised and Unrealised Profts or
Losses in the Context of Disclosure Pursuant to Bursa Malaysia Securities Berhad Listing Requirements as issued by
the Malaysian Institute of Accountants (MIA Guidance) and the directive of Bursa Malaysia Securities Berhad. In our
opinion, the supplementary information is prepared, in all material respects, in accordance with the MIA Guidance and
the directive of Bursa Malaysia Securities Berhad.
Other Matters
This report is made solely to the members of the Company, as a body, in accordance with Section 174 of the Companies
Act, 1965 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the content of
this report.
STYL ASSOCIATES SI CHAY BENG
CHARTERED ACCOUNTANTS APPROVED COMPANY AUDITOR
FIRM NO: AF-1929 TREASURY APPROVAL NO. 1200/8/12(J)
KUALA LUMPUR
DATE:
73
Independent Auditors Report (contd)
Statements Of Financial Position
As At 31 December 2010
GROUP COMPANY
2010 2009 2010 2009
Note RM RM RM RM
ASSETS
Non-current assets
Property, plant and equipment 4 5,396,001 5,982,974 2,735,417 3,137,440
Investment in subsidiary companies 5 - - 6,850,201 5,000,201
Investment in associated company 6 3,900,458 2,157,349 3,117,100 945,000
Other investment 7 3,530,738 3,530,738 3,530,738 3,530,738
Total non-currrent assets 12,827,197 11,671,061 16,233,456 12,613,379
Current assets
Inventories 8 756,364 646,381 749,093 646,381
Trade receivables 9 3,074,543 6,929,355 2,102,323 5,881,365
Other receivables and deposits 10 692,196 770,581 689,620 767,916
Short term investment 11 - 3,000,000 - 3,000,000
Amount due from associated company 12 598 - 598 -
Amount due from subsidiary companies 13 - - 5,146,247 5,730,727
Tax recoverable 109,569 136,778 - 54,748
Cash and cash equivalents 14 47,874,616 38,972,677 42,680,883 32,309,274
Total current assets 52,507,886 50,455,772 51,368,764 48,390,411
TOTAL ASSETS 65,335,083 62,126,833 67,602,220 61,003,790
EQUITY AND LIABILITIES
Capital and reserves
Share capital 15 16,500,000 16,500,000 16,500,000 16,500,000
Share premium 11,698,134 11,698,134 11,698,134 11,698,134
Exchange reserve 43,091 51,583 - -
Unappropriated proft 2,842,353 4,869,606 5,730,237 5,795,398
Total equity attributable to equity holders
of the Company 31,083,578 33,119,323 33,928,371 33,993,532
Minority interest - 1,649,397 - -
Shareholders equity 31,083,578 34,768,720 33,928,371 33,993,532
Non-current liabilities
Deferred taxation 16 - - - -
Total non-current liabilities - - - -
Current liabilities
Trade payables 17 434,474 330,725 433,868 330,725
Advanced payments 32,429,620 25,291,637 32,429,620 25,291,637
Other payables and accruals 18 1,353,370 1,733,081 776,320 1,385,226
Amount due to associated company 12 - 2,670 - 2,670
Provision for taxation 34,041 - 34,041 -
Total current liabilities 34,251,505 27,358,113 33,673,849 27,010,258
Total liabilities 34,251,505 27,358,113 33,673,849 27,010,258
TOTAL EQUITY AND LIABILITIES 65,335,083 62,126,833 67,602,220 61,003,790
The accompanying Notes form an integral part of the Financial Statements.
74
Statements Of Comprehensive
Income
For The Year Ended 31 December 2010
GROUP COMPANY
2010 2009 2010 2009
Note RM RM RM RM
Revenue 19 16,515,824 15,824,070 16,031,733 15,230,193
Direct costs (12,313,922) (12,127,525) (11,362,270) (11,610,408)
Gross proft 4,201,902 3,696,545 4,669,463 3,619,785
Other income 20 1,495,954 893,837 1,777,244 1,160,252
Administrative expenses (5,648,261) (8,611,051) (4,746,992) (7,710,433)

Share of associated companys result (112,830) 1,069,988 - -
(Loss)/Proft before taxation 21 (63,235) (2,950,681) 1,699,715 (2,930,396)
Taxation 22 (113,415) (82,043) (114,876) (101,000)
(Loss)/Proft for the year (176,650) (3,032,724) 1,584,839 (3,031,396)
Attributable to:
Equity Holders of the Company (377,253) (2,820,469) 1,584,839 (3,031,396)
Minority interest 200,603 (212,255) - -
(Loss)/Proft for the year (176,650) (3,032,724) 1,584,839 (3,031,396)
Earnings per ordinary share attributable to
ordinary equity holders of the Company
- Basic (sen) 23 (0.23) (1.71)
- Diluted (sen) 23 (0.23) (1.71)
75
Statements Of Changes In
Equity
Non-distributable Distributable

Share Share Exchange Unappropriated Minority Total
Capital Premium Reserve Proft Total Interest Equity
GROUP Note RM RM RM RM RM RM RM
Balance at
1 January 2009 16,500,000 11,698,134 (2,612) 9,340,075 37,535,597 1,861,652 39,397,249
Loss for the year - - - (2,820,469) (2,820,469) (212,255) (3,032,724)
Dividends 24 - - - (1,650,000) (1,650,000) - (1,650,000)
Currency translation
differences - - 54,195 - 54,195 - 54,195
Balance at
31 December 2009 16,500,000 11,698,134 51,583 4,869,606 33,119,323 1,649,397 34,768,720
Minority interest - - - - - - -
Acquisition of
minority interests 5 - - - - - (1,850,000) (1,850,000)
Loss for the year - - - (377,253) (377,253) 200,603 (176,650)
Dividends 24 - - - (1,650,000) (1,650,000) - (1,650,000)
Currency translation
differences - - (8,492) - (8,492) - (8,492)
Balance at
31 December 2010 16,500,000 11,698,134 43,091 2,842,353 31,083,578 - 31,083,578
Non-distributable Distributable
Share Share Unappropriated
Capital Premium Proft Total
COMPANY Note RM RM RM RM
Balance at 1 January 2009 16,500,000 11,698,134 10,476,794 38,674,928
Loss for the year - - (3,031,396) (3,031,396)
Dividends 24 - - (1,650,000) (1,650,000)
Balance at 31 December 2009 16,500,000 11,698,134 5,795,398 33,993,532
Proft for the year - - 1,584,839 1,584,839
Dividends 24 - - (1,650,000) (1,650,000)
Balance at 31 December 2010 16,500,000 11,698,134 5,730,237 33,928,371
76
Consolidated Statements Of
Cash Flows
2010 2009
Note RM RM
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before taxation (63,235) (2,950,681)
Adjustments for:
Allowance for dimunition in value of investment - 2,469,622
Allowance for doubtful debts 541,773 779,325
Depreciation 1,235,697 1,138,018
Gain on disposal of property, plant and equipment (12,782) -
Property, plant and equipment written off - 12,006
Interest income (662,946) (337,089)
Dividend received from investment in unit trust (333,353) (271,665)
Share of associated companys results 112,830 (1,069,988)
Operating proft/(loss) before working capital changes 817,984 (230,452)
Inventories (109,983) 421,179
Receivables 3,391,424 (1,053,032)
Payables 6,862,021 7,792,666
Associated company 59,872 2,670
Cash generated from operations 11,021,318 6,933,031
Tax paid (52,165) (219,214)
Net cash from operating activities 10,969,153 6,713,817
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in subsidiary company (1,850,000) -
Investment in associated company (2,172,100) -
Proceeds from disposal of property, plant and equipment 81,000 -
Purchase of property, plant and equipment (716,942) (841,327)
Interest received 662,946 337,089
Dividend received from associated company 244,529 200,000
Dividend received from investment in unit trust 333,353 271,665
Unit trust uplifted 3,000,000 -
Net cash used in investing activities (417,214) (32,573)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid (1,650,000) (1,650,000)
Net cash used in fnancing activities (1,650,000) (1,650,000)
NET INCREASE IN CASH AND CASH EQUIVALENTS 8,901,939 5,031,244
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 38,972,677 33,941,433
CASH AND CASH EQUIVALENTS AT END OF YEAR 14 47,874,616 38,972,677
77
Statements Of Cash Flows
2010 2009
Note RM RM
CASH FLOWS FROM OPERATING ACTIVITIES
Proft/(Loss) before taxation 1,699,715 (2,930,396)
Adjustments for:
Allowance for diminution in value of investment - 2,469,622
Allowance for doubtful debts 541,773 779,325
Depreciation 1,046,918 998,217
Gain on disposal of property, plant and equipment (12,782) -
Interest received (579,707) (283,504)
Dividend received from associated company (244,529) (200,000)
Dividend received from investment in unit trust (333,353) (271,665)
Operating proft before working capital changes 2,118,035 561,599
Inventories (102,712) 421,179
Receivables 3,315,565 (1,239,599)
Payables 6,632,220 7,647,015
Subsidiary companies 584,480 (950,072)
Associated company (3,268) 2,670
Cash generated from operations 12,544,320 6,442,792
Tax paid (26,087) (149,945)
Net cash from operating activities 12,518,233 6,292,847
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in subsidiary companies (1,850,000) -
Investment in associated companies (2,172,100) -
Proceed from disposal of property, plant and equipment 81,000 -
Purchase of property, plant and equipment (713,113) (809,378)
Interest received 579,707 283,504
Dividend received from associated company 244,529 200,000
Dividend received from investment in unit trust 333,353 271,665
Unit trust uplifted 3,000,000 -
Net cash used in investing activities (496,624) (54,209)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid (1,650,000) (1,650,000)
Net cash used in fnancing activities (1,650,000) (1,650,000)
NET INCREASE IN CASH AND CASH EQUIVALENTS 10,371,609 4,588,638
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 32,309,274 27,720,636
CASH AND CASH EQUIVALENTS AT END OF YEAR 14 42,680,883 32,309,274
78
Notes to the Financial
Statements
for the year ended 31 December 2010
1. CORPORATE INFORMATION
The Company is principally engaged in the following activities:
stem cell therapy and stem cell consultancy services;
collection, testing, processing and preservation of umbilical cord blood stem cells;
testing, processing and preservation of peripheral blood stem cells; and
investment holding.
The principal activities of its subsidiary companies are disclosed in Note 5 to the fnancial statements.
There have been no signifcant changes in the nature of these activities during the fnancial year.
The Company is a public limited liability company, incorporated and domiciled in Malaysia and is listed on the ACE
Market of Bursa Malaysia Securities Berhad.
The principal place of business is located at B-7-15, Megan Avenue II, 12, Jalan Yap Kwan Seng, 50450 Kuala
Lumpur.

The fnancial statements were authorised for issue by the Board of Directors in accordance with a resolution of the
Directors on.
2. SIGNIFICANT ACCOUNTING POLICIES
(a) Basis of preparation/accounting
The fnancial statements of the Group and of the Company have been prepared under the historical cost
convention and in compliance with the provisions of the Companies Act, 1965 and applicable Financial
Reporting Standards issued by Malaysian Accounting Standards Board (MASB).
On 1 January 2010, the Group and the Company adopted the following new and amended FRS and IC
Interpretations mandatory for annual fnancial periods beginning on or after 1 January 2010.
FRS 7 Financial Instruments: Disclosures
FRS 8 Operating Segments
FRS 101 Presentation of Financial Statements (Revised)
FRS 123 Borrowing Costs
FRS 139 Financial Instruments: Recognition and Measurement
Amendments to FRS 1 First-time Adoption of Financial Reporting Standards on FRS 127
Consolidated and Separate Financial Statements:
Cost of an Investment in a Subsidiary, Jointly Controlled Entity or Associate
Amendments to FRS 2 Share-based Payment - Vesting Conditions and Cancellation
Amendments to FRS 132 Financial Instruments: Presentation
Amendments to FRS 139 Financial Instruments: Recognition and Measurement
Amendments to FRS 7 Financial Instruments: Disclosures
Amendments to IC
Interpretation 9 Reassessment of Embedded Derivatives
IC Interpretation 9 Reassessment of Embedded Derivatives
IC Interpretation 10 Interim Financial Reporting and Impairment
IC Interpretation 11 FRS 2 - Group and Treasury Share Transactations
IC Interpretation 13 Customer Loyalty Programmes
IC Interpretation 14 FRS 119 - The Limit on a Defned Beneft, Minimum Funding Requirements and
their interaction.
79
Statements (contd)
2. SIGNIFICANT ACCOUNTING POLICIES (CONTD)
(a) Basis of preparation/accounting (contd)
Standards and interpretations issued but not yet effective
The following accounting standards, amendments, and interpretations have been issued by the Malaysian
Accounting Standards Board (MASB) but are not yet effective for the Group and the Company:
Effective for fnancial periods beginning on or after 1 March 2010:
Amendments to FRS 132, Financial Instruments: Presentation Classifcation of Right Issues
Effective for fnancial periods beginning on or after 1 July 2010:
FRS 1, First Time Adoption of Financial Reporting Standards (revised)
FRS 3, Business Combinations (revised)
FRS 127, Consolidated and Separate Financial Statements (revised)
Amendments to FRS 2, Share-based Payment
Amendments to FRS 5, Non-current Assets Held for Sale and Discontinued Operations
Amendments to FRS 138, Intangible Assets
IC Interpretation 12, Service Concession Agreements
IC Interpretation 16, FRS 2 Hedges of a Net Investment in a Foreign Operation
IC Interpretation 17, Distribution of Non-cash Assets to Owners
Amendments to IC Interpretation 9, Reassessment of Embedded Derivatives
Effective for fnancial periods beginning on or after 1 January 2011:
Amendments to FRS 1, First Time Adoption of Financial Reporting Standards
- Limited Exemption from Comparative FRS 7 Disclosures for First-time Adopters
- Additional Exemption for First-time Adopters
Amendments to FRS 7, Financial Instruments: Disclosure Improving Disclosures about Financial
Instruments
Amendments to FRS 2, Group Cash-settled Share-based Payment Transactions
IC Interpretation 4, Determining whether an Arrangement contains a Lease
IC Interpretation 18, Transfers of Assets from Customers
Improvements to FRSs (2010)
Effective for fnancial periods beginning on or after 1 July 2011:
Amendments to IC Interpretation 14, Prepayments of a Minimum Funding Requirement
IC Interpretation 19, Extinguishing Financial Liabilities with Equity Instruments
Effective for fnancial periods beginning on or after 1 January 2012:
FRS 124, Related Party Disclosures (revised)
IC Interpretation 15, Agreements for the Construction of Real Estate
The Group and the Company plan to adopt the abovementioned standards, amendments and interpretations:
from the annual period beginning on 1 January 2011 for those standards, amendments and interpretations
that will be effective for annual periods beginning on or after 1 March 2010, 1 July 2010 and 1 January
2011.
from the annual period beginning on 1 January 2012 for those standards, amendments and interpretations
that will be effective for annual periods beginning on or after 1 July 2011 and 1 January 2012.
The initial applications of the aforesaid applicable standards, amendments or interpretations are not expected
to have any signifcant fnancial impact to the fnancial statements upon their frst adoption.
Following the announcement made by the Malaysian Accounting Standards Board on 1 August 2008, the
Groups and the Companys fnancial statements for the year ended 31 December 2012 will be prepared in
accordance with International Financial Reporting Standards Framework.
80
Statements (contd)
(b) Basis of consolidation
(i) Subsidiaries
Subsidiaries are entities, including unincorporated entities, controlled by the Group. Control exists
when the group has the ability to exercise its power to govern the fnancial and operating policies of
an entity so as to obtain benefts from its activities. In assessing control, potential voting rights that
presently are exercisable are taken into account.
Investments in subsidiaries are measured in the Companys statement of fnancial position at cost less
any impairment losses, unless the investment is held for sale or distribution. The cost of investments
includes transaction costs.
The accounting policies of subsidiaries are changed when necessary to align them with the policies
adopted by the Group.
(ii) Associates
Associates are entities, including unincorporated entities, in which the Group has signifcant infuence,
but not control, over the fnancial and operating policies.
Investments in associates are accounted for in the consolidated fnancial statements using the equity
method less any impairment losses, unless it is classifed as held for sale or distribution. The coas of
the investment includes transaction costs. The consolidated fnancial statements include the Groups
share of the proft or loss and other comprehensive income of the equity accounted associates, after
adjustments if any, to align the accounting policies with those of the Group, from the date that signifcant
infuence commences until the date that signifcant infuence ceases.
When the Groups shares of the losses exceeds its interest in an associates, the carrying amount of that
interest including any long-term investments is reduced to zero, and the recognition of further losses is
discontinued except to the extent that the Group has an obligation or has made payments on behalf of
the investee.
Investment is associates are measured in the Companys statement of the fnancial position at cost less
any impairment losses, unless the investment is classifed as held sale or distribution as held for sale or
distribution. The cost of investments includes transaction costs.
(c) Property, plant and equipment
(i) Recognition and measurement
Plant and plant and equipment are stated at cost less accumulated depreciation and any accumulated
impairment losses.
Cost includes expenditures that are directly attributable to the acquisition of the asset and any other
costs directly attributable to bringing the asset to working condition for its intended use, and the costs
of dismantling and removing the items and restoring the site on which they are located. Purchased
software that is integral to the functionality of the related equipment is capitalised as part of that
equipment.
When signifcant parts of an item of plant and equipment have different useful lives, they are accounted
for as separate items (major components) of plant and equipment.
Gains and losses on disposal of an item of plant and equipment are determined by comparing the
proceeds from disposal with the carrying amount of plant and equipment and are recognised within
realised gains and losses in the income statement.
81
Statements (contd)
(c) Property, plant and equipment (contd)
(ii) Subsequent costs
The cost of replacing part of an item of plant and equipment is recognised in the carrying amount of the
item if it is probable that the future economic benefts embodied within the part will fow to the Group
and its cost can be measured reliably. The carrying amount of the replaced part is derecognised. The
costs of the day-to-day servicing of plant and equipment are recognised in the income statement as
incurred.
(iii) Depreciation
Depreciation is calculated over the depreciable amount, which is the cost of an asset, or other amount
substituted for cost, less its residual value.
Property, plant and equipment are depreciated on the straight-line method at rates based on their
estimated useful lives. The principal annual rates used are as follows:
Rate
Offce suite 2%
Laboratory equipment Over 7 years
Furniture and fttings 20%
Offce equipment 10 - 20%
Computer system 20%
Motor vehicle 20%
Computer equipment 25%
Renovation 10 - 25%
Advertising and exhibition equipment 33.33%
Depreciation methods, useful lives and residual values are reviewed, and adjusted as appropriate at end
of the reporting period.
(d) Investments
Investment in quoted and unquoted shares are stated at cost less any impairment losses. The policy for the
recognition and measurement of impairment losses is in accordance with Note 2 (k).
(e) Inventories
Inventories are stated at the lower of cost and net realisable value.
The cost of inventories is measured based on a frst-in, frst-out (FIFO) basis, and includes expenditure incurred
in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their
existing location and condition.
Net realisable value is the estimated selling price in ordinary course of business, less the estimated costs of
completion and the estimated costs necessary to make the sale.
(f) Provisions for liabilities
Provisions for liabilities are recognised when the Group have a present legal or constructive obligation as a
result of past events and it is probable that an outfow of resources embodying economic benefts will be
required to settle the obligation, and a reliable estimate of the amount can be made. Provisions are reviewed
at each balance sheet date and adjusted to refect the current best estimate. Where the effect of the time
value of money is material, the amount of a provision is the present value of the expenditure expected to be
required to settle the obligation.
82
Statements (contd)
(g) Revenue recognition
Revenue of the Group is recognised when goods and services are rendered and accepted by customers.
Other revenue earned by the Group are recognised on the following basis:
Dividend income when the shareholders right to receive payment is established.
Interest income as it accrues unless recoverability is in doubt.
(h) Income tax
Taxation in the income statement represents the aggregate amount of current and deferred tax. Current
tax is the expected amount of income taxes payable in respect of taxable income for the year and any
adjustments recognised in the year for current tax of prior years.
Deferred tax is recognised, using the liability method, on temporary differences except where the temporary
differences arise from goodwill or negative goodwill or from the initial recognition of an asset or liability in a
transaction, which is not a business combination and at the time of the transaction, affects neither accounting
proft nor taxable proft. Deferred tax is measured at the tax rates that are expected to apply in the period in
which the assets are realised or the liabilities are settled.
Deferred tax is recognised in equity when it relates to items recognised directly in equity. When deferred tax
arises from business combination that is an acquisition, the deferred tax is included in the resulting goodwill
or negative goodwill.
Deferred tax assets are recognised only to the extent that there are suffcient taxable temporary differences
relating to the same taxation authority to offset or when it is probable that future taxable income will be
available against which the assets can be utilised.
(i) Foreign currency
(i) Foreign currency transactions
Transactions in foreign currencies are translated to the respective functional currencies of Group entities
at exchange rates at the dates of the transactions.
Monetary assets and liabilities denominated in foreign currencies at the reporting period are retranslated
to the functional currency at the exchange rate at that date.
Non-monetary assets and liabilities denominated in foreign currencies are not retranslated at the end
of the reporting date except for those that are measured at fair value are retranslated to the functional
currency at the exchange rate at the date that the fair value was determined.
Foreign currency differences arising on retranslation are recognised in proft or loss, except for
differences arising on the retranslation of available-for-sale equity instruments or a fnancial instrument
designated as a hedge of currency risk, which are recognised in other comprehensive income.
(ii) Investment in foreign associates
The carrying amount of the investment is translated to RM at the exchange rates at the end of the
reporting period. The share of results for the year is translated at the average exchange rates applicable
throughout the year.
Foreign currency differences are recognised in foreign exchange reserve. On disposal, accumulated
foreign exchange differences are recognised in the consolidated income statement as part of the gain
or loss on sale.
83
Statements (contd)
(j) Cash fow statement
The Group and the Company adopt the indirect method in the preparation of the cash fow statements.
Cash equivalents are short term, highly liquid investments with maturities of three months or less from the
date of acquisition and are readily convertible to cash with insignifcant risk of change in value.
(k) Impairment
(i) Financial assets
All fnancial assets (except for fnancial assets categorised as fair value through proft or loss, investment
in subsidiaries and investment in associates) are assessed at each reporting date whether there is any
objective evidence of impairment as a result of one or more events having an impact on the estimated
future cash fows of the assets. Losses expected as a result of future events, no matter how likely, are
not recognised. For an equity instrument, a signifcant or prolonged decline in the fair value below its
cost is an objective evidence of impairment.
An impairment loss in respect of loans and receivables and held-to-maturity investments is recognised
in proft or loss and is measured as the difference between the assets carrying amount and the present
value of estimated future cash fows discounted at the assets original effective interest rate. The carrying
amount of the asset is reduced through the use of an allowance account.
An impairment loss in respect of available-for-sale fnancial assets is recognised in the proft or loss
and is measured as the difference between the assets acquisition cost (net of any principal repayment
and amortisation) and the assets current fair value, less any impairment loss previously recognised.
Where a decline in the fair value of an available-for-sale fnancial asset has been recognised in other
comprehensive income, the cumulative loss in other comprehensive income is reclassifed from equity
to proft or loss.
An impairment loss in respect of unquoted equity instrument that is carried at cost is recognised in
proft of loss and is measured as the difference between the fnancial assets carrying amount and the
present value of estimated future cash fows discounted at the current market rate of return for a similar
fnancial asset.
Impairment losses recognised in proft or loss for an investment in an equity instrument classifed as
available for sale is not reversed through proft or loss.
If, in a subsequent period, the fair value of a debt instrument increases and the increase can be
objectively related to an event occurring after the impairment loss was recognised in proft or loss, the
impairment loss is reversed, to the extent that the assets carrying amount does not exceed what the
carrying amount would have been had the impairment not been recognised at the date the impairment
is reversed. The amount of the reversal is recognised in proft or loss.
(ii) Non-fnancial assets
The carrying amounts of non-fnancial assets (except for inventories, assets arising from construction
contract, deferred tax asset, assets arising from employee benefts, investment property, that is measured
at fair value and non-current assets (or disposal groups) classifed as held for sale) are reviewed at the
end of each reporting period to determine whether there is any indication of impairment. If any such
indication exists, then the assets recoverable amount is estimated.
For the purpose of impairment testing, assets are grouped together into the smallest group of assets
that generates cash infows from continuing use that are largely independent of the cash infows of other
assets or groups of assets (the cash-generating unit). The goodwill acquired in a business combination,
for the purpose of impairment testing, is allocated to cash-generating units that are expected to beneft
from the synergies of the combination.
84
Statements (contd)
(k) Impairment (contd)
(ii) Non-fnancial assets (contd)
The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair
value less costs to sell. In assessing value in use, the estimated future cash fows are discounted to their
present value using a pre-tax discount rate that refects current market assessments of the time value of
money and the risks specifc to the asset.
An impairment loss is recognised if the carrying amount of an asset or its cash-generating unit exceeds
its recoverable amount.
Impairment losses are recognised in the proft or loss. Impairment losses recognised in respect of cash-
generating units are allocated frst to reduce the carrying amount of any goodwill allocated to the units
and then to reduce the carrying amount of the other assets in the units (groups of units) on a pro rata
basis.
An impairment loss in respect of goodwill is not reversed. In respect of the other assets, impairment
losses recognised in prior periods are assessed at the end of each reporting period for any indications
that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a
change in the estimates used to determine the recoverable amount since the last impairment loss was
recognised. An impairment loss is reversed only to the extent that the assets carrying amount does
not exceed the carrying amount that have been determined, net of depreciation or amortisation, if no
impairment loss had been recognised. Reversals of impairment losses are credited to proft or loss in
the year in which the reversals are recognised.
(l) Employee benefts
(i) Short term employee benefts
Short-term employee beneft obligations in respect of salaries, annual bonuses, paid annual leave and
sick leave are measured on an undiscounted basis and are expensed as the related service is provided.
A liability is recognised for amount expected to be paid under short-term cash bonus or proft-sharing
plans if the Group has a present legal or constructive obligation to pay this amount as a result of past
service provided by the employee and the obligation can be estimated reliably.
(ii) Defned contribution plans
The Group recognises all actuarial gains and losses arising from defned beneft plans in other
comprehensive income and all expenses related to defned beneft plans in personnel expenses in proft
and loss.
The Group recognises gains and losses on the curtailment or settlement of a defned beneft plan when
the curtailment or settlement occurs. The gain or loss on curtailment comprises any resulting change in
the fair value of plan assets, change in the present value of defned beneft obligation and any related
actuarial gains and losses and past service cost that had not previously been recognised.
(m) Financial instruments
(i) Initial recognition and measurement
A fnancial instrument is recognised in the fnancial statements when, and only when, the Group and the
Company become a party to the contractual provisions of the instrument.
A fnancial instrument is recognised initially, at its fair value plus, in the case of a fnancial instrument not
at fair value through proft or loss, transaction costs that are directly attributable to the acquisition or
issue of the fnancial instrument.
85
Statements (contd)
(m) Financial instruments (contd)
(i) Initial recognition and measurement (contd)
An embedded derivative is recognised separately from the host contract and accounted for as a
derivative if, and only if, it is not closely related to the economic characteristics and risks of the host
contract and the host contract is not categorised at fair value though proft or loss. The host contract, in
the event an embedded derivative is recognised separately, is accounted for in accordance with policy
applicable to the nature of the host contract.
(ii) Financial instrument categories and subsequent measurement
The Group and the Company categories fnancial instruments as follows:
Financial assets
(a) Financial assets at fair value through proft or loss
Fair value through proft or loss category comprises fnancial assets that are held for trading,
including derivatives (except for a derivative that is a designated and effective hedging instrument)
or fnancial assets that are specifcally designated into this category upon initial recognition.
Derivatives that are linked to and must be settled by delivery of unquoted equity instruments
whose fair values cannot be reliably measured are measured at cost.
Other fnancial assets categorised as fair value through proft or loss are subsequently measured
at their fair values with the gain or loss recognised in income statement.
(b) Held-to-maturity investments
Held-to-maturity investments category comprises debt instruments that are quoted in an active
market and the Group and the Company have the positive intention and ability to hold-to-maturity.
Financial assets categorised as held-to-maturity investments are subsequently measured at
amortised cost using the effective interest method.
(c) Loan and receivables
Loans and receivables category comprises debt instruments that are not quoted in an active
market (including fxed deposits with fnancial institutions) and loans and receivables.
Financial assets categorised as loans and receivables are subsequently measured at amortised
cost using the effective interest method.
All fnancial assets, except for those measured at fair value through proft or loss, are subject to review
for impairment.
Financial liabilities
All fnancial liabilities are initially measured at fair value and subsequently measured at amortised cost
other than those categorised as fair value through proft or loss.
Fair value through proft or loss category comprises fnancial liabilities that are held for trading,
derivatives (except for a derivative that is a fnancial guarantee contract or a designated and effective
hedging instrument) or fnancial liabilities that are specifcally designated into this category upon initial
recognition.
Derivatives that are linked to and must be settled by delivery of unquoted equity instruments whose fair
values cannot be reliably measured are measured at cost.
Other fnancial liabilities categorised as fair value through proft or loss are subsequently measured at
their fair values with the gain or loss recognised in income statement.
86
Statements (contd)
3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY
(a) Critical Judgement made in Applying Accounting Policies
In the process of applying the Groups and Companys accounting policies, which are described in Note 2,
management is of the opinion that there are no instances of application of judgement which are expected to
have signifcant effect on the amounts recognised in the fnancial statements.
(b) Key Sources of Estimation Uncertainty
Management believes that there are no key assumptions made concerning the future, and other key sources
of estimation uncertainty at the balance sheet date, that have a signifcant risk of causing a material adjustment
to the carrying amounts of assets and liabilities within the next fnancial period.
4. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment consist of the following:
Balance at Written off/ Balance at
GROUP 01.01.2010 Additions Disposals 31.12.2010
COST RM RM RM RM
Offce suite 2,317,700 - - 2,317,700
Laboratory equipment 3,451,770 279,475 - 3,731,245
Furniture and fttings 123,206 4,017 - 127,223
Offce equipment 721,572 3,829 - 725,401
Computer systems 688,711 21,000 - 709,711
Motor vehicle 395,707 260,001 (177,882) 477,826
Computer equipment 327,501 71,530 - 399,031
Renovation 1,845,234 75,700 - 1,920,934
Advertising and exhibition equipment 122,064 1,390 - 123,454
9,993,465 716,942 (177,882) 10,532,525
Balance at Charge for Written off/ Balance at
ACCUMULATED 01.01.2010 the year Disposals 31.12.2010
DEPRECIATION RM RM RM RM
Offce suite 175,019 46,354 - 221,373
Offce equipment 241,353 77,841 - 319,194
Motor vehicle 126,205 94,650 (109,664) 111,191
Renovation 1,189,014 296,655 - 1,485,669
4,010,491 1,235,697 (109,664) 5,136,524

87
Statements (contd)
4. PROPERTY, PLANT AND EQUIPMENT (CONTD)
Balance at Reclassifed/ Balance at
GROUP 01.01.2009 Additions Disposals 31.12.2009
COST RM RM RM RM

Offce suite 2,317,700 - - 2,317,700
Offce equipment 653,348 77,524 (9,300) 721,572
Motor vehicle 225,887 169,820 - 395,707
Renovation 1,700,651 148,283 (3,700) 1,845,234
9,165,138 841,327 (13,000) 9,993,465
Balance at Charge for Reclassifed/ Balance at
Offce suite 128,665 46,354 - 175,019
Offce equipment 170,559 69,552 1,242 241,353
Motor vehicle 72,537 53,668 - 126,205
Renovation 836,674 354,576 (2,236) 1,189,014
2,873,467 1,138,018 (994) 4,010,491
GROUP
2010 2009
NET BOOK VALUE RM RM
Offce suite 2,096,327 2,142,681
Laboratory equipment 1,447,734 1,645,554
Furniture and fttings 35,433 51,898
Offce equipment 406,207 480,219
Computer systems 481,249 597,990
Motor vehicle 366,635 269,502
Computer equipment 114,192 103,216
Renovation 435,265 656,220
Advertising and exhibition equipment 12,959 35,694
5,396,001 5,982,974
88
Statements (contd)
Balance at Balance at
COMPANY 01.01.2010 Additions Disposals 31.12.2010
COST RM RM RM RM
Offce equipment 241,301 - - 241,301
Motor vehicle 395,707 260,001 (177,882) 477,826
Renovation 1,366,331 75,700 - 1,442,031
6,712,567 713,113 (177,882) 7,247,798
Balance at Charge for Balance at

Offce equipment 163,035 25,894 - 188,929
Motor vehicle 126,205 94,650 (109,664) 111,191
Renovation 1,007,960 207,386 - 1,215,346
3,575,127 1,046,918 (109,664) 4,512,381
Balance at Reclassifed/ Balance at
COMPANY 01.01.2009 Additions Disposals 31.12.2009
COST RM RM RM RM
Offce equipment 188,051 49,550 3,700 241,301
Motor vehicle 225,887 169,820 - 395,707
Renovation 1,225,723 144,308 (3,700) 1,366,331
5,903,189 809,378 - 6,712,567
89
Statements (contd)
Balance at Charge for Reclassifed/ Balance at
Offce equipment 137,925 22,874 2,236 163,035
Motor vehicle 72,537 53,668 - 126,205
Renovation 701,784 308,412 (2,236) 1,007,960
2,576,910 998,217 - 3,575,127
COMPANY
2010 2009
NET BOOK VALUE RM RM

Laboratory equipment 1,447,734 1,645,554
Motor vehicle 366,635 269,502
Computer equipment 114,191 103,215
Renovation 226,685 358,371
2,735,417 3,137,440
Included in the property, plant and equipment of the Group and of the Company are the costs of the following fully
depreciated assets which are still in use:
GROUP AND COMPANY
FULLY DEPRECIATED ASSETS 2010 2009
COST RM RM

Laboratory equipment 172,362 105,601
Renovation 76,914 192,794
1,732,450 568,951
Included in property, plant and equipment of the Company are motor vehicle with a carrying amount of Nil (2009
RM133,633) registered under the name of a wholly-owned subsidiary company and held in trust.

90
Statements (contd)
5. INVESTMENT IN SUBSIDIARY COMPANIES
COMPANY
2010 2009
RM RM

Unquoted shares - at cost 6,850,201 5,000,201
Details of the subsidiary companies, which are all incorporated in Malaysia, are as follows:
% EQUITY HELD PRINCIPAL ACTIVITIES
NAME OF COMPANY 2010 2009
Stemlife Properties Sdn. Bhd. 100 100 Investment holding company
Stemlife Therapeutics Sdn. Bhd. 100 73 Harvesting, testing, processing and preservation
of peripheral blood stem cells
SL Diagnostics Sdn. Bhd. 100 100 Dormant
Stemlife Logistics Sdn. Bhd. * 100 100 Logistics of umbilical cord blood stem cells and
peripheral blood stem cells
Stemvet Sdn. Bhd. # 100 73 Dormant
Advent Capital Sdn. Bhd.## @ 60 60 Dormant
(Formerly Known as Meganext
Pavilion Sdn. Bhd.)
* Held jointly by the Company and a wholly-owned subsidiary Company Stemlife Properties Sdn. Bhd. on an
equal basis.
# Held indirectly through Stemlife Therapeutics Sdn. Bhd.
## Held indirectly through Stemlife Properties Sdn. Bhd.
@ Audited by other frm of auditors.
Acquisition of minority interests
On 21 December 2010, Stemlife Berhad acquired an additional 27% equity interest in Stemlife Therapeutics Sdn.
Bhd. from its minority interests for a cash consideration of RM1,850,000. As a result of this acquisition, Stemlife
Therapeutics Sdn. Bhd. became a wholly-owned subsidiary of Stemlife Berhad.
Consequently, Stemvet Sdn. Bhd., being a subsidiary of Stemlife Therapeutics Sdn. Bhd. also became a wholly-
owned subsidiary of Stemlife Berhad.
6. INVESTMENT IN ASSOCIATED COMPANIES
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Unquoted shares - at cost 3,117,100 945,000 3,117,100 945,000
Share of associated companiess result 783,358 1,212,349 - -
3,900,458 2,157,349 3,117,100 945,000
91
Statements (contd)
6. INVESTMENT IN ASSOCIATED COMPANIES (CONTD)
Details of the associated companies as follows:
COUNTRY OF % EQUITY HELD PRINCIPAL ACTIVITIES
INCORPORATION
NAME OF COMPANY 2010 2009
Thai Stemlife Co Ltd. Thailand 40 40 Stem cells bank
PT Prodia Stemlife Indonesia. Indonesia 40 Nil Stem cells bank
The summarised fnancial information of the associated company is as follows:
GROUP
2010 2009
RM RM

Assets and liabilities
Non-current assets 3,819,210 3,456,832
Current assets 5,795,599 7,738,196
Total assets 9,614,809 11,195,028
Non-current liabilities 4,262,325 3,781,890
Current liabilities 1,095,474 2,176,808
Total liabilities 5,357,799 5,958,698
4,257,010 5,236,330
GROUP
2010 2009
RM RM

Result
Revenue 6,763,919 11,293,792
Net (loss)/proft for the fnancial year (112,830) 1,069,988
7. OTHER INVESTMENT
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Non-current assets
Available-for-sale fnancial assets
Unquoted shares - at cost 6,000,360 6,000,360 6,000,360 6,000,360
Less: Allowance for diminution in value (2,469,622) (2,469,622) (2,469,622) (2,469,622)
3,530,738 3,530,738 3,530,738 3,530,738
92
Statements (contd)
8. INVENTORIES
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
At cost:
Consumables 652,073 565,025 652,073 565,025
Marketing related items 98,020 77,305 90,749 77,305
Printing and stationery 6,271 4,051 6,271 4,051
756,364 646,381 749,093 646,381
9. TRADE RECEIVABLES
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Trade receivables 4,395,641 7,708,680 3,423,421 6,660,690
Less: Allowance for doubtful debts (1,321,098) (779,325) (1,321,098) (779,325)
3,074,543 6,929,355 2,102,323 5,881,365
The Groups normal trade credit term is 30 days. Other credit terms are assessed and negotiated on a case-by-case
basis.
The ageing analysis of trade receivables as at 31 December 2010 is as follows:
2010
RM
Not past due 7,041,780
Less than 30 days past due 605,843
more than 30 days past due 1,138,011
8,785,634
Less: Advance payment (5,711,091)
3,074,543
10. OTHER RECEIVABLES AND DEPOSITS
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Other receivables 10,081 55,558 10,083 55,558
Deposits 218,107 230,127 218,107 230,127
Prepayment 464,008 484,896 461,430 482,231
692,196 770,581 689,620 767,916
93
Statements (contd)
11. SHORT TERM INVESTMENT
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Unit trust, quoted in Malaysia, at cost
At beginning of year 3,000,000 3,000,000 3,000,000 3,000,000
Less: Uplifted during the year (3,000,000) - (3,000,000) -
At end of year - 3,000,000 - 3,000,000
At market value - 2,972,700 - 2,972,700
12. AMOUNT DUE FROM/TO ASSOCIATED COMPANIES
These amounts are interest-free, unsecured and have no fxed terms of repayment.
13. AMOUNT DUE FROM SUBSIDIARY COMPANIES
These amounts are interest-free, unsecured and have no fxed terms of repayment.
14. CASH AND CASH EQUIVALENTS
Cash and cash equivalents included in the cash fow statements comprise the following balance sheet amounts:
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Cash and bank balances 10,351,483 8,167,465 5,157,750 5,398,049
Deposits with licensed bank 22,367,524 19,982,956 22,367,524 16,088,969
Investment in unit trust 15,155,609 10,822,256 15,155,609 10,822,256
47,874,616 38,972,677 42,680,883 32,309,274
The deposits of the Group and the Company earn interest at rates ranging from 1.50% to 2.90% (2009 2.00% to
3.00%) per annum.

15. SHARE CAPITAL
GROUP AND COMPANY
2010 2009 2010 2009
Number of shares RM RM
Authorised:
Ordinary shares of RM0.10 each 250,000,000 250,000,000 25,000,000 25,000,000
Issued and fully paid:
Ordinary shares of RM0.10 each 165,000,000 165,000,000 16,500,000 16,500,000
94
Statements (contd)
16. DEFERRED TAXATION
GROUP
2010 2009
RM RM

At beginning of year - 29,800
Transferred from income statement (Note 22) - (29,800)
At end of year - -
The deferred taxation is in respect of timing differences arising from capital allowances claimed in advance of
depreciation charge on property, plant and equipment.
17. TRADE PAYABLES
The normal trade credit term granted to the Group ranges from 30 to 90 days.
18. OTHER PAYABLES AND ACCRUALS
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Other payables 432,549 758,776 420,389 725,725
Accruals 459,701 718,295 355,931 659,501
Advance received 461,120 256,010 - -
1,353,370 1,733,081 776,320 1,385,226
19. REVENUE
Revenue represents the gross invoiced value less discount.
20. OTHER INCOME
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Consultant fee 486,873 268,059 486,873 268,059
Dividend income from:
- Available for sale fnancial assets 333,353 271,665 577,882 471,665
Net gain on foreign exchange - 2,982 - 2,982
Net gain on disposal of property, plant
and equipment 12,782 - 12,782 -
Interest income from:
- Held to maturity investment 662,946 337,089 579,707 283,504
Management fee - - 120,000 120,000
Miscellaneous - 14,042 - 14,042
1,495,954 893,837 1,777,244 1,160,252
95
Statements (contd)
21. (LOSS)/PROFIT BEFORE TAXATION
This has been determined after charging the following items:
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Allowance for diminution in value of investment - 2,469,622 - 2,469,622
Allowance for doubtful debts 541,773 779,325 541,773 779,325
Audit fee 57,700 54,700 35,000 32,000
Depreciation 1,235,697 1,138,018 1,046,918 998,217
Directors remuneration 494,200 564,600 494,200 564,600
Loss on foreign exchange 7,639 - 4,601 -
Property, plant and equipment written off - 12,006 - -
Rental - equipment 6,600 14,027 6,600 14,027
Rental - offce 522,840 444,290 440,540 329,870
Rental - laboratory 174,000 174,000 174,000 174,000
and crediting:
Dividends received 333,353 271,665 577,882 471,665
Gain on disposal of property, plant
and equipment 12,782 - 12,782 -
Gain on foreign exchange - 2,982 - 2,982
Interest received 662,946 337,089 579,707 283,504
Management fee - - 120,000 120,000
22. TAXATION
The provision for taxation for the fnancial year is computed at the prevailing tax rates.
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Provision for current year 147,300 109,600 145,000 101,000
(Over)/Underprovision in prior year (33,885) 2,243 (30,124) -
Deferred taxation (Note 16) - (29,800) - -
113,415 82,043 114,876 101,000
A reconciliation of income tax expense applicable to (loss)/proft before taxation at the statutory income tax rate
to income tax expense at the effective income tax rate of the Group and of the Company is as follows:
96
Statements (contd)
22. TAXATION (CONTD)
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
(Loss)/Proft before taxation (63,235) (2,950,681) 1,699,715 (2,930,396)
Taxation at the Malaysian statutory tax
rate of 25% (15,809) (737,670) 424,929 (732,599)
Effect of share of result of associates 105,125 (217,499) - -
Expenses not deductible for tax purposes 332,037 1,081,077 276,441 1,026,709
Effect of income exempted from tax (556,370) (193,110) (556,370) (193,110)
Deferred tax assets not recognised
during the year 282,317 182,809 - -
Utilisation of previously unrecognised tax losses - (6,007) - -
Reversal of originating timing differences - (29,800) - -
Under/(Over) provision in prior year (33,885) 2,243 (30,124) -
Tax expense for the year 113,415 82,043 114,876 101,000
No provision for taxation was made on business income as the Company was granted Bionexus Status by the
Malaysian Biotechnology Corporation, where the business income is tax exempted for a period of ten years
beginning 2007.
23. BASIC AND DILUTED LOSS PER ORDINARY SHARE
Basic loss per share is calculated by dividing the net loss for the year by the number of ordinary shares in issue
during the fnancial year.
GROUP
2010 2009
RM RM

Net loss for the year (RM) (377,253) (2,820,469)
Number of ordinary shares in issue 165,000,000 165,000,000
Basic loss per share (sen) (0.23) (1.71)
There is no dilution in loss per share.
97
Statements (contd)
24. DIVIDENDS
GROUP AND COMPANY
2010 2009
RM RM

A frst and fnal tax exempt dividend of 10% in respect of the year ended
31 December 2008 - 1,650,000
A frst and fnal tax exempt dividend of 10% in respect of the year ended
31 December 2009 1,650,000 -
1,650,000 1,650,000
At the forthcoming Annual General Meeting, a single tier fnal dividend of 10% on 165,000,000 ordinary shares
amounting to RM1,650,000 in respect of the fnancial year ended 31 December 2010 will be proposed for
shareholders approval. The fnancial statements for the current fnancial year do not refect this proposed dividend.
Such dividend, if approved by the shareholders, will be accounted for in equity as an appropriation of retained
earnings in the fnancial year ending 31 December 2011.
25. DIRECTORS REMUNERATION
During the year, the Directors of the Company were paid the following:
GROUP AND COMPANY
2010 2009
RM RM

Directors of the Company
Executives:
Fee - -
Salaries and other emoluments 479,200 549,600
Total 479,200 549,600
Non-executives:
Fee 15,000 15,000
Total 494,200 564,600
The number of directors of the Company whose total remuneration during the fnancial year fell within the following
bands is analysed below:
Number of directors
2010 2009
RM RM

Executive directors:
RM50,000 - RM100,000 - -
RM100,001 - RM150,000 4 3
RM150,001 - RM200,000 - 1
Non-Executive directors:
RM1 - RM50,000 1 1
98
Statements (contd)
26. EMPLOYEE INFORMATION
GROUP COMPANY
2010 2009 2010 2009
RM RM RM RM
Salary and wages 5,188,190 4,968,318 4,225,031 3,988,875
E.P.F. and Socso contributions 642,649 627,385 514,825 489,603
Other staff related expenses 65,313 67,720 48,020 47,268
5,896,152 5,663,423 4,787,876 4,525,746
Salary and wages include salaries, allowances and sales commission.
27. RELATED PARTY TRANSACTIONS
COMPANY
2010 2009
RM RM

Rental paid to subsidiary company 24,000 24,000
Management fee charged to subsidiary company 120,000 120,000
Logistics charged by subsidiary company 979,275 1,049,700
(a) Compensation of key management personnel (KMP)
Key management personnel are those persons having authority and responsibility for planning, directing and
controlling the activities of the entity either directly or indirectly.
The remuneration of key management personnel during the year was as follows:
Total KMPs remuneration
GROUP AND COMPANY
2010 2009
RM RM

Total 1,781,806 1,452,325
For the details of Board of Directors remuneration, please refer to Note 25.
99
Statements (contd)
28. DISCLOSURE OF REALISED AND UNREALISED RETAINED PROFITS
On 25 March 2010, Bursa Malaysia Securities Berhad (Bursa Malaysia) issued a directive to all issuers pursuant
to Paragraphs 2.06 and 2.23 of Bursa Malaysia Main Market Listing Requirements. The directive requires all listed
issuers to disclose the breakdown of the unappropriated profts or accumulated losses as at the end of the reporting
period, into realised and unrealised profts and losses.
On 20 December 2010, Bursa Malaysia further issued guidance on the disclosure and format required.
The breakdown of accumulated losses of the Group and the Company as at the reporting date, into realised and
unrealised losses, pursuant to the directive, is as follows:
GROUP COMPANY
2010 2009
RM RM

Total retained earnings of the Company and its subsidiaries
- Realised 2,102,046 5,730,237
- Unrealised - -
2,102,046 5,730,237
Total share of retained earnings from associate
- Realised 791,850 -
2,893,896 5,730,237
Less: Consolidation adjustments 51,543 -
Retained earnings as per fnancial statements 2,842,353 5,730,237
29. FINANCIAL INSTRUMENTS
(a) Classifcation of fnancial instruments
Loan and Receivables
GROUP COMPANY
2010 2009 2010 2009
Financial assets RM RM RM RM
Trade and other receivables 3,766,739 7,699,936 2,791,943 6,649,281
Amount due from subsidiary companies - - 5,146,247 5,730,727
Amount due from associated company 598 - 598 -
Fixed deposit 22,367,524 19,982,956 22,367,524 16,088,969
Investment in unit trust 15,155,609 10,822,256 15,155,609 10,822,256
Cash and bank balances 10,351,483 8,167,465 5,157,750 5,398,049
51,641,953 46,672,613 50,619,671 44,689,282
100
Statements (contd)
29. FINANCIAL INSTRUMENTS (CONTD)
Amortised Cost
GROUP COMPANY
2010 2009 2010 2009
Financial liabilities RM RM RM RM
Trade and other payables 1,787,844 2,063,806 1,210,188 1,715,951
Amount due to associated company - 2,670 - 2,670
1,787,844 2,066,476 1,210,188 1,718,621

(b) Financial risk management policies
The Group is exposed to a variety of risks in the normal course of business. The Groups risk management
seeks to minimize the potential adverse effects from these exposures. The management reviews and agrees
policies for managing each of these risks as follows:
(i) Interest rate risk
Cash fow interest rate risk is the risk that the future cash fows of a fnancial instrument will fuctuate
because of changes in market interest rates. Fair value interest rate risk is the risk that the value of
a fnancial instrument will fuctuate due to changes in market interest rates. As the Group has no
signifcant interest-bearing fnancial assets, the Groups income and operating cash fow are substantially
independent of changes in market interest rates. The Groups interest-bearing fnancial assets are
mainly short term in nature and have been mostly placed in fxed deposits or occasionally, in short term
commercial papers.
The following tables set out the carrying amounts, the weighted average effective interest rates
(WAEIR) as at the balance sheet date and the remaining maturities of the Groups and the Companys
fnancial instruments that are exposed to interest rate risk:
More
Within 1 2-5 than 5
Note WAEIR year years years Total
% RM RM RM RM

At 31 December 2010
Group
Deposits with licensed bank
Short term placements 14 2.30 22,367,524 - - 22,367,524
At 31 December 2009
Group
Deposits with licensed bank
Short term placements 14 2.44 19,982,956 - - 19,982,956
101
Statements (contd)
(b) Financial risk management policies (contd)
(ii) Credit risk
The Group is exposed to credit risk mainly from receivables. The Group extends credit to its customers
based upon careful evaluation of the customers fnancial condition and credit history.
The Groups exposure to credit risk in relation to its receivables, should all its customers fail to perform
their obligations as at year end, is the carrying amount of these receivables as disclosed in the balance
sheet.
The Group places its fxed deposits with credit worthy institutions. The carrying amount of fnancial
assets in the fnancial statements, net of any provision of losses, represents the Groups maximum
exposure to credit risk without taking account of the value of any collateral or other security obtained.
(iii) Market risk
Market risk arises mainly from uncertainty about future prices of investment in unit trust. The Group
manages the risk of unfavourable changes in prices by continuously monitoring the performance of the
unit trust.
(iv) Foreign currency risk
The Group is exposed to transactional currency risk primarily through purchases and undertakes
transactions with associated company that are denominated in a currency other than the functional
currency of the operations to which they relate. The currencies giving rise to this risk are primarily in
United States Dollar, Indonesia Rupiah, Thai Baht and Singapore Dollar. Foreign exchange exposures
in transactional currencies other than functional currencies of the operating entities are kept to an
acceptable level.
The net unhedged fnancial assets and fnancial liabilities of the Group companies that are not
denominated in their functional currencies are as follows:

Net fnancial assets/(fnancial liabilities)
held in non-functional currency
United States Thai Singapore Total
Functional Currency Dollar Baht Dollar
RM RM RM RM

At 31 December 2010
Group
Trade payables
Ringgit Malaysia 46,252 - - 46,252
At 31 December 2009
Group
Trade payables
Ringgit Malaysia - - - -
102
Statements (contd)
(b) Financial risk management policies (contd)
(v) Liquidity and cash fow risk
The Group reviews its cash fow position regularly to manage its exposure to fuctuations in future cash
fow associated with its monetary fnancial instruments.
The table below summarises the maturity profle of the Group and the Companys fnancial liabilities at 31
December 2010 and 31 December 2009, based on contractual undiscounted cash fows.
GROUP COMPANY
Less than Less than
1 year Total 1 year Total
RM RM RM RM
At 31 December 2010
Amount due from associated company 598 598 598 598
1,788,442 1,788,442 1,210,786 1,210,786
At 31 December 2009
Amount due to associated company 2,670 2,670 2,670 2,670
2,066,476 2,066,476 1,718,621 1,718,621
(c) Fair values
The carrying amounts of the fnancial assets and fnancial liabilities as refected in the balance sheet
approximate their respective net fair values.
30. SEGMENTAL REPORTING
No segmental information is prepared as the Group is principally engaged in investment holding and providing stem
cells therapy and stem cell consultancy services and collection, harvesting, testing, processing and preservation of
umbilical cord blood stem cells and peripheral blood stem cells and the Group operates principally in Malaysia.
31. MATERIAL LITIGATIONS
As at the date of this report, there are no material litigations against StemLife and its subsidiary companies or taken
by StemLife and its subsidiary companies except for the following:
(a) Suit against Bristol Myers Squibb Sdn Bhd (BMS) and Arachnid Sdn Bhd (ASB)
(i) As reported earlier in the 2nd Quarter Report for the fnancial period ended 30 June 2008, the suit
was fled by the Company in the Kuala Lumpur High Court on 22 May 2008 against BMS and ASB for
defamatory articles posted on the MeadJohnson Sdn Bhds website. The Company has sought relief by
way of an injunction and damages.
(ii) BMS and ASB have on 26 September 2008 and 28 October 2008 respectively fled applications to strike
out the Companys claim on, inter alia, the basis that it discloses no cause of action against them. The
Companys solicitors have fled Affdavits in Reply to the said applications on 30 January 2009.
103
Statements (contd)
31. MATERIAL LITIGATIONS (CONTD)
(a) Suit against Bristol Myers Squibb Sdn Bhd (BMS) and Arachnid Sdn Bhd (ASB) (contd)
(iii) BMS had also on 3 November 2008 amended its statement of defence and counter claim. As the
amendment had no signifcant effect on the Companys cause of action and its claim against BMS, the
Companys solicitors did not fle any amendments to the Companys reply to defence and counterclaim.
(iv) At the scheduled hearing of the suit for case management and the BMS and ASBs applications to strike
out the Companys claim on 17 February 2009, the Court directed as follows:
(a) In respect of ASBs striking out application, counsels for both ASB and the Company had fled
written submissions on 3 April 2009 and the hearing of the applications was fxed for 21 April
2009.
(b) With regard to BMSs striking out application, the hearing was fxed for 23 July 2009.

(v) The Companys suit against ASBs was struck off by the High Court on 21 April 2009. The Company has
appealed against the said decision on 30 April 2009.
(vi) At the hearing of BMSs application on 23 July 2009 the High Court struck out the Companys suit
against it. The Company had on 31 July 2009 fled an appeal against the said decision.
(vii) The Court of Appeal had on 18 August 2010 heard both the appeals against ASB and BMS respectively
and allowed both the Companys appeals. The High Court has now fxed 27 October 2010 for case
management.
(viii) At the case management hearing on 27 October 2010, the High Court directed the parties to fle, inter
ala, documents, statement of agreed facts and issues to be tried. It has then scheduled 23 February
2011 for further case management.
(ix) The Court has fxed 30 May 2011 for further case management for parties to comply with previous
directions.
(b) Suit against Cryocord Sdn Bhd (CC) and Esther Ho Sea Wai (EH)
(i) The Company had on 11 September 2008 fled a suit in the Kuala Lumpur High Court for injunction and
damages against CC and EH for defamatory statements made against the Company.
(ii) The Companys solicitors had effected service of the Writ and Statement of Claim against CCs addresses
on 12 and 13 November 2008. EH was served with the Writ and Statement of Claim on 19 November
2008.
(iii) The solicitors for CC and EH had fled their Statement of Defence on 6 January 2009. The Companys
solicitors have fled its Reply to Defence on 20 February 2009.
(iv) The hearing of the case management of the matter is fxed for 29 May 2009.
(v) At the hearing of the case management on 29 May 2009, the High Court directed the parties to prepare
bundle of documents and pleadings, statements of agreed facts and issues to be tried. It has fxed 11
September 2009 for the hearing of the 2nd case management of the suit.
(vi) The Court has fxed 3 September 2010 for further case management.
(vii) The hearing of the case management was further adjourned to 29 November 2010 for the parties to
comply with the directions of the Court.
104
Statements (contd)
31. MATERIAL LITIGATIONS (CONTD)
(c) Suit against Tan Yen Nee (TYN) and Cellsafe International Sdn Bhd (CSI)
(i) The Company had fled a suit in the Kuala Lumpur High Court on 11 August 2008 against CSI and TYN
for injunction and damages for defamatory statements made against the Company.
(ii) The Company had fled an amendment to its Statement of Claim on 17 October 2008. The amended
Writ and Statement of Claim was served on CSI and TYN on 12 and 13 November 2008 respectively.
(iii) The solicitors for TYN and CSI have fled an application to strike out the Companys claim and for leave
to defer the fling of Statement of Defense pending the disposal of the striking out application. The
solicitors for the Company have fled its affdavit in reply on 20 February 2009. The hearing is scheduled
for 1 April 2009 and the Court directed the parties to fnalise all affdavits by 19 May 2009.
(iv) On 19 May 2009, the case management of TYN and CSIs application to strike out was scheduled for 5
August 2009.
(v) On 5 August 2009, the High Court directed the parties to prepare and hand over their respective written
submissions on 15 September 2009 and scheduled the hearing date of TYN and CSIs application to
strike out for 8 October 2009.
(vi) TYN and CSIs application to strike out the Companys claim was dismissed with costs by the Court on
16 October 2009. The Company solicitors had applied for case management for the matter.
(vii) The Court has fxed 13 December 2010 for mention and for the Company to fle an application for to
amend its claim.
(viii) The Company has fled an application for to amend its claim. At the hearing of the aforesaid application
on 22 February 2011, the parties solicitors submitted written submissions. The Court then fxed 8
March 2011 for hearing / clarifcation. The case management is also fxed for 16 March 2011.
(d) Suit against Kuala Lumpur Sports Medicine Centre Sdn Bhd (KLSMC)
(i) StemLife Therapeutics Sdn Bhd (STSB), a subsidiary of the Company, fled a suit against KLSMC in
the Kuala Lumpur High Court on 26 August 2010 for a sum of RM426,500.00 being outstanding fees for
services rendered.
(ii) KLSMC fled its statement of defense on 12 October 2010.
(iii) STSB has on 27 October 2010 fled an application for summary judgment against KLSMC. STSBs
solicitors are still waiting for the extraction of sealed copy of the said application for service on KLSMC
together with its supporting affdavit.
(iv) The Court has fxed 11 April 2011 for parties to fle in their respective affdavits in relation to STSBs
summary judgment application.
32. SUBSEQUENT EVENT
Subsequent to the fnancial year end, on 25 February 2011, the Directors declared an interim dividend of 10% less
25% tax and single tier dividend in respect of the fnancial year ended 31 December 2011, will be paid on 18 March
2011 to Depositors whose name appear in the Record of Depositors on 11 March 2011.
105
List of Properties
Net Book
Values Approximate
Built Up as at Age of
Area Description / 31.12.2010 Building Date of
No. Location Tenure (Sq.Ft.) Existing Use RM000 (Years) Transaction
1. B-7-15, Megan Avenue Freehold 3,702 Offce Premise 652,169 15 20.07.2005
II, 12 Jalan Yap Kwan within a
Seng, 50450 Kuala commercial
Lumpur building
2. Unit 6.03, Wisma Freehold 908 Sports Medicine 375,549 5 18.07.2005
Perintis, Jalan Dungun, Centre within
Damansara Heights, a commercial
50490 Kuala Lumpur building
3. Unit 6.06, Wisma Freehold 877 Sports Medicine 563,040 5 23.10.2007
4. Unit 6.02, Wisma Freehold 1,028 Sports Medicine 505,570 5 26.11.2007
106
Analysis of Shareholdings
As at 31 March 2011
Authorised Share Capital RM25,000,000 of 250,000,000 ordinary shares of RM0.10 each
Issued and Paid-Up Share Capital RM16,500,000 comprising 165,000,000 ordinary shares of RM0.10 each
Class of Shares Ordinary shares of RM0.10 each
Voting Rights Every member of the Company, present in person or by proxy or attorney or
authorized representative, shall have on a show of hands, one (1) vote or on
poll, one (1) vote for each share held
Number of Shareholders 2,245
No of Holders Holdings Total Holdings %
7 Less than 100 0.31
477 100 to 1,000 21.25
892 1,001 to 10,000 39.73
755 10,001 to 100,000 33.63
111 100,001 to less than 5% of issued capital 4.95
3 5% and above of issued capital 0.13
2,245 100
SUBSTANTIAL SHAREHOLDERS
(HOLDING 5% OR MORE OF THE ISSUED AND PAID-UP SHARE CAPITAL)
AS AT 31 MARCH 2011
Direct Indirect
Substantial Shareholders No. of Shares Percentage (%) No. of Shares Percentage (%)
Dato Low Su-Shing 18,481,600 11.20 - -
Dato Lim Oi Wah 18,465,200 11.19 - -
Juara Sejati Sdn Bhd 16,575,000 10.05 - -
Emerging Markets Growth Fund, Inc 8,331,900 5.05 - -
Tan Sri Dato Seri Vincent Tan Chee Yioun - - 20,075,000* 12.17
Berjaya Corporation Berhad - - 20,075,000** 12.17
Capital Group International, Inc - - 14,664,300^ 8.89
* Deemed interested by virtue of his interest in Berjaya Corporation Berhad, the ultimate holding company of Juara
Sejati Sdn Bhd and Berjaya Sompo Insurance Berhad.
** Deemed interested by virtue of their 100% equity interest in Berjaya Group Berhad, the holding company of Juara
Sejati Sdn Bhd and by virtue of their 100% equity interest in Berjaya Group Berhad, the intermediate holding
company of Berjaya Sompo Insurance Berhad.
^ Deemed interested by virtue of being the parent company of companies that serve as investment managers to
various international institutional clients under discretionary investment management. Neither the Capital Group
of Companies, Inc. nor any of its affliates, own any shares for its own account.
107
Analysis of Shareholdings (contd)
As at 31 March 2011
DIRECTORS INTEREST BASED ON THE REGISTER OF DIRECTORS SHAREHOLDINGS
AS AT 31 MARCH 2011
Direct Indirect
Directors No. of Shares Percentage (%) No. of Shares Percentage (%)
Tan Sri Dato Seri Dr. Aseh bin Che Mat - - - -
Dato Low Su-Shing 18,481,600 11.20 - -
Dato Lim Oi Wah 18,465,200 11.19 - -
Prof. Aw Tar Choon 7,600,400 4.61 - -
Lim Jit Soon 2,755,120 1.67 - -
Loh Yoon Kwai 1,379,500 0.84 365,000** 0.22
bin Tan Sri Tengku Hamid Jumat - - - -
Yap Yu Ming - - - -
** Deemed interested by virtue of Hong Fook Ling @ Hoong Fook Ling, being his spouse.
LIST OF THIRTY (30) LARGEST REGISTERED SHAREHOLDERS AS AT 31 MARCH 2011
PER REGISTER OF DEPOSITORS
Name No. of Shares Percentage (%)
1. Dato Low Su-Shing 18,481,600 11.20
2. Dato Lim Oi Wah 18,465,200 11.19
3. Juara Sejati Sdn Bhd 16,575,000 10.05
4. HSBC Nominees (Asing) Sdn Bhd 9,224,400 5.59
Benefciary: Exempt An for J.P. Morgan Chase Bank,
National Association (U.S.A.)
5. Aw Tar Choon 7,600,400 4.61
6. Chew Koon 6,469,000 3.92
7. Wong San Jah 4,852,700 2.94
8. Chin Zee Sing 4,410,900 2.67
9. HSBC Nominees (Asing) Sdn Bhd 3,936,600 2.39
Benefciary: Exempt An for J.P. Morgan Bank Luxembourg S.A.
10. Berjaya Sompo Insurance Berhad 3,500,000 2.12
11. Lim Jit Soon 2,755,120 1.67
12. Yong Poh Choo 2,562,500 1.55
13. Low Shuhua, Daphne 2,000,000 1.21
14. Low Su-Hin, Hilary 2,000,000 1.21
15. MERCSEC Nominees (Tempatan) Sdn Bhd 1,786,200 1.08
Benefciary: Pledged Securities Account for
Siow Wong Yen @ Siow Kwang Hwa
16. HDM Nominees (Asing) Sdn Bhd 1,500,000 0.91
Benefciary: UOB Kay Hian Pte Ltd for Neo Beng Beng
17. Muhamad Aloysius Heng 1,396,000 0.85
18. Loh Yoon Kwai 1,379,500 0.84
19. TA Nominees (Tempatan) Sdn Bhd 1,090,000 0.66
Benefciary : Pledged Securities Account for Chua Kok Seng
108
Analysis of Shareholdings (contd)
As at 31 March 2011
Name No. of Shares Percentage (%)
20. HDM Nominees (Asing) Sdn Bhd 1,000,000 0.61
Benefciary: UOB Kay Hian Pte Ltd for Ong Lay Choo (Wang Lizhu)
21. HLG Nominee (Tempatan) Sdn Bhd 799,000 0.48
Benefciary: Hong Leong Bank Bhd for Oui Kee Seng
22. Dorris Ngin Eng 708,080 0.43
23. Vignesan A/L Soundrapandian 650,100 0.39
24. HSBC Nominees (Asing) Sdn Bhd 636,000 0.39
Benefciary: TNTC for Government of Singapore Investment Corporation
Pte Ltd
25. Lim Kian Hong 600,000 0.36
26. Tan Kah Lay 600,000 0.36
27. Mayban Nominees (Tempatan) Sdn Bhd 570,000 0.34
Benefciary: Pledged Securities Account for Sow Cheng Kow
28. Lau Hooi Kheng 560,000 0.34
29. CIMSEC Nominees (Tempatan) Sdn Bhd 540,000 0.33
Benefciary: Pledged Securities Account for Chan Foong Cheng
30. Chang Yoke Hee 500,000 0.30
Total : 117,148,300 70.99
109
Notice of Annual General
Meeting
1. To receive and adopt the Audited Financial Statements of the Company for the year ended 31
December 2010 and the Directors and Auditors Reports thereon.

2. To approve a First and Final tax-exempt dividend of 10% (RM0.01 per ordinary share of RM0.10
each) for the fnancial year ended 31 December 2010.

3. To re-elect the following Directors who retire pursuant to Article 116 of the Companys Articles
of Association: -
a. Tan Sri Dato Seri Dr. Aseh Bin Che Mat
b. Tengku Putra Haron Aminurrashid Bin Tan Sri Tengku Hamid Jumat
4. To re-elect the following Director who retires pursuant to Article 92(2) of the Companys Articles
of Association: -
a. Yap Yu Ming
5. To approve the payment of Directors Fees of RM15,000.00 for the fnancial year ended 31
December 2010.

6. To re-appoint Messrs. STYL Associates as Auditors and to authorize the Board of Directors to fx
their remuneration.

7. SPECIAL BUSINESS
To consider and, if thought ft, to pass the following Resolutions with or without modifcations
as Ordinary Resolutions:
Ordinary Resolution
Authority To Allot Shares Pursuant To Section 132D Of The Companies Act 1965
THAT subject to the Companies Act, 1965, the Articles of Association of the Company and the
approvals from Bursa Malaysia Securities Berhad and other relevant government / regulatory
authorities, where such approval is necessary, the Directors be and are hereby empowered
pursuant to Section 132D of the Companies Act, 1965 to issue new ordinary shares of RM0.10
each in the Company, from time to time and upon such terms and conditions and for such
purposes and to such persons whomsoever the Directors may, in their absolute discretion deem
ft and expedient in the interest of the Company, provided that the aggregate number of shares
issued pursuant to this resolution does not exceed 10% of the issued and paid-up share capital
AND THAT such authority shall continue in force until the conclusion of the next Annual General
Meeting of the Company.

NOTICE IS HEREBY GIVEN THAT the Ninth Annual General Meeting of StemLife Berhad will be held at Corus Hotel
Kuala Lumpur, Ballroom 1, Level 1, Jalan Ampang, 50450 Kuala Lumpur on Monday, 23 May 2011 at 2.00 p.m. for the
following business:
(Resolution 1)
(Resolution 2)
(Resolution 3)
(Resolution 4)
(Resolution 5)
(Resolution 6)
(Resolution 7)
(Resolution 8)
110
Meeting (contd)
8. Special Resolution
Proposed Amendments to the Articles of Association of the Company
THAT existing Article 133 in the Articles of Association of the Company be deleted in its entirety
and the following be substituted in lieu thereof:
New Article 133 Payment of Dividend
Any dividend or other money payable in cash on or in respect of a share may be paid by cheque
or warrant sent through the post to the registered address of the member or person entitled
thereto, or, if several persons are entitled in consequence of the death or bankruptcy of the
holder, to any one of such persons or to such persons and such address as such persons may by
writing direct or by directly crediting the dividend entitlement into the members bank account
as provided to the Central Depository from time to time. Every such cheque or warrant shall be
made payable to the order of the person to whom it is sent or such person as the holder may
direct and payment of the cheque or the direct crediting to the members bank account shall
be a good discharge to the Company. Every such cheque or warrant shall be sent or directly
credited at the risk of the person entitled to the money represented thereby. Where the members
have provided to the Central Depository the relevant contact details for purposes of electronic
notifcations, the Company shall notify them electronically once the Company has paid the cash
dividends out of its accounts. Any dividend or other money payable in cash on or in respect of
a share may by directly crediting the dividend entitlement into the members bank account of
the member or person entitled thereto in consequence of the death or bankruptcy of the holder
may in writing direct, and the Company shall have no responsibility for any sums lost or delayed
in the course of any such transfer or where the Company has acted on any such directions.

9. To transact any other business for which due notice has been given in accordance with the
Companys Articles of Association and the Companies Act 1965.

NOTICE OF DIVIDEND ENTITLEMENT
NOTICE IS HEREBY GIVEN THAT the tax exempt dividend of 10% (RM0.01 per ordinary shares of RM0.10 each) in
respect of the fnancial year ended 31 December 2010, if so approved at the Ninth Annual General Meeting, will be paid
on 15 June 2011 to Depositors whose names appear in the Record of Depositors at the close of business on 7 June 2011.
A Depositor shall qualify for entitlement to the dividend only in respect of:-
a. shares transferred in the Depositors Securities Account before 4.00 p.m. on 7 June 2011 in respect of shares; and
b. shares bought on Bursa Malaysia Securities Berhad (Bursa Securities) on a cum entitlement basis according to the
Rules of Bursa Securities.
By order of the Board,
LAANG JHE HOW (MIA 25193)
LIEW SIEW NGOR (MAICSA 0757010)
(Company Secretaries)
Kuala Lumpur
Dated: 20 April 2011
(Resolution 9)
111
Meeting (contd)
Note:
1. A member entitled to attend and vote at the meeting is entitled to appoint one or more proxies to attend and vote
instead of him, and that a proxy need not also be a member. A member may appoint any person to be his proxy
and provisions of Section 149(1)(b) of the Companies Act, 1965 shall not apply.
2. Where a member appoints more than one (1) proxy, the proportions of share holdings to be represented by
each proxy must be specifed in order that the appointments to be valid. Where a member of the Company is an
authorized nominee as defned under the Securities Industry (Central Depositories) Act, 1991, it may appoint at
least one (1) proxy in respect of each securities account it holds with ordinary shares of the Company standing to
the credit of the said securities account.
3. The instrument appointing a proxy shall be in writing under the hand of the appointor or his attorney duly authorized
in writing or, if the appointor is a corporation, either under the corporations common seal or under the hand of an
offcer or attorney duly authorized.
4. The instrument appointing a proxy, with the power of attorney or other authority (is any) under which it is signed or
certifed by a notary or offce copy of such power, must be deposited at the Registered Offce of the company at
149A, Jalan Aminuddin Baki, Taman Tun Dr Ismail, 60000 Kuala Lumpur not less than forty-eight (48) hours before
the time appointed for holding the meeting or adjourned meeting, as the case may be.
EXPLANATORY NOTES TO SPECIAL BUSINESS:
(a) Resolution 8
Ordinary Resolution
Authority to allot And Issue Shares Pursuant to Section 132D of the Companies Act 1965
The Company wishes to renew the mandate on the authority to issue shares pursuant to Section 132D of the
Companies Act 1965 at the Ninth AGM of the Company (hereinafter referred to as the General Mandate).
The Company has been granted a general mandate by its shareholders at the Eighth AGM of the Company held
on 25 May 2010 (hereinafter referred to as the Previous Mandate).
The Previous Mandate granted by the shareholders had not been utilized and hence no proceed was raised
therefrom.
The purpose to seek the General Mandate is to enable the Directors of the Company to issue and allot shares at
any time to such persons in their absolute discretion without convening a general meeting as it would be both time
and cost-consuming to organize a general meeting.
This authority unless revoked or varied by the Company in the general meeting, will expire at the next Annual
General Meeting. The proceeds raised from the General Mandate will provide fexibility to the Company for any
possible fund raising activities, including but not limited to further placing of shares, for purpose of funding future
investment project(s), working capital and/or acquisitions.
All other information remains unchanged.
(b) Resolution 9
Special Resolution
Proposed Amendments to the Articles of Association of the Company
The proposed Special Resolution will render the Companys Articles of Association to be in line with the ACE
Market Listing Requirements of Bursa Malaysia Securities Berhad and to enable the Company to implement the
Electronic Dividend Payment (eDividend).
112
Statement Accompanying Notice
Of Annual General Meeting
1. Date, Time and Venue of the Ninth Annual General Meeting (AGM)
The Ninth AGM of the Company will be held as follows:
Date : Monday, 23 May 2011
Time : 2.00 p.m.
Venue : Corus Hotel Kuala Lumpur, Ballroom 1, Level 1, Jalan Ampang, 50450 Kuala Lumpur
2. Directors who are standing for re-election/re-appointment at the Ninth AGM
Directors standing for re-election pursuant to Article 116 of the Companys Articles of Association are:
a. Tan Sri Dato Seri Dr. Aseh Bin Che Mat
b. Tengku Putra Haron Aminurrashid Bin Tan Sri Tengku Hamid Jumat
Director standing for re-election pursuant to Article 92(2) of the Companys Articles of Association is:
a. Yap Yu Ming
The profles of the above three (3) Directors and the record of their attendances at Board Meetings held in the
fnancial year ended 31 December 2010 are presented in the Directors Profle section on pages 42 to 45. Their
securities holdings in the Group are presented in the Directors Interests section on page 68.
3. Board Meetings held in the fnancial year ended 31 December 2010
Four (4) Board Meetings were held during the fnancial year ended 31 December 2010. A record of the Directors
attendances at the Board Meetings is presented in the Statement of Corporate Governance appearing on page
53 of the Annual Report 2010.
Proxy Form
for Annual General Meeting
RESOLUTIONS FOR AGAINST
1. To receive and adopt the Audited Financial Statements for the fnancial year ended 31
December 2010 and the Reports of Directors and Auditors thereon.
2. To approve a First and Final tax-exempt dividend of 10% (RM0.01 per ordinary shares of
RM0.10) for the fnancial year ended 31 December 2010.
3. To re-appoint the Director, Tan Sri Dato Seri Dr. Aseh Bin Che Mat pursuant to Section 116
of the Companies Act, 1965.
4. To re-appoint the Director, Tengku Putra Haron Aminurrashid Bin Tan Sri Tengku Hamid
Jumat pursuant to Section 116 of the Companies Act, 1965.
5. To re-appoint the Director, Yap Yu Ming pursuant to Section 92(2) of the Companies Act,
1965.
6. To approve the payment of Directors fees amounting to RM15,000.00 for the fnancial year
ended 31 December 2010.
7. To re-appoint Messrs. STYL Associates as auditors of the Company and to authorize the
Directors to fx their remuneration.
8. Authority to issue shares pursuant to Section 132D of the Companies Act, 1965.
9. Proposed Amendment to the Articles of Association of the Company
(Special Resolution).
*I/We NRIC/Company no.

of
being *a member / members of STEMLIFE BERHAD (566770 - D), do hereby appoint
NRIC No. /Passport No.
of
or failing him/her NRIC No. /Passport No.

of

or failing *him /her* the Chairman of the Meeting as *my/our proxy to vote for *me/us on *my/our behalf at the Ninth Annual General
Meeting of the Company to be held at Corus Hotel Kuala Lumpur, Ballroom 1, Level 1, Jalan Ampang, 50450 Kuala Lumpur on Monday,
23 May 2011 at 2.00 p.m. and at any adjournment thereof.
Please mark with X in either box if you wish to direct the proxy how to vote. If no mark is made the proxy may vote on the resolution
or abstain from voting as the proxy thinks ft.
* Strike out whichever not applicable.
Signed this day of 2011 No. of Shares held
Signature(s) of Member(s) Affx Companys Seal (if applicable)
Notes:-
1. A member entitled to attend and vote at the meeting is entitled to appoint one or more proxies to attend and vote instead of him, and that a proxy
need not also be a member. A member may appoint any person to be his proxy and provisions of Section 149(1)(b) of the Companies Act, 1965 shall
not apply.
2. Where a member appoints more than one (1) proxy, the proportions of share holdings to be represented by each proxy must be specifed in order
that the appointments to be valid. Where a member of the Company is an authorized nominee as defned under the Securities Industry (Central
Depositories) Act, 1991, it may appoint at least one (1) proxy in respect of each securities account it holds with ordinary shares of the Company
standing to the credit of the said securities account.
3. The instrument appointing a proxy shall be in writing under the hand of the appointor or his attorney duly authorized in writing or, if the appointor is
a corporation, either under the corporations common seal or under the hand of an offcer or attorney duly authorized.
4. The instrument appointing a proxy, with the power of attorney or other authority (is any) under which it is signed or certifed by a notary or offce copy
of such power, must be deposited at the Registered Offce of the company at 149A, Jalan Aminuddin Baki, Taman Tun Dr. Ismail, 60000 Kuala Lumpur
not less than forty-eight (48) hours before the time appointed for holding the meeting or adjourned meeting, as the case may be.
AFFIX
STAMP
THE COMPANY SECRETARY
STEMLIFE BERHAD (566770-D)
149A Jalan Aminuddin Baki
Taman Tun Dr. Ismail
60000 Kuala Lumpur
Please fold here
Please fold here

Stem Life

Încărcat de

Informații document

Descriere originală:

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Stem Life

Încărcat de

Drepturi de autor:

Formate disponibile

Contents

Our Advisory Panels

PROF. MAUDE ELVIRA

DR. TECK LING

FLEET OF DEDICATED VEHICLES including

S-ar putea să vă placă și